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Abstract
Vaccination is centra! to prevention of infectious disease in modern livestock production 
systems. Accurate assessment of the many factors controlling immune responses to 
vaccination is crucial to maximising their effectiveness. Identification of the genetic 
component of those immune responses is a prelude to selection for disease resistance. 
Assignment of those effects at a molecular level should lead to a more complete 
understanding of the complex processes underlying immunity.
The overall aim of this study was to evaluate the IgG antibody responses induced by 
vaccination in a juvenile, fully pedigreed bovine population of Holstein-Charolais 
crossbred animals. Vaccines against bovine respiratory syncytial virus (BRSV), bovine 
parainfluenza 3 virus (PIV3) and bovine herpesvirus 1 (BHVl) were administered to 
463 calves, aged 60 to 167 days old. Antibody responses to field infections against 
bovine coronavirus (BCV) were also examined. The experimental population comprised 
second-cross Holstein-Charolais F2, Holstein-backcross and Charolais-backcross 
animals with a daiiy-type calf-rearing scheme employed for females and a beef-type 
calf-rearing method for males.
All datasets were extensively investigated using Residual Maximum Likelihood 
(REML) procedures. Across the population, there was a broad spectrum of antibody 
responses to vaccination. Mean antibody half-lifes were estimated as -24 days for total 
BRSV-IgG, -72 days for BRSV-IgGz, -32 days for total PIV3-IgG and -26 days for 
total BHVl-IgG. Although PIV3 and BHVl are both components of a multivalent 
intranasal vaccine, the BHVl-IgG response was poor while the PIV3-IgG response was 
substantial. Sex, year-of-birth, cross-breeding, animal age, and levels of pre-existing 
antibody were significant sources of variation for levels of IgG antibodies against all 
viruses in this population. Although the effect is confounded by management, female 
calves had higher levels of BRSV-IgG and PIV3-IgG. Despite year-of-birth effect, 
including seasonality in climate, environment, wild-type infections and management, it 
accounted for a lower order of the observed variation than sex. Pre-vaccination, calves 
firom dams with higher percentages of the Holstein breed had higher levels of BRSV- 
IgG and PIV3-IgG. Dam-age was also positively correlated with pre-vaccination levels 
of BRSV-IgG, the effect plateauing at about 4 years old. Although calf-age was a 
significant pre-vaccination determinant, its effect on post-vaccination levels of IgG was 
much less pronounced. The inhibitoiy effect of pre-existing BRSV-IgG and PlV3-IgG 
on vaccine response was analysed using logistic regression and respective relative 
optical density thresholds of -26% and -35% established. Pre-vaccination IgG above 
these levels meant a positive antibody response was less likely than a negative one. 
Pre-vaccination, maternal heritable effects dominated total phenotypic variance but post­
vaccination, additive heritable effects became more important. Estimates of heritability 
(±se) peaked at 0.29 (±0.17) for total BRSV-IgG (Day 35); 0.52 (±0,26) for the 
deviation in BRSV-IgG levels between Day 0 and Day 35; 0.47 (±0.28; Day 28) and 
0.51 (±0.31; Day 42) for total PIV3-IgG in the male and female calves, respectively. 
Much lower values were recorded for BHVl and BCV IgG responses.
All calves underwent genotyping and were mapped for 139 microsatellite markers with 
an average marker interval of 15.8 centiMorgans (cM). Interval analysis for quantitative 
trait loci (QTL) using the above antibody phenotypes revealed a large number of loci 
(positions in cM) influencing levels of IgG. Quantitative trait loci on BTAl (59 cM), 
BTA2 (108 cM), BTA7 (29 cM), BTA8  (41 cM), BTAIO (55 cM), BTAl2 (84 cM), 
BTA24 (44 cM) and BTA28 (2 cM) proved significant for one or more of the BRSV-, 
P1V3- and BHVl-IgG antibody traits.
Although the QTL for antibody phenotype identified here are preliminaiy, they could 
plausibly be incorporated into breeding programmes to influence antibody response to 
vaccination. Further, they could act as a basis for further QTL research in this area 
leading to precise isolation of the relevant genes involved, to a molecular level. However 
most of all, these results prove that antibody production in cattle is under quantitative 
genetic control and this influential element should not be disregarded in the futuie.
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Chapter 1
General Literature Review
1.1 General Introduction
Infectious disease among domestic animals is currently controlled using many 
methods including eradication, quarantine, disinfection, sanitation, medication 
and vaccination (Detilleux et a l, 1994). Control is imperfect, and real or 
perceived disadvantages of the existing systems include: the high cost of 
replacing culled animals, increasing public concerns about animal welfare, side- 
effects and withdrawal times of drugs, development of antimicrobial drug 
resistance, environmental damage due to chemical residues, poor performance in 
preventing clinical disease, and ever escalating difficulties and costs in the 
development o f new medication (Rauw et a l, 1998). A more sustainable 
approach would be to optimise host immunity, removing or diminishing many of 
these difficulties and reducing the need for more invasive methods (Lofthouse 
and Kemp, 2002).
Present levels o f disease resistance among farm animals are a product of natural 
selection/survival and those immune responses which fit with production aims 
(Visscher et a l, 2002). Reduction of disease by improving natural immunity 
would have cumulative and permanent effects, through successive generations. 
Disease transmission should drop as more resistant animals persist, resulting in 
lower pathogenic contamination o f the environment (MacKenzie and Bishop,
1999). Furthermore improvements in genetic resistance-based disease status, 
could lower susceptibility to other pathogens and ultimately would lead to 
improvement in general health and welfare (Simm et a l, 1996). Additionally, an 
adequate and competent natural resistance should reduce opportunities for 
pathogens to evolve and overcome the host immune response (Bishop, 2003). 
Resistance to infectious disease is likely to be under polygenic control (Wilkie 
and Mallard, 1999) with the involvement and regulation of both innate and 
acquired immune systems (Malo and Skamene, 1994). Even for immune 
mechanisms expressed by a single genetic locus, other loci will nonetheless 
modulate and regulate the resistance (Adams and Templeton, 1998). 
Development o f disease is confounded by so many additional factors to genetic
i
resistance, that heritabilities tend to be significant but low (Soller and Andersson,
1998).
Direct selection based on obseiwation o f resistance and susceptibility to specific 
infections is not feasible on a commercial scale (Wilkie and Mallard, 1998). 
Indirect selection criteria may be used, based on morphological, physiological 
and immunological characteristics. Surrogate indicator traits such as serum 
antibody responses, in vitro cellular bioassays, and similar correlates of 
protection could be used to quantity immune reactions which could then be 
linked to genetic markers and eventually to the relevant immune system genes 
(Detilleux e ta l,  1994).
By more closely reflecting protection, this approach may be used effectively to 
advance beneficial traits without minute knowledge of gene function. Such 
selection may be achieved by incremental quantitative improvements in 
resistance, without major changes in mechanisms of overall action (Gavora,
1996). Thus this approach is exposed to less detrimental effects than other 
“genetic modification” techniques, and lends itself for use in conventional 
breeding programmes (Shook, 1989).
1.2 The Immune System
Living animals make a very attractive resource to microorganisms, to the extent 
that resistance to infection is paramount to any animal’s survival. Multicellular 
organisms must be able to eliminate infectious agents capable of causing disease, 
or inhibit the replication of pathogens, once the host has been invaded (Tizard,
2000). This is a dynamic process with pathogen gene frequencies coevolving and 
tracking those genes involved in host defences (Dybdahl and Storfer, 2005). To 
deal with a highly variable range o f pathogens, from viruses to nematodes, the 
immune system has evolved multiple, intricate defence mechanisms (Engelhard, 
1994). Mammals possess two highly integrated defence systems, the innate and 
the acquired immune systems which cooperate and interact extensively, 
depending on the pathogen and its route of entry (Kaiifmann and Kabelitz, 1998). 
Innate immune responses act as limited but rapid responses to infection, without 
prior exposure to the pathogen (Parham, 2004), whereas the acquired immune
î
Isystem relies on direction from the innate immune system, focuses on specific pathogen epitopes, and leads to cellular memoiy (Bachmann and Kopf, 1999). Pathogens, themselves, can alter immune function. The likelihood of secondary 
bacterial pneumonia is greatly increased by the lethal effect of bovine 
herpesvirus 1 infection on the pulmonaiy epithelium, directly compromising 
ciliary activity in the respiratory tract (Babiuk et al, 1988). Bovine viral 
diarrhoea virus (BVDV) infection produces a lymphopaenia in cattle with severe 
depletion of B-cell and T-cell populations throughout many lymphoid tissues. In 
addition, neutrophil functions are depressed and surviving B-cells are poor 
producers of antibodies (Radositis et a l, 2003). Bovine respiratory syncytial 
virus (BRSV) infection depresses lymphocyte blastogenesis in sheep (Keles et 
al, 1999).
Furthermore, imbalances in immunity such as immunodeficiencies and
autoimmune diseases stress the importance of the controlled production of the
multitude of factors involved in a normally functioning immune system; any
. . .departure from this dynamic equilibrium increases susceptibility to disease 
(Klein and Horejsi, 1997).
Many of the various components of the immune system are peptides and 
glycoproteins coded for in the genome, although post-transcriptional and post- 
translational modifications mean the functional proteome greatly exceeds the 
genome. In the text that follows, where possible reference will be be made to the 
coding chromosome {Bos taurus autosome (BTA)) and the segment (q) or 
position on that BTA e.g. [BTA.. q..; published reference].
1.3 The innate immune system
Innate immunity acts as a sentinel system at the interface between the host and 
the environment. The innate immune system recognises pathogenic material via 
cellular pattern recognition receptors (PRR), typically found on macrophages and 
dendritic cells (Lazarus et a l, 2002). PRR are stimulated by pathogen-associated
molecular patterns (PAMP), essentially consei’ved molecular constituents of
.microbial pathogens such as lipopolysacchride, peptidoglycan, lipoteichoic acid.
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unmethylated DNA (CpG motif) as well as various endogenous molecules from 
dead or dying cells (Medzhitov and Janeway, Jr., 1997).
It is a key role of the innate immune system to trigger and channel an appropriate 
response from the acquired immune system. The cumulative action of many 
genes, structural, physiological and immunological, determine this phenotype, 
which is responsible for 95% of host defence. Although relative to the diversity 
of pathogens the number of innate immunity genes is small, they gain functional 
plasticity by high rates of polymorphism and heterodimerisation (Lazarus et al,
2002). Due to their critical position in initialising and dictating the type of 
acquired immunity, any genetic variation could have a major impact on all 
downstream immune respones, including antibody production. Innate immunity 
also includes physical defences; for example, the lungs have developed innate 
defences to protect the airways from infection such as the cough reflex, 
mucociliary clearance, extensive patrolling populations of immune cells and 
antimicrobial properties o f the mucosal surface (Strieter et a l, 2003).
1.3.1 Cell-mediated innate immunity
Although many subsets of leukocytes contribute to a complete immune response, 
the term “cell-mediated immunity” broadly describes any response in which 
antibody plays a subordinate role. Pluripotent hematopoietic stem cells in the 
bone marrow differentiate into lymphoid and myeloid stem cells, a further 
segregating development of the lymphoid stem cells producing the three major 
populations of mature lymphocytes: T-cells, B-cells and Natural Killer (NK) 
cells. Myeloid stem cells differentiate into granulocytes and other non-immune 
system blood cells (Chaplin, 2003). Cell-mediated immunity (CMI) is operated 
and coordinated primarily by T-cells (Janeway, Jr., 1994) but is not totally 
dependent on this cell-type (Bancroft et a l, 1991). By common convention, 
leukocyte cell surface molecules are named by assigning them a cluster of 
differentiation (CD) antigen number, dependent on the reactivity to a panel of 
monoclonal antibodies. Lymphocytes may have over 100,000 CD and they are 
extremely useful in determining cellular function.
1.3.1.1 Antigen presenting cells
Antigen processing serves to regulate the amount and type of antigen presented
t
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Ito the immune system allowing the development of a restricted and specific
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response. Dendritic cells appear to the most potent antigen presenting cells 
(APC) but B-cells, macrophages, epithelial Langerhans cells, hepatic Kupffer 
cells and nervous microglial cells are also important APC (Tizard, 2000).
Antigen presenting eell involvement is essential for the active induction of helper 
T-cell function whereas APC interact with other cell types to modulate the 
homeostatic maintenance of an effective immune system (Glass and Spooner,
1989).
1.3.1.2 Dendritic cells
Dendritic cells (DC) are professional, myeloid-derived APC, distributed in small 
numbers throughout the body, but concentrated in the secondary lymphoid 
tissues where they are ideally placed for antigen uptake (Howard et al., 1999). A 
number o f phenotypic subsets have been distinguished with different functions, 
locations, structure, trafficking properties and levels of maturity (Shortman and 
Caux, 1997). Dendritic cells are highly efficient processors of antigen and form a 
widespread surveillance network, the local density of which depends on the 
likelihood of insult. Dendritic cells may be the only cells able to present antigen 
to naïve T-cells, thereby initiating the acquired immune response (Banchereau 
and Steinman, 1998). Furthermore, as part of a secondaiy immune response, 
follicular DCs trap circulating antigen-antibody complexes and process them into 
iccosomes (Tew et a l, 1997). These packaged antigen-antibody complexes are 
then ingested by B-cells, processed, and T-cell help elicited, greatly amplifying 
the resulting immune reaction (Bajer et a l, 2003). Dendritic cells are critical to 
the initation of many acquired immune responses, acting as an intelligent bridge 
between the innate and acquired immune systems.
1.3.1.3 M onocytes
Monocytes are physically the largest o f all blood cells, but form only 5% of the 
total leukocyte population (Tizard, 2000). Monocytes leave the systemic 
circulation by diapedesis and develop into larger, more efficient and specialised
phagocytes in the tissues: macrophages (Volkman, 1970).
*
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1.3.1.4 M acrophages
Macrophages are long-lived, mononuclear phagocytes, capable of longer, 
repeated phagocytic activity than neutrophils (Klein and Horejsi, 1997). They kill 
ingested pathogens using nitric oxide and release many cytokines including 
interleukin (IL)-6 , IL-10, IL-12 and IL-18, acting as regulators in acquired 
immune responses (Mosser and Karp, 1999). Pulmonaiy alveolar macrophages 
and pulmonary intravascular macrophages are specialist populations of 
macrophages found in cattle, the latter in intimate association with the 
endothelial cells of pulmonary capillaries (Ackermann and Brogden, 2000).
1.3.1.5 Neutrophils
Neutrophils have been described as the primary cellular killers of invading 
micro-organisms (Hasui et a l, 1989). Their major importance iiiimunologically 
derives from their ability to sequester microbes and particles internally. The 
neutrophil is the major descendant o f the myeloid lineage in all species, forming 
however a much lower proportion o f total leukocytes in healthy ruminants 
(-25% ) than other animals (-70% ) (Carlson and Kaneko, 1973). Neutrophils 
play a major role in the clearance of microbial pathogens and repair of tissue 
ill)my (Chertov et a l, 2000).
A common form of bacterial bovine pneumonia, caused by Mannheimia
haemolytica, is characterised by a profound influx of neutrophils into lung tissue
(Caswell et a l, 1998). Neutrophil migration into the lung parenchyma occurs
from capillaries, as opposed to post-capillary venules in most other tissues
(Albertine et al., 1993). Due to their large size, neutrophils must adopt an
elongated shape to pass the lung capillaries (Gebb et a l, 1995). When activated,
.neutrophils become enlarged and inflexible which increases their pulmonary 
retention (Soethout et a l, 2002). Upregulation of the adherence molecules, 
integrins, is critical for neutrophil migration to the lung in cattle (Wagner and 
Roth, 2000), with bovine leukocyte adhesion deficiency (BLAD) affected cattle 
demonstrating atypical pneumonic pathology.
1,3.1.6 Toll-like receptors
Toll-like receptors (TLR) are one of the primary types of PRR expressed on the 
surface of many cells. Stimulation of TLR initiates the production of reactive 
oxygen and nitrogen intermediates and induces secretion of many pro- 
inflammatory cytokines and co-stimulatory molecules (Chaplin, 2003) to further 
amplify the innate immune response. In cattle, ten TLR have been identified with 
vaiying functions (McGuire et a l, 2005). Generally, the TLR trigger specific 
signalling pathways leading to pathogen-specific immune response serving as a 
crucial link between innate and acquired immunity through the entirety of the 
host immune response (Table 1.1).
TLR Ligand
Bovine
chrom osom e R eference
TLR-1 G+ bact, lipoprotein, interacts BTA6 (McGuire et al, 2005)
with TLR2
TLR-2 G± bact. lipoprotein BTA 17 (White et al, 2003)
TLR-3 viral ssRNA, type 1 IFN BTA27 (McGuire et al., 2005)
(Alexopoulou et al, 2001)
TLR-4 G- bact. Lipopolysacchride BTA8  distal (White et al, 2003)
hRSV F-protein (Tal et a l, 20 0 4 )
TLR-5 flagellin BTA 16 (McGuire et al, 2005)
TLR- 6 lipoproteins, interacts with BTA6 (McGuire et al, 2005)
TLR2
TLR-7 Imiquimol, resiquimol X (McGuire et al, 2005)
TLR- 8 sRNA X (McGuire et al, 2005)
TLR-9 methylated CpG dinucleotides BTA22 (McGuire et a l , 2005)
TLR-10 asthma in humans BTA6 (McGuire et al, 2005)
Figure 1.1 Toll-like receptors (TLR) identified in cattle. Natural ligands, genomic position 
and related references included. G± bact. (Gram positive / negative bacteria), sRNA 
(single stranded DNA), ssRNA (double stranded DNA), CpG (cytosine guanine DNA
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1.3.2.1 Cytokines -  innate imm unity
Cytokines are proteins, active at picomolar concentrations, which control the 
complex interactions between cells of the immune system (Lunney, 1998). They 
have transient expression and tend to be limited to local action. There is a good 
deal of redundancy, ambiguity and pleiotropism in the action of most cytokines. 
Cytokine production is stimulated by a multitude of mechanisms: antigen or 
antigen-MHC aggregates acting via T-cell or B-cell receptors, antigen-antibody 
complexes acting through Fc receptors, superantigens acting through T-cell 
receptors or directly by T-cell interaction with microbial constituents such as 
lipopolysaccharides (Slifka and Whitton, 2000). Many cytokines such as
interleukins (IL): IL-1 and IL-6 ; interferons (IFN): IFN-a and IFN-P and tumour 
necrosis factor alpha (TNF-a) are produced by and act on multiple cell types but 
some such as IL-2, IL-3, IL-4 and IL-5 are secreted by specialised subsets of 
cells (Carter and Swain, 1997).
Cytokines have a central role in orchestrating the normal maturation of the 
immune system and regulating defence against infectious disease (Fresno et a l, 
1997). A series of pro-inflammatoiy cytokines including IL-1 a, IL-ip, IL-6 , 
TNF-a and the type I interferons are synthesized de novo following bacterial or 
viral infection (Lunney, 1998). The broad effect of this is to stimulate the 
phagocytic cells (monocytes, macrophages, neutrophils and endothelial cells) to 
attach to or react against pathogens, and to attract other immune cells to the 
infection site. Some virus constituents can mimic mammalian cytokines, 
allowing them to suppress and evade the immune response (Kluczyk et a l, 
2002 ).
1.3.2.2 Interferon
Interferons (IFN) are major factors in the successful clearance of viral and 
intracellular infections. There are 3 main types of IFN: IFN-a, IFN-P and IFN-y, 
although the latter is unrelated to the former two and will discussed later. These 
molecules are generated by fibroblasts, T-cells, NK cells and macrophages and 
have wide ranging effects on many target cells (Boehm et a l, 1997). Interferon-a
;ï
and IFN-P [both BTA8 ; q l5; (Adkison et a l, 1988)] activate macrophages and 
directly influence virus-infected cells to suppress viral growth.
1.3.2.3 Interleukin-1
Interleukin-1 (IL-1) is produced predominantly by mononuclear phagocytes 
following induction by bacteria, bacterial products and other soluble factors (Yu 
et a l, 1998). It is potently pro-inflammatory and critical to the mobilisation of 
the effector cells of the innate immune response (Murtaugh and Foss, 2002).
Interleukin-1 [B TA ll; (Yoo et a l, 1994)] induces pyrexia, initiates the acute 
phase response, activates many cell types including hepatocytes, osteoclasts and 
synovial cells, stimulates selectin expression on endothelial cells and is a co­
factor for the proliferation and activation of lymphocytes (Dinarello, 1996).
1.3.2.4 Interleukin-12
Interleukin-12 (IL-12) is produced by many types of immune cells, including 
monocytes, macrophages, dendritic cells and B-cells. Interleukin-12 [BTAl q34- 
q36; (Schmidt et al., 2000)] enhances cell-mediated cytotoxicity and 
mitogenicity and has a pivotal role in directing the immune response to a Thl- 
type (Collins et aL, 1998). Two mediators p35 [BTAl; (Zarlenga et ah, 1995)] 
and p40 [BTA7 q23-q24; (Zarlenga et ah, 1995)] control the bioactivity of IL-12. 
Interleukin-12 also suppresses IL-4 synthesis, driving the immune reaction away 
from antibody production (Trinchieri, 2003).
1.3.2.5 Tumour Necrosis Factor-alpha
Tumour Necrosis Factor-alpha is expressed early in pneumonia (Mehrad et ah,
1999) and is involved in the recruitment and direction of phagocytic cells. 
Depletion of TNF-a [BTA23 q22; (Agaba et ah, 1996)] impairs the clearance of 
micro-organisms from the lungs (Mehrad et ah, 1999) while TNF-a also 
upregulates genes critical to the innate immune response.
1.3.2.6 Other mediators
There are many other cytokines, lymphokines, interferons and other chemical 
mediators forming a complex network of factors controlled by regulation of 
receptor expression, specific binding proteins and antagonistic effects from other 
cytokines. A host of mediators are involved in each immune response, allowing
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it to adapt and evolve to best cope with attack from diverse pathogens (Table 
1.1). The precise cytokine pathways which direct resistance to disease remain as 
yet unclear in larger vertebrates. Excessive production of pro-inflammatoiy 
cytokines such as IL-1, IL - 6  and TNFa have been associated with the pathogenic 
effects of Theileriosis and variability in their production linked to disease 
resistance (Glass et a l, 2005).
M e d ia to r T yp e C h r o m o so m e R efer en ce
IL-2 Thl BTA17q22-q23; (Chowdhaiy et a l ,  1994)
lL-3 Treg BTA7 (Mwangi et a l ,  1995)
lL- 6 Thl (innate) BTA4 (Barendse et a l ,  1997)
lL-7 Treg BTA14 (Barendse et a l ,  1997)
lL- 8 Thl (innate) BTA6 (Modi et a l ,  1990)
lL-10 Th2 (adaptive) BTA16ql2 (Beever et a l ,  1997)
lL-13 Th2 (adaptive) BTA7 (Buitkamp et a l ,  1999)
IL-15 Treg BTA17ql3-ql4 (Sonstegard et a l ,  2000)
lL-18 Thl (iimate) BTA15ql3-ql4 (Sonstegard et a l ,  2000)
TGF-a Treg BTA5 (Kappes et a l , 1997)
TGF-p Th2 (adaptive) BTAl8  q24-q25 (Sonstegard et a l , 2000)
LTA Thl (innate) BTA23 q22 (Cludts et a l ,  1993)
CSF-1,-2, -3 Treg BTA3, 7, 19 (Zhang et al., 1992)
PAX- 8 tumours ? BTAll (Lopez-Corrales é t a l ,  1999)
PAX- 6 tumours ? BTAl5 q25-q27 (Kuiper et a l ,  2005)
Figure 1.1 Chemical mediators which act as signalling mechanism for mammalian 
immune system. Position on bovine genome and related references included. BTA {Bos 
taurus autosome). Type (Thl, Th2 and Treg (T regulatory)). Interleukin (IL), tumour 
growth factor (TOP), lymphotoxin alpha (LTA), colony stimulating factors (CSF), 
naired box orotein (PAX)
1.3.2.7 Acute phase proteins
The acute phase proteins (APPs) are soluble factors released early in the innate 
immune response with a wide range of pathophysiological effects including 
pyrexia, leukocytosis, alterations in levels o f hormones and serum trace elements 
and muscle protein depletion (Eckersall, 2000b). Stimulated by cytokines such as
11
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Non-Specific innate immunity is expressed constitively and actively from genes 
regulating phagocyte uptake and killing, genes encoding cytokines, their 
receptors and the complement proteins, specific genes such as those coding for 
Natural Resistance Associated Macrophage Protein (NRAMP) active against 
intracellular pathogens and others (Rumyantsev, 1998). Almost eveiy aspect of 
acquired immunity is triggered and governed by signals from the innate immune 
response, the progression o f the former entirely dependent on direction from the 
latter. General innate immune responses often progress into specific acquired
12
IL-1, IL- 6  and TNF-a, the APPs include C-reactive protein, serum amyloid A 
(SAA), haptoglobin (HP), fibrinogen, ceruloplasmin and at-anti protease 
(Eckersall, 2000a). In cattle, two hepatically derived APPs, SAA and HP, are the 
most important, the former mapping to BTA29 while the latter is coded for on 
BTA 18 (Barendse et a l, 1997). Serum amyloid A is involved in leukocyte 
activation, chemotaxis and phagocytosis while HP acts as a haemoglobin 
scavenger (Eckersall, 2000a).
1.3,2.8 Complem ent
The complement system is a very powerful cascade of at least 30 serum proteins 
(Manderson et a l, 2001) and is a sequential, self-catalysing system that binds 
specific proteins to the surface o f invading pathogens (Klein and Horejsi, 1997). 
Complement is involved in viral infections in many ways (Lachmann and 
Davies, 1997). Following virus invasion, complement proteins may directly coat 
virus particles, preventing further cellular infection or leading to virus lysis 
(Carroll, 1998). Complement can bind and lyse virus-infected cells (Sissons and 
Oldstone, 1980) and the specific anti-viral antibody response is enhanced by 
complement components (Fearon and Carter, 1995). A heritable deficiency of the 
bovine complement receptor, CR-3, has been described in association with 
BEAD; (Cox et a l, 1997)) and results in impaired phagocyte microbiocidal 
activity (Nagahata et a l, 1996). Other soluble mediators released at this phase 
include mannose-binding protein, serum amyloid protein and the alternative 
complement pathway proteins (Tizard, 2000). In Norwegian Red cattle, 
heritability for haemolytic complement activity was high, estimated at 0.75 (Lie 
e ta l,  1983).
Æâ
immune response. These two branches of the immune system, although 
fundamentally different in their mechanisms, act together, their synergy being 
essential for a fully effective immune response. Each has strengths and 
weaknesses, a balance of both being desirable to optimise immune function when 
selecting for disease resistance (Campos and Godson, 2003).
1,4 The acquired immune system
Acquired immunity involves the induction of cellular and humoral responses 
directed against a specific antigen alongside the development o f cellular 
memory, thereby permitting a more rapid secondary response on re-exposure to 
the antigen (Roitt, 2001). Acquired cell-mediated immunity is generally focussed 
on intracellular pathogens whereas acquired humoral immunity is typically 
directed against extracellular pathogens (Janeway, Jr., 1994). Unlike the “hard­
wired” innate immunity, the acquired immune system relies on immense 
populations of clonal receptors, generated via somatic expansion during an 
individuafs development, to mediate antigenic recognition (Lazarus et a l, 
2002).
1.4.1 Cell-mediated acquired immunity
1.4.1.1 Lymphocytes
Lymphocytes play a central role in orchestrating the acquired immune response 
(Figure 1.1) and are essential in the specific recognition of pathogens (Roitt,
2001). Two of the three major populations o f lymphocytes: T lymphocytes (T- 
cells) and B lymphocytes (B-cells) originate from lymphoid stem cells. T-cells 
undergo final maturation in the thymus (Klein and Florejsi, 1997) while in 
mammals B-cells develop in several peripheral lymphoid sites (Meyer et ah,
1997). The ileal Peyer’s patch is the site of primary B-cell development in 
ruminants (Meyer et a l, 1997).
A third significant type of lymphocyte, the NK cell, recognises virus-infected or 
tumour cell targets through the use of a sophisticated system of stimulatory and 
inhibitory cell surface receptors (Moretta et a l, 2002). Once activated, NK cells 
develop into lymphocyte-activated killer (LAK) cells. In cattle, NK cells are
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inhibited by MHC class 1 molecules and are regulated by bovine homologues of 
the human KIR and mouse Ly49 genes [BTAl 8 ; (Storset et a l , 2003)].
1.4.1.2 T-cells
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IT lymphocytes express the T-cell receptor (TCR), a transmembrane 
heterodimeric surface protein. T-cells exist in several functionally significant 
subtypes and subsets, acting as the principal managers and coordinators of cell- 
mediated, antibody and memory immune responses (Howard et a l, 2004).
To correctly identity foreign antigen or infected cells, T-cells must discriminate 
between se lf components and associated non-self components such as microbial 
or other exogenous structures (Germain, 1994). T-cells receive these signals via 
the TCR, engaged by the antigen bound to a Major Histocompatibility Complex 
(MHC) molecule on the interacting cell. Antigen presenting cells are particularly 
involved in the presentation of processed peptide fragments bound with surface 
bound MHC to T-cells but also provide the co-stimulatoiy signals obligatory for 
full T-cell activation (Meliman and Steinman, 2001). Adhesion molecules, APC- 
derived cytokines, bacterial products such as endotoxins and vaccine adjuvants 
can all operate as co-stimulatoiy signals to T-cells undergoing activation 
(Schwartz, 2003). When fully activated, T-cells differentiate and expand into 
infinite clonal populations each expressing a unique TCR (Tanaka et a l, 1995), 
in close association with a surface bound complex of transmembrane 
polypeptides, termed CD3 [BTA 15 (Li et a l, 1992)].
A recent expansion o f the se lf  nonself discrimination paradigm is the “Danger 
model” that proposes that distressed or damaged cells of normal bodily tissues
activate local APC which then proceed to alert the immune system proper 
(Matzinger, 2001).
T-cells may be subdivided into functional subsets according to the dominant 
surface markers expressed, two major categories being ap and y 6  T-cells. Levels 
of y ô  T-cells peak at birth and gradually decline with age in cattle and sheep 
(Washington et a l, 1992), so that y ô  T-cells are believed to provide an early 
general purpose CMI defence in ruminant neonates, alongside colostral antibody. 
Ovine y ô  T-cells respond more rapidly to mitogens in vivo (Evans et a l, 1994)
!
and it has been suggested that this cell type provide a contingency protection 
until ap T-cell-dependent mechanisms have fully developed (Ramsburg et a l,
2003).
1.4.1.3 ap T-cells
The aP T-cells exist as two main subpopulations, each with defined repertoires of 
effector functions, distinguished by their exclusive surface expression of CD4 
and CDS molecules. CD4"CD8^ T-cells are selected for class I MHC molecules 
while CD4^CD8" T-cells are selected for class II MHC recognition and both 
types have been described in cattle (Ellis et a l, 1996; Howard et a l, 1989). 
CD 8 + T-cells show major cytotoxic activity against tumour cells and cells 
infected with intracellular pathogens, and some regulatoiy, mainly suppressive, 
effects. CD4^ T-cells are designated as helper T-cells, which assist the activation 
of humoral and cellular immune responses. In young ruminants, double negative, 
CD4 CD8 ' T-cells comprise up to 80% of the lymphocyte population (Ayoub and 
Yang, 1996).
Both CD4^ and CD8  ^ T-cells differentiate into functional effector cells after 
exposure to antigen. Early following stimulation by antigen and APC, CD4^ T- 
cells secrete IL-2 and are designated ThO, while the APC mature to produce IL- 
12. As the ThO cells continue to respond to the activating stimulus, they progress 
towards two polar extremes of differentiation: Thl and Th2 cells (Mosmann and 
Coffman, 1989). This progression is illustrated in Figure 1.1. Thl cells produce 
the inflammatoiy cytokines: IL-2, IL-12, IL-18 and IFN-y, and are associated 
with predominantly CMI responses while Th2 cells, by releasing IL-4, IL-5, IL- 
9, IL-10, IL-13, are associated with expansion of regulatoiy T-cell numbers in 
concert with B-cell proliferation and differentiation thereby inducing an antibody 
response (Constant and Bottomly, 1997).
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Commonly, helper T-cells show a combination of Thl and Tli2 features, 
although following prolonged stimulation in mice the response will polarise, 
becoming dominantly Thl or Th2. Such polarisation appears to be much less 
evident in cattle (Estes and Brown, 2002). Simultaneous induction of regulatoiy 
and effector cytokines may represent a normal strategy of the immune system to 
control immune responses and reduce inflammation as an over-exuberant Thl 
response is often the underlying cause of the observed pathology and illness. :
In cattle, IFN-y and IL-4 have been proposed as the respective signature 
cytokines for Thl and Th2 responses (Estes and Brown, 2002). The specific IgG 
subclass pattern expressed is dictated by the availability o f these two molecules;
Bovine IL-4 (Th2) induces IgGi and IgE preferentially over IgG2 while bovine 
IFN-y (Thl) induces IgG2 over IgGi production (Estes and Brown, 2002). Potent 
Till response and subclass IgG2a inducers in rodents, such as bacterial DNA- 
based vaccines and adjuvants, elicit predominantly IgGi responses in cattle 
(Arulkanthan et a l, 1999). The cytokines IL-I2 and IL-I3 are thought to both 
modulate and augment the respective type Thl and Th2 responses, channelling 
antibody production in particular directions (Trigona et a l, 1999; Tuo et a l,
1999). For viral infections in mice, Thl cytokines inducing an early cytotoxic 
lymphocyte response are more important in recoveiy from infection while Th2 
responses are better for prevention (Karupiah, 1998).
1.4.1.4 The major histocom patability complex
Genes in the Major Histocompatability Complex (MHC) produce proteins that 
determine which antigens are presented and processed by the rest of the immune 
system (Engelhard, 1994). Overall mammalian MHC genetic structure is well 
conserved, with three broad classes; (regions o f DNA) MHC I, II and III, each 
with different types of genes. Class I [BTA23 q22; (McShane et aL, 2001)] and 
class II [BTA23 q l2-ql3; (Hess et a l, 1999)] genes code for cell surface 
glycoproteins while class III [also BTA23] genes code for other immune proteins 
such as the complement proteins, lymphotoxin and isoforms o f TNF (Nonnecke 
and Harp, 1989).
Class I MHC proteins combine with (32-microglobulin [BTAIO; (Clawson et a l,
2004)] to form the class I MHC receptor found on virtually all mammalian 
nucleated cells (Kelm et a l, 2001). Class I MHC receptors communicate with
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cytotoxic T-cells, expressing endogenously produced peptides and critically 
identifying cells infected with intracellular pathogens, e.g. viruses. Class II MHC 
receptors are found primarily on APC. Exogenous proteins ingested by the APC 
are displayed in association with the highly polymorphic MHC class II receptors 
which are recognised by CD4^ helper T-cells (Chaplin, 2003). The nomenclature 
o f the MHC is species-specific and is known as the bovine lymphocyte antigen 
system (BoLA) in cattle (Spooner et a l, 1979), largely mapping to bovine 
chromosome 23 (BTA23; (Fries et a l, 1986)).
Class I MHC molecules consist o f one heavy chain and a veiy much smaller p2 
microglobulin chain (Engelhard, 1994). The loci coding for class I MHC can be 
divided into those that are highly polymorphic: class la loci and those which 
show little polymorphism: class Ib, Ic, and Id loci (Amills et a l, 1998). Non- 
MHC genes occupy a common framework - in the same order relative to each 
other - with classical class I genes filling the variable spaces between (Amadou,
1999).
This level of high polymorphism is maintained by mutation, gene conversion, 
recombinational “hot spots” and unequal crossing over of genes (Paterson et a l,
1998) and is driven by selective pressure from rapidly evolving pathogens 
(Yeager and Hughes, 1999). The polymorphism is concentrated in the floor and 
sides of the antigen-binding groove in the MHC molecule. In humans, there are 
three major class la molecules, termed A, B and C, each highly polymorphic, so 
that heterozygous individuals have a possible six distinct peptide-binding 
grooves. As each class I protein can bind many different peptides, this system 
can cope with a wide diversity of smaller antigenic peptides (Stern and Wiley,
1994).
The endogenous peptides bound to the peptide-binding groove in MHC class I
molecules are generally synthesized within the actual cell bearing the class I
molecule (Niedermann, 2002). The complex of class I MHC molecule and
antigenic peptide result in a composite structure that is the molecular target for
the T-cell TCR. The peptide alone or the MHC molecule plus a less compatible 
. . .peptide will have negligible affinity for the TCR and so are not recognised by the 
T-cell, this is termed “MHC restriction” (Zinkernagel and Doherty, 1997). In 
cattle, there are between 10 and 20 genes involved in the class I region of the 
BoLA [BTA23 q22; (Lewin, 1996)] (Lindberg and Andersson, 1988).
1.4.1.5 Bovine lymphocyte antigen system
The pattern of expression of BoLA class I genes appears to be similar to that of
humans (Di Palma et a l, 2002) with early studies describing expression of six or
more classical class 1 loci depending on haplotypes (Ellis, 2004).
However the genetic structure o f BoLA class II has some atypical features such
as its division into two distinct regions Ha and Ilb (van Eijk et a l, 1992). Other
unusual elements include expression of ruminant specific DY genes (Ballingall et
a l, 2004a), a chromosomal inversion (Band et a l, 1998) and variable numbers of
DQ genes (Lewin et a l, 1999). Eleven class II BoLA loci have been identified
but only protein products encoded at the DR and DQ loci in the MHC class Ha
region {DRA, DRJB3, DQA, DQBl and DQB2) have been demonstrated in cattle.
The BoLA-DR genes and their protein products are among the best characterised
of the MHC genes in cattle (Ledwidge et a l, 2001). The BoLA-DRB3 [BTA23
q21; (Russell et a l, 2000)] is a highly polymorphic gene, with more than 170
haplotypes having been identified in the major dairy and beef cattle breeds
(Lewin, 1996). Recent work has demonstrated breed-specific levels of
heterozygosity on this chromosome (Weimann et a l, 2003). Expression of BoLA
.class II has been documented on a wide range o f bovine cell-types including B- 
cells (Lewin et a l, 1985), activated T-cells (Taylor et a l, 1993) and mammary 
epithelial cells (Fitzpatrick e ta l,  1992).
7 .4 .2  Soluble acquired immunity
There are a multitude of cytokines secreted by a multitude of cell types acting as 
the soluble mediators of acquired immunity. However, IFN-y and IL-4 are taken 
as the signature cytokines of Th-1 and Th-2 type immunological responses.
1.4.2.1 Interferon-y
Interferon-T is produced by a subset of T-cells (Th-I), some CD 8 + T-cells and 
NK cells and activates T-cells, B-cells, NK cells and macrophages. Interferon-y 
[BTA5 q22-q24; (Chaudhary et aL, 1993)] is a major stimulatory signal for 
macrophages (Foss and Murtaugh, 2000). It enhances NK cell activities and 
stimulates B-cell production o f the immunoglobulin IgG2a while lowering
1
,ï;
19
,T?
Î
_
production of IgGs, IgG], IgGzb and IgE in mice (Finkelman et a l, 1988). 
Production of IL-4 by helper T-cells is inhibited by IFN-y while T-cell 
production of MHC Class I but not Class II molecules is enhanced (Billiau, 
1996). Interferon-y also activates macrophages, greatly promoting the 
destruction of ingested microorganisms.
1.4.2.2 Interleukin-4
Interleukin-4 (IL-4) is secreted by activated Th-2 cells and targets B-cells, T- 
cells, macrophages, endothelial cells, fibroblasts and mast cells. IL-4 [BTA7 
ql5-q21; (Buitkamp et aL, 1995)] is required for stimulation and differentiation 
of B-cells (Estes et a l, 1995) and is important for the progression o f resting T- 
ceils into cytotoxic T-cells (Klein and Horejsi, 1997).
1.4.2.3 Hum oral acquired im m unity
Having invaded the body, pathogens may replicate in two main sites. If they 
become intracellular, they tend to be controlled by cell-mediated immunity 
whereas if they multiply in the extracellular fluids, they are dealt with by 
humoral immunity via antibody.
1.4.2.4 B-cells
B lymphocytes (B-cells) are phenotypically defined by expression of the B-cell 
receptor (BCR), effectively membrane-anchored immunoglobulin (Chaplin, 
2003). The majority o f B-cells are concentrated within the tissues, especially the 
cortex o f lymph nodes, the splenic marginal zone, the bone marrow and intestinal 
Peyer’s patches, with the remainder found in the circulation (von Boehmer and 
Kisielow, 1990). B-cells defend against extracellular pathogens by (1) producing 
antibodies (Morafo et al., 1999) and (2) endocytosis with subsequent antigen 
processing and expression of peptide fragments with MHC Class II proteins. B- 
cells are dependent on dendritic cells for activation and modulation at all stages 
of development, either directly or indirectly via helper T-cells (Banchereau and 
Steinman, 1998).
The BCR is Y-shaped, just like immunoglobulin consisting of both heavy and 
light chains. Another B-cell receptor, the FcR, has two general classes: activation 
(ITAM) and inhibitoiy (ITIM). Both types o f FcR bind antibody with similar
2 0
affinity and specificity so that a functional balance operates and they are often 
found co-expressed on the B-cell surface (Kurosaki, 1999).
Random genetic rearrangement during B-cell differentiation, including allelic 
exclusion and editive processes on self-reactive proteins, leads to the assembly of 
the mature BCR antigen receptor (Bassing et a l, 2002). As Figure 1.2 shows, 
when a foreign multivalent antigen binds to the BCR, four processes are 
triggered: (1) B-cell proliferation, (2) B-cell differentiation into antibody- 
producing plasma cells, (3) memory cell formation and (4) antigen presentation 
to T-cells (Alam and Gorska, 2003).
Lymph node germinal centres are areas of intense B-cell division, with constant 
selective mutative pressures for improved antibody affinity (Przylepa et a l,
1998). Activated T-cells “help” B-cells to mature, by releasing cytokines and by 
direct cellular interaction via the CD40 receptor (Chaplin, 2003). This
Iengagement facilitates B-cell proliferation and differentiation, the development of immune memory, controlled somatic hypermutation, antibody secretion and 
antibody isotype switching. Naïve B-cells express only IgM antibody in cattle, 
but following stimulation by helper T-cells, other antibody isotypes, IgG, IgE 
and IgA, are produced with identical antigen specificity (Alam and Gorska, 
2003). The primary humoral immune response is characterized by detectable 
serum IgM and reactive IgM-expressing B-cells (Abbas et a l, 1996).
■ i'S
Following clonal expansion, most B-cells differentiate into plasma cells and 
enter into the tissues but a small yet critical memory cell subset migrate centrally 
to the lymph node germinal centres (Berek, 1992). Any persistent antigen 
fragments sequestered onto follicular dendritic cells will continue to drive 
memory cell expansion even after resolution of the initial infection (Campos and 
Godson, 2003). The anti-apoptotic factor BCL2 [BTA24; (Larsen et a l, 1999)] 
and the associated pro-apoptotic factor BAX [BTA 18; (Reyes and Cockerell, 
1998)] are important molecules at this stage. Effector memory cells tend to 
concentrate in tissues at or near the initial site of antigen encounter (Picker et a l, 
1993), where they produce a broader spectrum of cytokines than naïve cells 
(Kaech et a l, 2002) and proliferate and differentiate much faster than naïve cells 
(Rogers et a l, 2000). This means that memory cells can respond more quickly to
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lower levels of antigen, presented by more types o f APC than naive cells, which 
translates to a faster, more effective secondary humoral response. However, there 
is a transitionary delay as memoiy cells convert to effector cells, which 
depending on the pathogen may prove significant (Zinkernagel, 2002).
As effector B-cells can bind only one antigen they make very effective APC,
capable of activation with 1000-fold less antigen than non-specific APC such as ..........................macrophages. Following initial priming, the existence of so many identical B-cell 
clones makes secondaiy antibody responses much stronger and more rapid (as 
shown in Figure 1.2). With age, effector B-cell clonal populations expand and 
contract according to antigen exposure but B-cell memory populations persist 
(Maruyama et a l,  2000). Many cytokine and receptor molecules are involved in 
this process but CD40 and CD 154 (Manoj et al, 2003), and CD28 [ BTA2 q31; 
(Parsons et a l, 1996)] are of particular importance.
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.The provoking antigen and the prevailing cytokine environment deteiinine how 
the B-cell reacts and the immune response is produced. T-cell-independent 
mechanisms of B-cell activation do exist for polymeric antigens such as bacterial 
lipopolysaccharides (eg. Escherichia coli, Salmonella flagellin) but produce IgM 
only and result in weak immune memory. Without helper T-cell support, 
antibody isotype class-switching is not triggered. The Th2 subpopulation of 
helper T-cells promote IgGi, IgA and IgE specific immunoglobulin by secretion 
of IL-4, IL-5, IL-6 , IL-10 and IL-13 whereas Thl cells secrete 11-2 and IFN-y 
which produces a much more generalised B-cell proliferation and polyclonal 
antibody secretion (Tizard, 2000).
Using human influenza virus as an infection model, Ada (2001) found that 
systemic levels of infectious virus and numbers of CD8 + cytotoxic T-cells rise in 
the first four days post-infection. Serum levels of infectious virus fall as the 
number of CD8 + cytotoxic T-cells peaks but both fall to low levels by day 10.
Large numbers of memoiy cytotoxic T-cells are present between 14 and 40 days,
some persisting for up to a year. After 4 days, the levels of effector B-cells begin
■ „to increase, IgM-producing cells developing first followed by IgG- and IgA- 
producers, peaking at about 2  months, again persisting systemically for about a 
year (Ada, 2001).
1.4.2.5 Im m unoglobulins
Immunoglobulins are soluble B-cell receptors or antibodies found unbound in 
plasma and other secretoiy fluids. Immunoglobulins are products unique to B- 
cells, glycoproteins that bind antigen, the interaction being non-covalent 
(reversible) and highly specific (Tizard, 2000). Bound BCR or free antibody 
differ from TCR (of T-cells) in that the former can bind unprocessed antigen 
molecules.
The humoral response is based on antigen epitopes. An epitope is the portion of 
an antigen which is targeted and bound by an antibody. Binding affinity is the 
strength of the interaction between a single antigen binding site on the antibody 
and its specific antigen epitope, i.e. valency = one. Avidity is the total affinity of 
a single multivalent antigen molecule with a single multivalent antibody 
molecule. Antibody affinity intensifies with repeated antigen exposure while
antibody avidity increases with the number of repeating identical epitopes per 
antigen molecule. The ten antigen binding fragments {Fab) of an IgM molecule 
may have only moderate affinity individually but due to the large number of 
antigen-binding sites the molecule has high overall avidity. In murine viral 
models, neutralizing IgG antibodies are required in serum concentrations of 1 X 
10'  ^ M and with an avidity of at least 1 X 10  ^ M to be protective (Zinkernagel, 
2003).
All immunoglobulins have a similar basic monomer structure comprised of two 
heavy chains (50 kDa) (a, y, 5, e, p) and two light (25 kDa) chains (k  or 1). 
Heavy chains [BTA21 q23-q24; (Chowdhaiy et a l, 1996)] contain 4-5 domains 
each of about 110 amino acids while light chains [BTAl7; (Tobin-Janzen and 
Womack, 1992)] have only about 220 amino acids.
Genes identified within the heavy chain cluster include IGHM, IGHGl, IGHG2, 
IGHG4, IGHA and IGHE. There are three expressed cattle Cy genes, each 
different in structure and by implication, function (Symons et a l, 1987; Symons 
e ta l,  1989).
The amino acid sequence at the amino (N) terminal portions of the heavy (H) and 
light (L) chains vary greatly from one antibody molecule to another and are 
termed Vh and Vl, respectively. It is the juxtaposition of one hypervariable Vh 
segment and one V l segment that creates the Fab domain, duplicated on each 
arm of the molecule. This determines the specificity of the antibody. There are 
three hypervariable regions in both the heavy and light chains which through 
folding give the molecule specific and unique antigen binding pockets (Chaplin, 
2003). At the other end o f the immunoglobulin molecule, the carboxyl (C) 
terminal portions of the heavy and light chains are constant within each subclass. 
The heavy chain constant regions link to form the Fc (crystalizable fragment) 
domain of the molecule, responsible for the biological activity of that antibody. 
There are five distinct classes or isotypes of immunoglobulin dependent on the 
constituent heavy chains (in brackets): IgA (a), IgD (5), IgE (e), IgG (y) and IgM 
(p), with distinct structural and functional characteristics, each optimised for a 
specific group of pathogens or deployment within a specific environment 
(Tizard, 2000).
Serum IgM has a pentamer structure, -5  day half-life, and potentially ten 
epitope-binding sites. It is too large to leave the circulation but is a potent
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complement activator. Monomeric IgG, with two epitope-binding sites, has the 
longest half-life ( - 2 0  days), enters and is effective in tissues and is involved in 
complement activation and antigen opsonization. In total, more IgA is produced 
than any other antibody. Dimeric IgA has a half-life of ~5 days and predominates 
in mucosal secretions with the Fc portion attaching firmly to the mucous matrix. 
The polymeric immunoglobulin receptor (pIgR) [BTA 16 ql3; (Kulseth et a l,
1995)] is important to the transcytosis of IgA at mucosal surfaces. 
Immunoglobulin-E is a monomer with two epitope binding sites and an Fc 
portion which readily binds with eosinophils. It mediates parasitic and allergic 
reactions, triggering mast cell and basophil activation in skin and mucosae.
The isotype of an immunoglobulin molecule can change; “class switching” is the 
process by which a B-cell alters expression of heavy chain isotype thereby 
altering the Fc domain and function o f the antibody (Estes, 1996). Class 
switching is coordinated by T-cell derived cytokines and T-cell/B-cell 
interactions via the CD40 receptor (Estes, 1996). Each B-cell can produce only 
one light chain isotype. Minor diversity in the actual amino acid sequence of a 
particular isotype produces different antibody allotypes, i.e. IgG2g, IgG2b.
During development, the random shuffling o f the many variable-region genes 
confers each B-cell with a capacity to produce a distinctive and unique antibody 
(Matsuda and Honjo, 1996). The binding site consists of at least five fragments 
of random peptides, encoded and blended from a libraiy o f genes allowing very 
diverse structures to be created from a limited genetic “hardware”. Germ line 
antibodies are those produced based on recombination of inherited genetic 
information. In addition, selective somatic mutation of the B-celFs variable- 
region genes continues within the germinal centres o f secondary lymphoid 
tissues, to force the evolution of B-cells that produce higher affinity antibodies 
(Schwartz, 2003). Together, these processes ensure the diversity o f antibody 
repertoire critical to animal survival (Butler, 1998). In mice, quantitative trait loci 
(QTL) for IgG antibody against exogenous rhodopsin were mapped to murine 
chromosomes 1, 5 and 13 -  all iion-MHC immune response genes (Wu et a l,
1996).
Actual binding of antibody to antigen occurs by two competitive models; lock- 
and-key and induced-fit forces, with hydrogen bonds, ionic bonds, hydrophobic 
and Van-der-Waals interactions all involved (Braden and Poljak, 1995). On
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initial encounter, a large germliiie antibody molecule modifies and re-conforms 
its shape to flexibly grasp antigens by a process of induced-fit. As the interaction 
continues, somatic mutation produces antibody molecules with binding sites 
precisely complementaiy to the antigen in shape and electronic charge so that the 
grasp becomes fixed and affinity increases (Mariuzza et a l, 1987).
Infection is controlled by circulating IgG and IgM antibodies by: (1) 
agglutination of infectious agents and opsonization of particles, both of which 
facilitate phagocytosis, (2) serum neutralisation of viruses and toxins, (3) binding 
to pathogen thereby blocking host cell attachment or initiating the classical 
complement pathway with membrane-attack-complex (MAC) formation, (4) 
mediating antibody-dependent cell-mediated cytotoxicity and (5) immobilisation 
of bacteria/protozoa (Roth and Perino, 1998).
Once released systemically, levels o f IgG negatively feedback to regulate their 
own production. This IgG-mediated suppression is antigen-specific, non-epitope- 
specific in most cases and stronger in higher affinity antibodies than lower 
affinity (Heynian, 2003). The inhibition may act by (1) antigen/antibody 
complexes co-binding to specific BCR and FcyRIIB receptors on B-cells to 
directly down-regulate antibody secretion or (2 ) antibodies “masking” antigen 
from B-cells, blocking interaction and subsequent immunostimuiation. In 
addition antigen/antibody immunocomplexes may be taken up by B-cells more 
efficiently than antigen alone with either positive or negative feedback effects 
(Heyman, 2003).
Bovine humoral immunity is unusual, as cattle appear to lack functional IgD 
antibody (Zhao et a l, 2002) and have a unique distribution of antibodies within 
specialised secretions such as colostrum (Butler, 1983). The levels of IgGi and 
IgG2 in normal adult bovine sera are almost equivalent (Butler et a l, 1994), the 
latter being the most important opsonin for neutrophil and macrophage 
phagocytosis. As with most mammalian species, IgM and IgA form a small 
proportion of overall serum immunoglobulins, but unlike most species, IgA in 
cattle exists in a dimeric form. Cattle are unusual in having light chains with 20- 
fold more X-chains than K-chains (Butler, 1998). Allotypic variants o f bovine 
immunoglobulins exist for IgGi, IgG2 and IgGs (trace) but only appear to be 
functionally significant for IgG] (Bastida-Corcuera et a l, 1999).
s
It should always be recalled that due to the transient and compartmentalised 
dynamics of immune reactions, the processes and genes detected as important by 
any particular experimental investigation will vary according to what, when and 
how measurements are made (Hawken et a l, 1998). For each 
immunostimulatoiy event or infection, a unique host/pathogen/environment 
combination occurs which may defy exact field repetition or experimental 
replication (Horin, 1998).
i.5  Colostrum
Due to the syndesmochorial arrangement o f the ruminant placenta, calves are 
born agammaglobulinémie (Redman, 1979). Bovine colostrum contains large 
amounts of immunoglobulins derived from the maternal bloodstream (Sasaki et 
al, 1977), which the calf absorbs intact into its systemic circulation, after 
ingestion. As endogenous production is neglible, levels of passive serum 
antibody in calves are therefore determined within 24 hours of birth (Besser et 
a l, 1987). However this passive immunity does not provide complete protection 
from infection (Baker et a l, 1989), but rather attentuates neonatal disease 
allowing a form of physiological vaccination to occur (Zinkernagel, 2003).
1.5.1 Colostrum metabolism and function
Bovine colostrum contains highly enriched levels of fats, proteins and peptides, 
fat-soluble vitamins, minerals, nucleotides, poly amines, enzymes, hormones, 
growth factors and cytokines (Campana and Baumrucker, 1995) and most 
crucially, greatly elevated concentrations of antibodies (Morin et a l, 1997). 
Typically bovine colostrum contains 100-700 mg/dl IgA, 300-1300 mg/dl IgM 
and 3400-8000 mg/dl IgG, thus IgG accounts for 65-90% o f the total antibody 
content. Colostrum quality is affected by the balance between colostrogenesis 
and lactogenesis, parity o f the dam, vaccination programmes, previous wild-type 
infections, length o f diy period and prepartum milking (Quigley and Drewiy, 
1998).
Transport of colostral antibodies occurs through a transiently permeable 
intestinal wall, then via the lymphatic system into the ca lf s general peripheral 
circulation (Arthington et a l, 2000), with absorption localised primarily to the
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jejunum and ileum (Bush et a l, 1971). A combination of high abomasal pH, 
colostral tiypsin-inhibitors causing low intestinal proteolysis and unique 
pinocytic activity of the neonatal intestinal epithelial cells permits absorption of 
intact protein macromolecules (Clover and Zarkower, 1980). On contact, 
colostral antibody binds to a specific Fc receptor {FcRri) on the neonatal intestine 
(Mayer et a l, 2002), exciting a limited burst of pinocytosis. Macromolecule 
internalisation halts after exhaustion o f this pinocytic activity, and maturation of 
the enterocyte's intracellular digestive apparatus has occurred (Stott et a l, 1979). 
The FcRn [BTA l8  81cM; (Doleschall et al., 2005)] receptor has a molecular 
structure very similar to the MHC class I molecule and in adult life protects IgG 
from catabolism and degradation, acting as a chaperone protein inside the 
phagocytic lysosome (Ghetie and Ward, 1997).
Antibody isotypes are absorbed by different mechanisms: IgG absorption has 
been shown to be linearly proportional to colostral concentration up to a ceiling 
value (Stott and Fellah, 1983). Antibody transfer is thought to be highly 
enhanced from serum to colostrum in the dam, with no significant difference in 
rate reported in BRSV and BHV-1 specific colostral antibody levels, in titre- 
matched vaccinated and unvaccinated dams (Ellis et a l, 1996). Vann et al 
(1995) ranked absorption efficiencies as IgM > IgG] > IgA > IgGi with an 
overall effective immunoglobulin uptake o f - 2 2 % after six hours. 
Immunoglobulin-G absorption decreases linearly from 6  to 48 hrs post-calving in 
bovine neonates, effectively ceasing after 36 hours (Abel Francisco and Quigley, 
1993; Vann et a l, 1995). The decline is due to a combination o f enterocyte 
maturation, intensifying secretion of digestive enzymes (Guilloteau et a l, 1984) 
and bacterial colonisation o f the sterile gut (James et a l, 1981). However, up to 
30% of neonatal calves which ingest colostrum remain 
hypogammaglobulinaemic (Burton et a l, 1989b), with serum IgGi levels less 
than 10 mg/ml post-absorption (Rea et a l, 1996).
Passive serum antibody levels have peaked at 24-26 hours postpartum in suckled 
beef calves (Logan and Gibson, 1975). From then to -1 0  weeks old, total serum 
antibody declines with negligible endogenous production evident (Rajala and 
Castren, 1995). Maternally-derived antibodies become undetectable between 95 
and 231 days (Brar et a l, 1978).
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1.5.2 Other colostral functions
1.5.3 Environm ental effects on colostrum
Final levels of absorbed colostral antibody depend on many highly variable 
factors: antibody isotype (Selman et a l,  1971a), volume and quality of 
colostrum, time of first feeding, feeding method, environmental temperature 
(Donovan et a l, 1986; Olson et a l, 1980), seasonal effects (Gay et a l, 1983), 
dystocia (Weaver et a l, 2000), calf stress (Johnston and Stewart, 1986), and calf 
birthweight, vigor, and dam behaviour (Selman et a l, 1970). Heifers produce 
lower quality colostrum than cows (Chelack et a l, 1993) and lactation number or 
parity has been linked to colostral quality (Pritchett et a l, 1991), Hammon and
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In addition to a transient proteinuria post-natum, antibody clearance occurs 
primarily due to resecretion into the small intestine. This process allows 
significant functionality to be retained, providing useful local but short-term 
protection from enteritis (Besser et a l, 1987). Some antibody clearance is also 
accounted for by dilution effects due to increasing body size and blood volume 
and general protein catabolism and turnover.
Although the primary purpose of colostrum is the passive transfer of antibodies, 
it contains a substantial and viable cellular element, predominantly lymphocytes. 
This component may be at concentrations of 1x10^ per ml, the majority of which 
are T-cells, the remainder containing a high macrophage component (Ellis et a l, 
1996). These cells can survive up to 36 hrs once ingested, often penetrating the 
intestinal wall and migrating to mediastinal lymph nodes (Liebler-Tenorio et a l,
2002). Calves which received leukocyte-depleted colostrum had significantly 
lower IgA and IgM levels than calves which ingested whole colostrum (Riedel- 
Caspari and Schmidt, 1991).
Beyond its immunomodulatoiy role, the volume, quality and timing of colostrum 
intake greatly affects many metabolic and endocrine factors in neonatal calves, 
significantly the levels of insulin, glucagon, prolactin and growth hormone 
(Blum et a l, 1997; Hadorn et a l, 1997; Hammon et a l, 2000; Rauprich et a l,
2000).
I
1.5.4 Anim al effects on colostrum
Blum (1998) obsei-ved prolonged elevation o f serum IgG levels from extended 
feeding o f colostrum. Poor dam pre~partnm nutrition reduced IgG absorption in 
the resulting calf (Hough et a l, 1990). Many of these factors combine to 
contribute to the wide range of maternally-derived serum antibody levels in 
calves, even within identical management systems.
The regime of colostrum feeding can greatly influence resulting efficacy of 
antibody uptake (Quigley and Drewry, 1998). Calves that suckle their dams tend 
to begin consumption later and consume a smaller critical volume than nipple- 
fed animals, so reducing the total efficiency of passive antibody transfer 
(Brignole and Stott, 1980; Logan et a l, 1981; Selman et a l, 1970). In contrast, 
Suh et a l (2003) described significantly higher serum IgG levels in beef calves 
compared to dairy calves. Use of oesophageal feeding as a method of colostrum 
administration is contentious. Lee et a l (1983) found marginally lower IgG 
serum levels with this method, the rationale being that oesophageal feeding 
places colostrum into the neonatal rumen delaying entry into the abomasum and 
intestine (Lateur-Rowet and Breuink, 1983). However other authors reported no 
detrimental immune effects (Adams et a l, 1985; Molla, 1978). Best practice was 
described as four litres of colostrum supplied inside the first six hours of life 
(Besser et a l, 1991). The reported half life of bovine maternally derived passive 
IgGi ranges from 16 to 26 days (Besser et a l, 1987; Brar et a l, 1978; Gay et a l, 
1983; McGuire et a l, 1976; Sasaki et a l, 1977).
Holstein calves were described as being more efficient at absorbing colostral
antibody than Ayrshire calves (Baumwart et a l, 1977). Jersey calves were
.reported as having twice the passive antibody levels of comparable Holsteins 
(Tennant e ta l,  1969) and Friesian/Ayrshire crossbreds have been documented as 
having greater antibody absorption than purebred Ayrshires (Selman et a l,
1971a).
Bradley et a l (1979) found Hereford calves to have significantly greater levels of 
antibody than Simmental calves, with offspring from multiparous dams having 
significantly more passive serum antibody than those from primiparous dams.
Halliday et a l (1978) recorded Shorthorn/Galloway crossbred calves as having
1;
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higher concentrations of colostral IgGi and IgM than Hereford/Friesian crossbred 
calves. Similar differences between crossbreds were demonstrated by O ’Kelly 
(1991). Offspring vigour may be important in these findings as less vigorous 
(very heavy or very light) calves consume less colostrum during the first crucial 
hours. Muggli et al (1984) described significant variation due to calf breed in 
neonatal passive serum antibody levels in Angus, Red Poll and Hereford breeds, 
ranked as listed. A general increase in calf post-natal activity in the former cattle 
breeds may increase colostrum consumption, explaining this difference (Muggli 
e ta l,  1987).
No significant differences in colostral IgGi concentration were reported for calf 
sex, calf sire, sire-line or dam-age (Gilbert et a l, 1988). However sire-within-line 
and level of dam inbreeding were found to be highly significant at 24 and 36 
hours. Levels of absorbed serum IgGi were found to decrease as inbreeding 
increased but this effect may be confounded by management differences (Gilbert 
e ta l,  1988).
In another study, Norman et al (1981) found calf sex was not generally 
significant apart from a dilution effect in male calves (commonly larger), but did 
find dam-age as significant. The study reported that crossbred dams produced 
calves with higher IgG and IgM concentrations than purebred dams with 
heritabilities of 0.52±0.28 and 0.69±0.30 for IgGi at 24 and 36 hrs with 
equivalent values of 0.30±0.26 and 0.35±0.26 for IgM. Two further studies also 
found levels of calf IgGi positively correlated with dam age (Frerking and 
Aeikens, 1978; Mueller and Elleinger, 1981). Muggli et a l (1987) described no 
difference in serum IgGi levels related to sex of calf but found antibody 
negatively correlated with birthweight in Herefords and positively correlated in 
Angus calves. Later studies found that cows producing crossbred calves had 
greater total immunoglobulins and total IgG and IgA concentrations in colostrum 
than cows producing purebred calves (Muggli et a l, 1987; Vann et a l, 1995), 
termed the sire-of-foetus effect on the dam’s lactation.
A negative correlation has been described for birthweight and neonatal IgGi 
levels in both cattle and sheep (Cabello and Levieux, 1981; Selman et a l, 
1971b). Positive selection for this production trait may indirectly lead to 
reductions in transferred IgGi levels, due simply to dilution effects. However 
other authors found this association not significant (Muggli et a l, 1984). That
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study found dam (1) dystocia (p<0.05); (2) calf-age (p<0.05); (3) dam-age 
(p<0.05) and calf-breed (p<0.01) as significant for levels of maternally-derived 
calf serum IgGi. Heritabilities for sire and maternal effects were established as 
0.09±0.09 and 0.27±0.17 respectively (Muggli e ta l,  1984). Levels of IgG], IgG] 
and IgM were found to be positively correlated with daily weight gain until 42 
days old; thereafter the association subsides (Halliday e ta l,  1978).
Laegreid et al (2002) described a significant association with poor colostrum 
absorption and specific haplotypes (especially haplotype 3) for the FCGRT gene 
(coding for the FcRN receptor) on B T A l8 . A strong linkage between failure of 
transfer o f passive antibody and the p]M gene on BTAIO was reported by 
Clawson et a l (2004). Calves with the p]M marker AH27-3 were 10-fold less 
likely to absorb adequate passive antibody than other genotypes.
1.5.5 Immune effects o f colostrum
Neonatal immune unresponsiveness has many causes including phenotypic and 
functional immaturity in CD4+ T-cells, low expression of MHC class II in 
neonatal dendritic cells and actual numbers o f T-cells and APC being several 
orders lower in infants compared to adult humans (Jafarzadeh and Shokri, 2003). 
A similar immunological immaturity is described in young calves (Barrington 
and Parish, 2001).
Receiving antibodies passively via colostrum actually inhibits the development 
o f the endogenous immune system across many species (Crowe, 2001; Fitch, 
1975; Smith and Ingram, 1965). Both systemic and mucosal immunoglobulin 
responses are all down-regulated by feeding of colostrum (Kimman et al, 
1987a). In colostrum-deprived calves low level antibody synthesis begins within 
one week, but this is delayed up to one month in colostrum-fed calves (Clover 
and Zarkower, 1980). The mechanism is believed to act by specific antibody 
binding to the B-cell FcyRIIB surface receptor signalling inhibition o f antibody 
production (Heyman, 2003) or by formation of antigen-antibody complexes 
leading to the removal of the stimulus, without reaction from the host immune
S '
system (Crowe et a l, 2001). The immune suppression exerted by passive
i
antibody may also be due to “hiding” o f antigenic sites by maternal passive IgG, 
diminished helper T-cell activity or increased suppressor T-cell activity, a
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general immaturity of the immune system or any combination of these factors 
(Kimman et a l, 1987a).
Bovine virus diarrhoea virus challenge experiments have found anamnestic 
responses at second challenge in calves previously challenged when they had 
high serum levels o f passive serum antibody (Ridpath et a l, 2003). Maternally- 
derived antibody may permit limited viral replication at the first challenge. This 
viral replication occurs below the threshold that would cause clinical disease but 
is high enough to produce a weakly protective T-cell and B-cell lymphocyte 
response. Evidence of such physiological vaccination is consistent with 
organised perinatal vaccination studies in calves (Ellis et a l, 1996).
In mice and humans, the relative eontribution of cellular immunity, primarily 
CD4^ and CD8  ^ T-cells, has been found to increase according to circulating 
levels of passive serum antibody (Crowe et a l, 2001). This type of short duration 
immunity is an important substitute until induction of a more sustained antibody 
response occurs (Connors et al, 1991).
1.6 Vaccination
Vaccination has had a greater economic impact on livestock and poultry 
production than all other therapeutic and prophylactic disease treatments 
combined (Babiuk et a l, 1999) and remains one o f the most cost-effective 
method of reducing economic loss and suffering from animal disease 
(Bowersock and Martin, 1999).
Ideally vaccines should mimic natural infection by inducing strong, lifelong 
protective immunity against infection, in particular stimulating immunological 
memory (Terpstra and Kroese, 1996). Immunological memory results from both 
antigen-specific and non-specific signals during the primary immune response, 
producing memory cells from naïve precursors in the host (Campos and Godson,
2003).
Four properties o f vaccines are critical to their effectiveness: (I) antigen- 
presenting cells must be stimulated to process antigen efficiently and induce 
appropriate cytokine production (2) both T-cells and B-cells should be stimulated
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in order to establish large populations o f their respective memory cells (3) helper 
and effector T-cells must be generated to several epitopes in the vaccine to 
overcome individual animal variation in MHC class II polymorphism and epitope 
properties (4) antigen should persist in appropriate lymphoid sites so that a 
population of antibody producing cells is established, providing medium-term 
protection (Tizard, 2000).
For viruses in particular, vaccines can act to (1) prevent initiation of primary 
infection by viral field strains, (2) reduce virus replication at site o f entry, (3) 
prevent or minimise systemic spread, (4) reduce virus shedding and (5) prevent 
establishment of viral foci which can lead to second waves of infection (Terpstra 
and Kroese, 1996).
As most infectious agents enter via mucosal surfaces, oral or intranasal vaccine 
delivery produces a local immunity with the greatest chance of preventing 
infection (Babiuk et a l,  1999). Individual host factors such as extremes o f age, 
poor nutritional status and pregnancy reduce the immunogenicity of a vaccine 
but the intrinsic pathogenesis of the infection and biological constraints of the 
immune system also limit vaccine effectiveness (Campos and Godson, 2003). 
Completely perfect protection without any pathogen replication is rarely 
achieved (Zinkernagel, 2003).
1.6.1 Types of vaccine
Live viral vaccines are based on avindent mutants, produced by treatment with 
mutagens, chemicals, radiation or multiple passage. Vaccine strain and inoculum 
concentration are critical factors dictating the immune response especially in the 
face o f maternally derived passive immunity (Hanly et a l, 1995).
Classically, inactivated vaccines contain virus rendered non-infectious by 
chemical inactivation (Van Oirschot, 2001). They are stable and safe but 
generally require adjuvant bases and repeat inoculations. As adjuvants improve, 
inactivated vaccines may provide a more prolonged immunological stimulus 
inducing higher booster effects than currently possible (Kerkhofs et a l, 2003). 
Inactivated vaccines have no replication phase in the host, so minimal cytotoxic 
cellular responses are triggered, and often, secretoiy IgA is not induced. Overall,
35
inactivated vaccines tend to provide a shorter and slower immunity than 
modified live vaccines (Hjerpe, 1990).
:
1.6.2 Factors controlling imm une responses to vaccines
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Live vaccines need fewer inoculations, no adjuvants and usefully induce IFN but 
do have disadvantages: ( 1 ) they are more labile, (2 ) are potentially open to 
recombinational events (Ridpath and Bolin, 1995), (3) may be contaminated with
■V
extraneous virus, (4) tend to be more pathogenic than inactivated vaccines and 
(5) can induce a carrier state (Roth, 1999).
Inactivated vaccines act as exogenous antigens, generally processed by CD4+ 
helper T-cells. The inclusion of adjuvants primes for a Th2 response producing 
an enhancement of the humoral response, while intranasal live vaccines induce 
predominantly a Thl response (Karupiah, 1998; London et a l,  1998). By 
definition, live virus vaccines infect cells and undergo replication, antigen being 
processed endogenously by host cells. Cytotoxic T-cells have a dominant role in 
the subsequent immune reaction. As IFN-y is induced by live vaccines (Woolums 
et a l, 2003), protection can be veiy rapid in susceptible animals even in the face 
of an outbreak (Makoschey and Keil, 2000). Activated T-cell clones and non- 
MHC restricted NK cell cytotoxicity act as the major sources o f this IFN-y 
production (Woolums et a l, 1999). Polarisation by IFN-y production towards a 
Thl response has not been described in cattle to date (Brown et a l, 1998). If a 
live vaccine is boosted with an inactivated vaccine, the immune effect is 
enhanced, perhaps due to the Thl priming (Kerkhofs et a l, 2003).
Farm management influences, such as nutrition, animal density and environment
.can all physiologically confound immune responses (Ott, 1996). In addition, the
...
physiological status of the individual, i.e. pregnancy, puberty, or lactation, 
tremendously influences the transcription of genes related to the immune 
response (Kelm et a l , 2001).
As previously discussed, maternally-derived passive antibody suppresses the 
immune response induced by vaccination, the effect being dose-dependent, and 
isotype- and antigen-specific (Ellis et a l, 2001a). Colostrum ingestion eliminates 
IgG-positive B-cells from mesenteric and peripheral lymph nodes (Aldridge et
'
al, 1998) which may facilitate immunotolérance o f maternally-derived antibody 
and increase its longevity.
The immune response of animal populations, influenced by genetic and 
environmental factors, follows a Gaussian distribution so that 100% protection in 
all animals is an aspirational goal rather than realistic objective (Tizard, 2000). 
Using vaccines in outbred populations will always result in considerable 
variability in the level and type of immune response and the subsequent 
protection generated (Lofthouse and Kemp, 2002). Commercial cattle producers 
use vaccines to control disease at a population level rather than at individual 
animal level with herd immunity being the primary aim so reducing overall 
disease transmission rates.
Similarly, the critical dose o f vaccine necessaiy to stimulate effective protection 
varies among individual animals. Using an inactivated BRSV vaccine, Ellis et al 
(2 0 0 1 b)reported substantial differences in immune response by vaiying the 
inocculated antigen concentration. The minimal vaccinal dose required for 
effective individual immunity within any given population also has a normal 
distribution, termed the “tolerance distribution” (Terpstra and Kroese, 1996). 
Within any genetically heterogenous population, vaccine responses are a 
continuous, quantitative phenomenon due to both environmental and host factors. 
It is oversimplistic to divide vaccine responses into success or failure, as a rich 
spectrum of responses is much more appropriate (Ovsyannikova et a l, 2004a). 
Sex may affect vaccine response. The onset of puberty in cattle is strongly 
influenced by nutrition (Sejrsen, 1994) and is also heritable (Splan et a l, 1998). 
Hypothalmic gonadotrophin-releasing-hormone has been implicated in the 
modulation of humoral and cellular immune responses and the hormone 
oestradiol is immunostimulatory while testosterone is immunosuppressive 
(Tanriverdi et a l, 2003).
Vaccine non-responsiveness has been explored previously. Expression of 
specific MHC haplotypes causing defects in antigen presentation, deficient 
antigen-specific T-cell or B-cell repertoires, weak helper T-cell function and 
various degrees o f immunological antigen tolerance are all possible reasons for 
failure of a humoral response (Jafarzadeh and Sliokri, 2003). Concurrent 
stimulation by several antigens seems to have no deleterious effect. No 
significant differences were reported in clinical signs or immune response
between weanling heifers, which received a live BRSV vaccine alone or in 
conjunction with 18 other polyvalent live or inactivated antigens (Carmel et al, 
1992).
1.6.3 Antibody response to vaccination
Generally, the levels of antibodies induced do not depict the extent, efficacy or 
entirety of the immune response and are a crude measure of the degree of 
immunoactivation (Martin and Bohac, 1986). Although vaccination and serum 
antibody levels are strongly associated, the humoral component represents only a 
portion of total immune mechanisms induced by the respiratoiy pathogens: 
BHVl (Denis et a l, 1994), BRSV (Sandbulte and Roth, 2002) and PIV3 
(Henrickson, 2003). A study by Bryson et al (1999) showed little correlation 
between the extent of pneumonic lesions and levels of serum PIV3 antibody. 
That study concluded that the level of antibody in nasal secretions provides a 
better index of host resistance to PIV3 infection than serum antibody levels 
(Biyson et a l, 1999).
Protection against BRSV has been reported without demonstrable antibody 
response (Ridpath et a l, 2003) but most human and bovine RSV studies suggest 
accumulative acquisition of resistance to lower respiratory disease associated 
with increasing levels of serum antibody (Ellis et a l, 1990). Recent work in 
cattle has suggested that although IgA dominates in nasal, lacrimal and salivary 
secretions, IgG is found in higher concentrations in the lower respiratoiy tract 
(Kalina et a l, 2005). Hammond et a l (1999) found that, in ponies, although no 
single in vitro parameter provided an adequate measure o f protection, a 
composite of several antibody characteristics such as serum level, avidity index 
and molecule conformation ratio could be used as a reliable measure of challenge 
resistance following vaccination against Equine Infectious Anaemia. Serum 
antibody concentrations do form an objective, reliable method, capable of 
assessing the immunogenic properties o f different vaccine products (Tollis et al,
1996), There are few workable alternatives: it is scientifically laborious and 
seems to be economically prohibitive to assess clinical efficacy of vaccines using 
field challenge trials beyond that required for drug registration.
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1,6.4 Adverse effects
Î
Vaccine failure can occur for many reasons, with unsatisfactory administration, 
immunosuppression, or inhibition by maternally-derived antibody being the most 
common. Management activities such as dehorning, weaning, handling, forced 
exercise and transportation are stressful to cattle. Stress has important 
immunosuppressive effects including decreased antibody response to primary 
vaccination, reduced phagocytic cell migration and inhibited lymphocyte 
function (Roth and Peri no, 1998). In pigs, both cell-mediated and antibody-based 
immune responses are influenced by basal levels of circulating corticosteroid 
which in turn are dictated by the animals social rank (Messing et a l, 1995). 
Although live vaccines are in the main safe, some adverse effects have been 
reported. Some viral transmission from vaccinated to unvaccinated animals was 
recorded using live BHVl vaccines (Baker et a l, 1989). In addition, live BHVl 
vaccines have been found to enhance the clinical severity of infectious 
keratoconjunctivitis (George et aï., 1988), to induce meningoencephalitis 
(Furuoka et a l, 1995) and were implicated in vaccine-induced outbreaks of 
infectious bovine rhinotracheitis in cattle (Whetstone et a l, 1986).
Bovine respiratory disease (BRD) has been extensively investigated in recent 
years with numerous vaccines and antibiotics developed for its control. Bovine 
respiratory disease was described as the principal health problem for calf 
producers worldwide (Lekeux, 1995). It is particularly common during the initial 
45 days after calves have been weaned, transported and mixed with other animals 
(Roth and Perino, 1998), with cattle being highly susceptible when passive serum 
antibody wanes at three to four months old (Bryson et a l , 1978).
In a Northern Ireland bovine mortality study, encompassing 38% of the total 
cattle population, respiratoiy diease was the most common cause of death in 
animals aged between 1 and 24 months (Menzies et a l, 1996). An Irish feedlot 
survey based on 6400 cattle over 6  months found respiratory disease to be the 
most frequent cause of morbidity and mortality (Healy et a l, 1993). In US
a
feedlot cattle, BRD morbidity can reach 75% with case mortalities up to 50% 
(Rivera et a l, 2002). Gardner et a l (1999) found that steers treated for BRD had 
lower live and carcase weights, lower average daily weight gain and poorer 
grading scores. Substantial economic losses occur, as demonstrated by a Scottish 
study which found costs of £21 per animal at risk for 152 outbreaks (Gunn and 
Stott, 1996). The potential for viral disease will only increase as cattle 
populations grow larger and production intensification continues.
Viruses have multiple effects on antibacterial defences including impairment of 
mucociliary clearance, suppression of phagocytic cell function, and interference 
with lymphocyte function (Roth and Perino, 1998). Indeed, lung pathology is 
often enhanced due to the synergistic effects of superinfection by more than one 
respiratory virus (Kelling et a l, 1996). In particular, BVDV infection in cattle 
affects lymphocyte, macrophage and neutrophil function (Ketelsen et a l, 1979; 
Roth et a l, 1986) with immunosuppressive effects leading to enhanced disease 
from other concurrent infections (Elvander et a l, 1998).
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Ninety per cent of bacterial bovine pneumonias develop subsequent to a viral 
infection (Babiuk et a l, 1988). Viruses are obligatoiy, intracellular parasites with 
limited genomes that code for functions they cannot adopt from host cells 
(Strauss et a l, 1991). Viruses evolve by gene mutation, recombination and 
duplication and have very short generation intervals and high mutation rates 
(Gavora, 1996). A high reproduction capacity, short generation time and high 
mutation rate allow rapid changes in genotype. DNA viruses such as bovine 
herpesvirus 1 are more stable than RNA viruses (BRSV and PIV3) and tend to 
produce persistent or latent infections unlike the rapidly moving pandemics 
typical of RNA viruses (Strauss et a l, 1991). The latter tend to mutate at a much 
higher rate than DNA viruses, allowing their populations to contain a good deal 
more variability, so that many RNA virus quasi-species may exist within a single 
host (Domingo et a l, 2000). The cyclic emergence of virulent new strains of the 
avian pathogen Marek’s Disease virus, capable of overcoming previous 
generations o f vaccines, is typical of this constant viral evolution (Nair, 2005). 
Figure 1.3 illustrates the breakdown of bovine respiratoiy disease cases as 
submitted to the Scottish Agricultural College, Veterinary Service in 2002.
N o antiviral phannaceutical drugs are currently  m arketed for large anim al use 
and their deploym ent into such farm anim al species appears unlikely. C urrently  
in the UK, com m ercial vaccines are com m only used against m any viral 
pathogens o f  cattle including BRSV , B H V l, PIV3, BVDV, bovine coronavirus 
(B C V ) and bovine rotavirus.
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Figure 1.3 Breakdown o f confirmed causes of respiratory disease in cattle submitted 
to Scottish Agriculture College (SAC) over 2002. Data from SAC Veterinary Service 
monthly report, October 2002. Also shown are incidence levels o f Mycobacterium 
bovis, Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and 
Actinomyces pyogenes.
V accination will rem ain central to m anaging respiratory virus disease in cattle. 
B reeding for increased resistance to clinical viral disease and/or greater 
responses to vaccines is likely to  be a feasible and productive approach to this 
problem , rather than attem pting com plete pathogen eradication. A strategy o f  
optim ising anim al genetics to respond to vaccination has m any advantages, 
already discussed, including: public health and ethical issues, sustainability.
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product quality and animal welfare. It is a system readily adaptable to a wide 
range of management practices and is open-ended, encouraging host immunity to 
match the relentless evolution o f pathogens they must overcome.
-,L8 Genetic Control o f Disease Resistance
>
Resistance to infectious disease is extremely complex. It involves innate and 
acquired humoral and cell-mediated mechanisms, all o f which are under genetic 
control (Wilkie, 1984). Genetic control suggests effects on phenotype should be 
predictable, permanent and transmissible. It is this transmissibility that implies 
immune effects could be a target for selection. Ideally, breeding strategies should 
enhance both the humoral and cell-mediated components of immunity in a 
balanced manner so that extreme, harmful phenotypes are avoided (Mallard et 
a l, 1992).
The development and maintenance of resistance mechanisms has an energetic 
cost, i.e. energy is then not available for reproduction and survival, otherwise 
genes underlying host resistance would rapidly fix within a population. 
Counterintuitively, extreme dimorphism in innate resistance is a likely natural 
outcome as highly resistant animals compete successfully, then lose their 
competitive advantage over highly susceptible animals as pathogen exposure 
diminishes with the result that their resistance advantage declines (Boots and 
Bowers, 2004). Strong immune responses are favoured by extensive antigenic 
heterogenicity and sustained pathogen evolution but autoimmunity and auto- 
aggressive reactions favour individuals genetically programmed to have lower 
immune responsiveness (Wu et a l, 1996). These twin pressures are antagonistic, 
which, in addition to intricate host-pathogen relationships, means that no single 
genetic solution exists for all “real-world” scenarios. Functional diversification 
of immune responses is optimal in natural populations and, to some degree, is a 
constructive objective o f mass breeding programmes (Wu et a l, 1996).
Although species-specific and breed-specific resistances are important, it is the 
variability m an individual’s disease resistance that has the most potential for 
inclusion in future breeding programmes (Horin, 1998). Within any breeding 
programme, deliberate efforts should be made not to over-emphasise currently
%With particular reference to bovine respiratory disease, heritabilities (±sd) for 
incidence of pneumonia were estimated as 0.07 (±0.02), 0.29 (±0.03) and 0.17 
(±0.05) in Danish Red, Danish Friesian and Danish Jersey cattle breeds, 
respectively (Wassmuth et al., 2000). In a long-term study of beef calves, 
Snowder et al. (2005) found a peak heritability (±se) estimate o f 0.26 (±0.04) for 
resistance to bovine respiratory disease in composite cross-bred calves. However
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important but nonetheless singular aspects of the phenomenon of disease 
resistance (Horin, 1998). Enhancing resistance by breeding for single genes is 
possible, as exemplified by immunity to Escherichia coli diarrhoea in piglets 
(Edfors-Lilja and Wallgren, 2000), BEAD in cattle (Nagahata, 2004) and the 
prion diseases (Hunter et a l,  1997), but this is uncommon at present. The 
NRAMPl gene identified in cattle (Feng et a l, 1996) is responsible for resistance 
against intracellular pathogens in mice (Vidal et a l, 1993). Mutations in this 
bovine gene may predispose to diseases associated with Brucella abortus, 
Mycobacterium paratuberculosis and Salmonella spp. (Adams and Templeton, 
1998). Adverse effects are also possible — a defiency of IgGa antibody resulted in 
chronic non-responsive pneumonia in a young Holstein heifer (Francoz et a l,
2004) and in a young Holstein bull, an X-chromosome mutation affecting 
mucous gland function was described, predisposing to repeated rhinotracheitis 
(Seeliger et a l, 2005).
Heritable effects are also detectable for more complex phenotypes. Glass et al 
(2005) described differences in the kinetics of responses to Theileria annulata
infection based on cattle-breed (Holstein vs Sahiwal) in the acute phase protein, 
ai acid glycoprotein, as well as peripheral blood parasitaemia. Hansen et al 
(2003) described non-zero heritabilities for postnatal mortality among Danish 
Holstein calves due to non-specific infectious diseases. An association between 
polymorphisms at the defensin loci [BTA27 q l3-ql4; (Tarver et a l, 1998)] and 
somatic cell counts was reported in Holstein-Friesian cows (Ryniewicz et al,
2003). Abdel-Azim et a l (2005) described heritabilities (±s.d.) of 0.14 (±0.07) 
and 0.16 (±0.08) for uterine infections and udder health, respectively, in a four 
year study of milking Holstein cows (n =14473).
associations between human MHC and antibody responses to measles, mumps, 
rubella and hepatitis B. In particular, loci HLA-B8, HLA-B13 and HLA-B44 were 
correlated with seronegativity and HLA-B7 and HLA-B51 were associated with 
seropositivity.
Associations have been reported between both class I and class II BoLA genes 
and the incidence o f some bovine diseases including persistent lymphocytosis 
(Stear et a l, 1988), ketosis (Mejdell et a l, 1994) and mastitis (Oddgeirsson et 
al, 1988; Park et a l, 2004; Sharif et a l, 2000). Different BoLA haplotypes have 
been associated with resistance/susceptibility to mastitis in different breeds o f 
cattle (Mallard et a l, 1995; Mejdell et a l, 1994; Park et a l, 2004). Particular 
BoLA alleles have been linked with enhanced neutrophil function (Weigel et a l, 
1991), resistance to bovine leukosis (Xu et a l, 1993), dermatophilosis (Maillard
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.Muggli-Cockett et al (1992) were unable to detect significant heritable effects in
■a similar though smaller study o f bovine field respiratoiy infections.
Continuation of the existing tightly controlled and intensive breeding o f cattle 
has the potential to cause the loss of immunological fitness, due to restriction of 
genetic BoLA polymorphisms, with particular vulnerability to new emerging 
pathogens (Ballingall et a l, 2004b). Selection based on production traits alone 
may inadvertently lead to animals which cannot produce appropriate infection or 
vaccine responses (Newman et a l, 1996). Incorporating immunological traits, 
when designing classical biometrical genetic improvement programmes for farm 
animals is one solution (Soller and Andersson, 1998). This process is facilitated 
by the availability of new genomic techniques such as QTL analysis.
1.8.1 MHC control of im m unity
An association between the MHC and resistance/susceptibility to disease has 
been described in many species (McDevitt, 2002). In man, the genetic effects are 
significant but never absolute and such MHC-linked diseases tend to have 
prominent autoimmune characteristics (Sonderstrup and McDevitt, 2001). Major 
histocompatability complex genotype can also underlie responsiveness to 
vaccination, as demonstrated in human hepatitis B vaccines by MHC-DR3 (Alper 
et a l, 1989; Desombere et a l, 1998). Ovsyannikova et al (2004b) reviewed
et a l, 1996) and vaccine response/protection (Garcia-Briones et a l, 2000). Many 
authors have described positive correlations between .SoZX-associated genes and 
resistance to clinical or subclinical mastitis in cattle (Aarestrup et a l, 1995; Kelm 
et a l, 1997; Sharif et a l, 1998; Sharif et a l, 2000). Substitutions at the DRB3 
locus have been shown to significantly influence mastitis resistance in many 
breeds o f cattle (Dietz et a l, 1997). A successful reduction in prevalence of 
dermatophilosis was achieved by Maillard et al (2003) by selection against a 
BoLA susceptibility allele in the cattle population native to the island of 
Martinique.
Some BoLA haplotypes express products of single loci which, if promoted within 
intensive selective breeding programmes, could result in populations with limited 
MHC diversity and therefore questionable immunological fitness (Ellis, 2004).
1.8.2 Genetic control o f hnmoral im m nnity - all species
The genetic control of antibody response has been studied in many species, in 
addition to cattle. In a seminal experiment in selectively-bred mice, Biozzi et a l, 
(1982) reported that although antibody-dependent immunity (against 
extracellular pathogens) improved, macrophage-dependent immunity (against 
intracellular pathogens) decreased in mice selected for high serum antibody 
concentrations. It was concluded that in this group, extended persistence of 
antigen, due to a diminished macrophage function, prolonged the period of 
antibody stimulation so allowing serum antibody levels to increase but,by 
defmtion, decreasing CMI (Biozzi et a l, 1984; Ibanez et a l,  1988). By the 
sixteenth mouse generation, antibody levels in the high (H) antibody line were 
200-fold those o f the low (L) antibody line with 14% of this variation due to 
MHC gene effects (Mouton et a l, 1988). However, a comparable study in the pig 
failed to show a similar effect (Buschman, 1982).
Again, in selected lines of mice Covelli et al (1989) and Fuel et al (1995) linked 
H and L antibody responses back to the genome, in particular to markers on 
Mmu 12 {Igh locus), Mmu 17 {H~2 locus) and Mmu 6  {lyt~3, Tcrb or IgK  loci). 
To a lesser extent, Mmu 4, Mmu 6  and Mmu 8  also showed involvement. 
Another study estimated at least three additional loci controlling anti-rabies 
antibody production in mice previously bred for H and L antibody responses to
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sheep erythrocytes (De Franco et a l, 1996). Wu et a l (1996) tested IgM and IgG 
responses to bovine rhodopsin in F2-crossbred mice and calculated 67% of the 
total variance as genetic in origin. Strong QTL associated with antibody 
responsiveness were identified on Mmu 1 {D1MU14 locus), Mmu 5 {D5MU122 
locus) and Mmu 13 (D13Mit35 locus). The authors suggested that
polymorphisms from several loci contribute to each specific antibody response so 
that the inheritance of humoral response to any single antigen is, at least 
partially, dependent on transfer of these loci to progeny.
The more intensively farmed species have been investigated most in this area. 
Two experiments assessing levels of antibody in chickens induced by sheep 
eiythrocytes (SE) (Pinard et a l, 1992) and two bacterial antigens (Kean et a l, 
1994) reported heritabilities o f 0.31 and 0.21, respectively. Further poultry 
studies showed that females had greater anti-SE antibody levels than males 
suggesting sex-Iinkage in this species (Parmentier et a l, 2001), and heritabilities 
of 0.15 and 0.28 in chickens selected for FI and L antibody responses to SE, 
respectively (Bovenhuis et a l, 2002). Quantitative trait loci for SE-induced 
antibody responses in a second-generation F2-cross of H and L lines were 
identified on chicken {Gallus gallus autosome); GGA6, GGA9, GGA15, GGAI6 
(MHC-linked), and GGA27 (Siwek et a l,  2003b). The same study highlighted 
distinct sets of QTL operating for primary and secondary antibody responses and 
further investigation by Siwek et a l (2003a) differentiated exclusive antigen- 
specific QTL e.g. primaiy antibody responses to SE on GGA5 and GGA23, from 
general non-specific QTL, on GGA3 and GGA14, for SE and keyhole limpet 
hemocyanin antibody responses.
In four generations, Krausslich et al (1983) produced a high-antibody line of 
pigs with a 64% improvement in antibody responses over non-selected animals. 
A heritability of 0.27 was estimated for antibody responses induced by keyhole 
limpet hemocyanin within chosen pig lines (Joling et a l, 1993). Strong evidence 
suggests positive production qualities associated with pigs selected for higher 
immune responses to chicken albumen (Mallard et a l, 1998). Pigs selected for 
high (H) immune response had larger litters, increased weight gains, and better 
vaccine responses than pigs selected for low immune responses (Magnusson et 
al, 1997; Mallard et a l, 1992). This was a general enhancement, with both 
vaccines formulated on carbohydrate and lipospolysacchride antigens inducing
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stronger genetic control than secondaiy responses, with heritabilities (h^ (±s.e.)) 
of 0.56 (±0.33) and 0.15 (±0.19), respectively. The same author reported 
associations between BoLA~W16 and high antibody response to human serum 
albumin, and BoLA-W2 and low antibody responses to the same antigen (Lie, 
1985). In adult daiiy cows, Mazengera et al. (1985) calculated mean heritabilities 
of 0.10 (±0.06), 0.10 (±0.07), 0.09 (±0.06) and 0.14 (±0.07) for naturally 
occurring levels of IgG], IgG2 , IgM and IgA, respectively.
Immunisation of three-week old calves with the antigens human erythrocytes and 
ovalbumin (OVA) produced antibody responses with h  ^ of 0.51 (±0.42) and 0.87
3
I ' .higher antibody levels in the H group, itself selected earlier on responses to 
another antigen. The frequency o f non-responders to both viral and bacterial 
vaccination was significantly greater in the L pig group as opposed to the H pig 
group (Wilkie and Mallard, 1998). Heritabilities for IgG response to Escherichia 
coli antigens 0149 and K 8 8  were estimated as 0.29 and 0.45, respectively, in a 
Yorkshire/Landrace crossbred population (Edfors-Lilja et a l, 1994). 
Furthermore, QTL with strong effects on IgG levels to these Escherichia coli 
antigens, 0149 and K 8 8 , were identified on pig chromosomes SSC6  and SSC5, 
respectively (Edfors-Lilja et a l, 1998).
Some researchers have investigated associations between production traits and 
immune responsiveness. Mashaly et a l (2000) reported that chickens selected for 
low (L) antibody response to SE were heavier than chickens with high (H) 
antibody respones while Cheng et a l (2001) demonstrated a negative correlation 
between levels of total IgG and productivity/survivability in selected chicken 
strains. In turkeys, selection for increased body weight lowered immune 
responses (Bayyari et a l, 1997). Cattle become more susceptible to bovine 
leukaemia virus as milk yields rise (Simianer et a l, 1991), and in an extension of 
the pig study described above (Magnusson et a l, 1997), mycoplasmal arthritis 
was more severe, but mycoplasmal pleuritis and peritonitis less severe, in the 
high antibody response pigs.
1.8.3 Genetic control o f humoral imm unity - cattle
A study by Lie (1979) in young Norwegian Red bulls vaccinated with human 
serum albumin found that primaiy antibody responses were influenced by
I
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(±0.50) respectively (Burton et a l, 1989a). Calves ranked consistently as high, 
moderate or low antibody producers to both antigens. Secondaiy responses to 
both antigens appeared more heritable than primaiy responses, although there 
was no correlation between responses to each antigen (Burton et a l, 1989a).
In the péripartum period, Detilleux et al. (1994) described mean h  ^ of between 
0.55 to 0.84 for naturally occurring levels of IgM, 0.24 to 0,63 for IgGz and up to 
0.43 for IgG] in adult Holstein cows. Newman et al. (1996), identified significant 
effects of both sire and BoLA type (in particular BoLA-W4, B0LA-W6 and BoLA- 
W7) on levels o f IgG antibody, induced by immunisation against the bacterium 
Brucella abortus in juvenile beef heifers. An association between the bovine 
allele LgG2^ (A2) and mastitis-based breeding values has been recorded (Kelm et 
a l, 1997) and Dietz et a l (1997) reported that the expression of allele BoLA 
DRBi.2'^24 correlated with increased levels of serum IgGa.
The antibody responses of Holstein cows to the antigens OVA and Escherichia 
coli J5 were evaluated and i f  were estimated as between 0.32 to 0.50, and 0.50 to 
0.58, respectively, vaiying significantly around parturition (Wagter et a l, 2000). 
Furthermore, Garcia-Briones et al. (2000) described associations between allelic 
variability in specific BoLA genes and the humoral response of Hereford steers, 
induced by vaccination against foot-and-mouth disease. In this study, BoLA gene 
types DRB3.2^12 and *18 were linked to high antibody levels without protection 
while DRB3.2*1, *3, and *7 were correlated with increased clinical protection to 
the virus. Recently, microarrays have been used to identify gene variability 
associated with high and low antibody responsiveness, in adult cattle to chicken 
albumin (Hernandez et a l, 2003), e.g. genes for IL-1(3, IL-11 and NK-cell 
(protein 4 precursor) were linked to low antibody responders.
Breed-associated differences in humoral responses have also been described. 
Following injection o f porcine erythrocytes, Angus calves had significantly 
higher antibody responses than Simmental calves (Engle et a l, 1999). Cole et al 
(2 0 0 1 ) linked dam-breed with antibody responsiveness to immunisation with a 
live BHVl vaccine. Purebred Angus dams had calves which responded more 
strongly to the vaccine than those from crossbred or purebred Brahma dams. 
Kashino et a l (2005), investigating antibody response to tick saliva {Boophilus 
microplus), described significant differences in specific IgG] and IgG2 between 
Nelore (resistant) and Holstein (susceptible) cattle breeds. Further bovine
humoral research has revealed a selective IgGz deficiency among Danish Red 
cattle which has been associated with reduced disease resistance (Jensen et a l,
1981).
It should be noted that a wide variety of techniques were used to measure 
antibody levels in the above studies including serum neutralisation, radial 
immunodiffusion, microhaemagglutination, flow cytometiy and ELISA. This 
reflects not only progress in laboratoiy practice and technology but also the 
individual strengths and weaknesses of each assay.
1.9 Project aims and objectives
Vaccination against bovine viral respiratory pathogens elicits a systemic 
antibody response in juvenile cattle. It was assumed that this is a polygenic, 
quantitative trait resulting in a wide range of response phenotypes. In this project, 
a large crossbred population o f juvenile cattle was immunised with three 
commercial respiratoiy viral vaccines. Using specific antibody response as a 
phenotypic trait, detailed models were fitted. It was hypothesized that this 
immune response could be modelled using multivariate analysis so that it would 
be possible to decompose and quantify intrinsic, extrinsic and genetic influences. 
Using detailed pedigrees for the animals involved, in conjunction with genetic 
marker data, quantitative trait loci (QTL) were sought for antibody based 
immune function. It was hoped that any QTL identified could be incorporated 
into selective breeding programmes, to anchor desirable immune response 
characteristics in conjunction with improvements in production traits. Improving 
or maintaining immunological performance, by this method, will have valuable 
survival and welfare benefits.
Fit an accurate multivariate model o f antibody responses induced by a 
live intramuscular cattle vaccine against bovine respiratoiy syncytial 
virus (BRSV).
I
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• Fit an accurate multivariate model of antibody responses induced by a
live intranasal cattle vaccine against bovine parainfluenza 3 virus (PIV3).
• Fit an accurate multivariate model of antibody responses induced by a
live intranasal cattle vaccine against bovine herpesvirus 1 (BHVl).
• Metrically determine correlations, relationships and associations between 
the many environmental factors involved for these phenotypes.
• Identify and assess QTL relevant to the genetic component of the 
phenotypes observed.
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Chapter 2
Demographics, management and health of the crossbred 
cattle population
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2.1 Introduction
Cattle breeds have been discrete socioeconomic entities for hundreds of years,
evolving to cope with a diversity of climatic, disease and nutritional pressures, a
.process consolidated recently by restrictions imposed by pedigree registration and the 
widespread use of artificial insemination. Modern cattle breeds have been developed 
for distinct production objectives, perhaps the most obvious being the division into 
dairy and beef types. This functional separation is best typified by the Holstein 
Friesian, the predominant milk producing cattle breed worldwide and the Chaiolais, 
principally a beef producing breed (Bellmann et a l,  2004).
Although European Bos taurus cattle breeds appear to be much more closely related 
than the Bos indiens breeds o f Africa and Asia (MacHugh et al., 1994), the Charolais 
breed was reported as a genetic outgroup based on the analysis of 1 2  microsatellite 
markers among six European breeds (MacHugh et a l, 1994). Further research (Blott 
et a l, 1998) found two major groupings of cattle breeds: a Southern continental group 
which included Charolais, Limousin, Simmental and Jersey cattle and an Anglo- 
Northern continental group which included the Holstein Friesian, Belgian Blue, 
Hereford and Aberdeen Angus breeds. Those authors also found that the Charolais 
and Holstein-Friesian breeds had little evidence o f “genetic bottle-necking” i.e. low 
levels o f heterozygosity and small numbers o f alleles. Another study using a 
combination of microsatellite and biochemical (e.g. blood groups) markers identified 
similar findings, positioning the Charolais cattle breed (together with the Parthenis 
breed) some distance on phenograms from the Holstein breed (Moazami-Goudarzi et 
a l, 1997). As Charolais and Holstein breeds are genetically significantly distant, they 
may be expected to have larger potential differences in gene frequencies. A study by
Weiner et a l (2004), based on native British cattle breeds, emphasized the importance
of including phenotype alongside genotype in all inter-breed comparisons.
The Roslin Bovine Genome Programme (RoBoGen) is a collaborative project
between the Roslin Institute, the University of Nottingham, the University of Bristol
and the University of Glasgow (SLP LINK Project LK0618). The primaiy goal was to
.map the bovine genes controlling traits relevant to the efficient and healthy production
of higher quality meat and milk. An experimental herd was established according to a 
controlled breeding programme and a veiy large number of traits were measured 
under standardised conditions, generating phenotypic data on a per-animal basis. The
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traits examined ranged from feed conversion efficiency, growth rate, carcase 
conformation, meat quality, meat tenderness to immune responsiveness associated 
with disease resistance (Work Package 6 ). All of the work documented here was 
completed under Work Package 6 .
Charolais and Holstein-Friesian breeds were chosen as founder breeds for the
RoBoGen project. It was postulated that such genetically distinct breeds will have
differences not only in production traits but also immune capacity due to the selective
pressure o f the distinct sets of environmental factors and pathogen exposures which
beef and daiiy cattle encounter. As a result, different alleles or genes may have
become fixed or appear at different rates in the two different cattle breeds.
Subsequently, when crossed in a structured breeding programme, such contrasting
.genetic pools should permit maximum information from the experimental population. 
This in turn will facilitate the detection o f QTL relevant to the particular phenotype 
under investigation. Studies such as that by Heaton et al. (2001) have demonstrated 
breed-based differences in the frequencies o f immunity related gene haplotypes in 
Holstein and Charolais cattle.
As the Charolais-Holstein is a typical terminal cross used by commercial producers by 
breeding beef sires on non-elite dairy cows, all empirical results for immune response 
are of direct practical relevance too, especially in relation to the many production 
traits assessed. In addition, the design o f the project allowed the influence o f both 
traditional dairy and beef calf rearing systems on immunological function to be 
examined. As respiratory disease is a foremost cause of morbidity and mortality 
among dairy and beef calves, responses to vaccination against three principal 
respiratoiy viruses were evaluated. In the same population, other immune function 
traits measured included T-cell responses to the bacterial mastitis pathogen. 
Staphylococcus aureus (Young, 2002; Young et a l, 2005).
The three viral pathogens selected for detailed investigation were Bovine Respiratory 
Syncytial Virus (BRSV; Chapter 3), Bovine Parainfluenza-3 virus (PIV3; Chapter 4) 
and Bovine Herpesvirus 1 (BHVl; Chapter 4). Respiratoiy disease in cattle is often 
due to multiple pathogens, and commonly presents as a disease complex rather than 
due to a single agent. To assess interactions and the influences which could affect 
antibody response phenotype under test, the population was also screened for Bovine 
Viral Diarrhoea Virus (BVDV; section 2.3.1) and Bovine Coronavirus (BCV; section 
2.6.2). Such data, collected on circulating wild-type infections, could give some
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indication of baseline levels of heritabilily for antibody response expected when 
naturally occurring pathogens affect the study animals.
2 . 2  Materials
2.2.1 Cattle
;
The study population was a herd of second-generation Holstein-Charolais calves, 
founded from four purebred Charolais (FO) sires and eight first-cross Flolstein- 
Charolais (FI) sires, maintained at Blythbank Farm, The Roslin Institute, Edinburgh.
This resource herd had been established primarily to identify QTL associated with 
commercially relevant production traits such as growth rate, meat quality, pubeity 
onset and carcass conformation.
The four FO Charolais sires used were coded: CHIOS, CH158, CH200 and CH219 and 
the eight FI Holstein-Charolais sires were coded ROl, R02, R05, R11, R12, R15, R19 
and R21. These twelve sires were used to produce an interline resource that included 
91 Holstein backcross [FI J  X Holstein Ç] (BH), 80 Charolais backcross [Charolais 
(S X FI $] (BCH) and 292 second-cross [FI 6 ' X FI $] (F2) calves. Relative breed- 
cross percentages were therefore BH (20%), BCH (17%) and F2 (63%). The breeding 
programme is shown schematically (Figure 2.1).
Figure 2.2 shows how the calves were subdivided on sex, breed-cross and year-of-
■:3."
birth. A total of 463 (53% male, 47% female) calves entered the study over four 
successive years: relative cohort sizes being 57(12%), 120(26%), 141(30%) and
' I.:
148(32%) in 1998, 1999, 2000 and 2001, respectively.
Four [sire X dam] pairings: [R15 X R09], [R19 X RllO] (both 2000 cohort), [R02 X 
R59] and [R02 X R98] (both 2001 cohort) were selected for multiple ovulation and 
embryo transfer resulting in 7, 8 , 10 and 11 calves, respectively. Excluding these four 
dams, the study used 197 dams averaging 2.22 calves each over the study period.
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Figure 2.2 Breakdown o f Robogen herd grouped on main parameters outer circle 
(year-of-birth: 1998, 1999, 2000 and 2001), middle circle (breed-cross: BCH, BH 
and F2) and inner circle (sex: female and male). Actual number o f calves per group 
included in italics. All groups sum to 463 calves.
2.2.2 General managem ent
All calves received ~2 litres o f  b irth-dam  colostrum  via stom ach-tube, before six 
hours o f  age. C alves w ere w eighed at birth, tagged and assigned to one o f  tw o 
groups, dependent on sex.
All m ale calves w ere returned im m ediately to their birth dam s and had 
unrestricted suckling w ith the ir dam s at grass, until approxim ately six m onths
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.old. Males were not castrated as they were to be finished as entire bulls with a 
target weight of 550 kg (for other aspects o f the Robogen project). Accurate 
bodyweight and other conformational data was collected from the male calves 
regularly at -60  day intervals, in addition to being linear-type scored by a 
Holstein Breed Society inspector for conformation and locomotion.
All female calves were weaned by 36 hours, segregated from the rest of the herd 
and raised indoors, initially on milk-replacer then switched early onto a 
proprietary compound diet. Female calves continued to be housed separately 
until the start of the vaccine study. Any differences in results between sexes 
were, therefore, confounded by differences in the management o f calf rearing, 
essentially representative of the beef and dairy systems of calf production.
2.2.3 Vaccination protocol
For the 77-day duration o f the study, all calves were housed in single-sex groups 
of similar weights. Both male and female calves were treated just before the 
vaccine study commenced with ivermectin (Ivomec, Merial Animal Health,
Essex, UK) to treat for both internal and external parasites. Over the 
experimental study period, all calves were housed and fed an age-appropriate 
concentrate diet, with water and straw supplied ad libitum.
On Day 0, each calf received 2 ml of the attenuated BHVl and P1V3 vaccine,
Imuresp RP (Pfizer Animal Health, Surrey, UK), according to the manufacturer’s 
recommendations. Rehydrated vaccine was administered intranasally in a 2 ml 
dose, half of which was placed in each nostril. On Day 28, each calf received 2 ::
ml o f Rispoval RS, (Pfizer Animal Health, Surrey, UK), an attenuated BRSV 
vaccine, by prescapular intramuscular injection, according to the manufacturer’s 
recommendations. All calves were re-immunized with 2 ml o f Rispoval RS, 
intramuscularly on Day 49 after primaiy vaccination.
Blood samples were collected by jugular venepuncture on Days 0, 14, 28, 42, 63 
and 77, providing six longitudinal samples per calf (Figure 2.3). Approximately 
3-5 ml of serum were separated by centrifugation within two hours o f sampling 
and stored at -20°C until testing.
Follow ing the com pletion o f  the vaccine study, both sets o f  calves entered feed 
trials which lasted for six m onths in the case o f  the fem ales, and until slaughter 
for the m ales.
Day 0 
PIV3/BHV1 
vaccination
Day 28 Day 49
BRSV \ °  BRSV 2°
vaccination vaccination
DayO Day 14 Day 28 D ay4 2I I I
r
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D ay63 Day 77I I I
10 20 30 40 50 60 70 80 90 100
Day
Figure 2.3 Respiratory virus vaccination and sampling time-line. Sera collected on 
sampling days: Days 0, 14, 28, 42, 63 and 77, marked in blue. PIV3/BHV1 vaccination on 
Day 0, marked in red. BRSV vaccination on Days 28 and 49, marked in green.
2.2.4 Date-of-birth
C alving seasons rem ained alm ost constant betw een cohorts. Table 2.1 show s the 
range o f  birth dates and overall size o f  the cohorts.
Cohort First birth Last birth Length(days)
No. of 
calves
1998 31/03/98 03/07/98 94 57
1999 28/03/99 04/07/99 98 120
2000 22/03/00 22/06/00 92 141
2001 22/03/01 20/06/01 90 145
Table 2.1 First and last dates-of-birth, length o f  calving season and number o f  calves, 
per cohort in years 1998 to 2001.
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There was no evidence of significant differences of date-of-birth between cohorts 
(Figure 2.4), tested using one-way analysis of variance (ANOVA; p >0.1). Births 
were evenly spread over each calving season, with no evidence of clustering in 
any o f the four cohorts. The coefficients o f variation were relatively stable at 
19.8, 24.4, 21.7 and 20.6 for years 1998, 1999, 2000 and 2001, respectively.
At the start of sampling, calves ranged between 60 and 167 days old. The 
experiment began (Day 0) on 01/09/1998, 01/09/1999, 05/09/2000 and 
04/09/2001 for each o f the respective cohorts. There were small but statistically 
detectable differences between the mean cohort ages (ANOVA; p <0.005) with 
1998, 1999, 2000 and 2001 having mean ages of 148.4, 154.2, 162.5 and 158.1 
days, respectively. However there was no significant difference between the
mean age of male and female calves (t-test; p > 0 .1 ).
-All statistical analysis was performed using age as continuous variate. To 
facilitate graphical visualisation of results, the continuous variate age was 
recoded into the factor age, categorised into five 21-day intervals. Calves aged 
60-81 days were classified as age-group I, those aged 82-103 days as age-group 
II, those aged 104-125 days as age-group III, those aged 126-147 days as age- 
group IV and those aged 148-169 days as age-group V. There were 23, 62, 70,
128 and 184 calves in age-groups I, II, III, IV and V, respectively.
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Figure 2.4 Robogen calf date-of-birth, grouped on cohort: 1998 to 2001, Each birth 
event is represented by a horizontal line. Dates shown in days from January T' (Day 0) 
for each respective year.
2.2.5 Dam-age
Date-of-birth was not recorded for 14 o f the birth-darns used in the study and 
these were excluded from the analysis below.
The mean age of cows at calving was 3.91 years (-47 months), with a minimum 
of 1.93 years (-23 months) and a maximum of 7.41 years (-89 months). There 
were 45, 115, 128, 132, 30 and 3 biifh-dams which had calves in their 2" ,^ 3"^ ,^ 
4 '^\ 5**^, 6 ’^' and 7^ '’ years, respectively. The factor dam-age was defined as the age 
at calving of the birth-dam (rounded to the nearest year).
:
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2.2.6 Birthweight
Tw enty-three calves had unrecorded birthw eights and w ere excluded from the 
analysis below .
M ale calves w ere heavier than fem ale calves at birth (t-test; p <0.001), with 
mean w eights o f  45.5 kg and 41.6 kg, respectively. There w as no evidence o f  
significant d ifferences in b irthw eight due to breed-cross (A N O V A ; p >0.1). 
There was som e evidence (A N O V A ; p <0.01) that birthw eight increased over the 
four years in the study w ith m eans o f  40.6 kg, 42.6 kg, 43.7 kg and 45.5 kg for 
cohorts 1998, 1999, 2000 and 2001, respectively. Figure 2.5 show s that w ithin 
each cohort, m ale calves tended to be heavier than fem ale calves in addition to 
the gradual overall increase in b irthw eight over the four cohorts. W ithin cohorts, 
there w as som e evidence o f  a positive relationship (correlation r  =  0.236; p 
<0.001) betw een date-of-birth  and birthw eight, i.e. calves born later in the year 
w ere m arginally heavier than those born earlier. Figure 2.6 show s that there was 
a small increase in b irthw eight up to dam -age =  four, the effect stabilising 
thereafter at -4 7 .4  kg in the m ale and -4 3 .7  kg in the fem ales.
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Figure 2.5 RoboGen calf birthweights (kg) grouped by year-of-birth; 1998 
(blue), 1999 (red), 2000 (green) and 2001 (black) and by sex: male (M) and 
female (F) as marked.
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Figure 2.6 Calf birthweights (kg) grouped by dam-age: two (blue), three (red), four 
(black), five (green) and six (brown) and by sex: male (M) and female (F) as 
labelled. (Dam-age seven not shown as n=3 in this group).
2.3 Pathogen screening
The Robogen cattle population w as screened for antibodies to tw o com m on 
bovine pathogens found in the UK. Both o f  these pathogens have been 
im plicated in the bovine respiratory disease com plex (Ellis, 2001).
2.3.1 Bovine viral diarrhoea virus
The first, bovine viral diarrhoea virus (B V D V ), is an endem ic cattle pathogen in 
the British Isles (Paton et a l ,  1998), responsible for a disease com plex which 
includes abortion, d iarrhoea, lam eness, pneum onia and im m unosuppression 
(G raham  el a l ,  1998a). A ny interference with im m une capability  could have 
serious consequences for the current study, thus prior exposure to BVDV was 
assessed.
Sera w ere tested quantitatively by solid-phase antibody capture ELISA specific 
for B V D V -lgG  according to the m anufacturer’s guidelines (Svanovir B V D V -A b, 
SV A N O V A  Biotech, U ppsala, Sw eden). Technical m ethodology w as according
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to the manufacturer’s instructions without modification and is described in detail 
later (Chapter 3 -  section 3.2.2).
2.3.2 Bovine coronavirus
Paton et al (1998) reported that bovine coronavirus (BCV), the second pathogen 
screened for here, was almost ubiquitous in the UK cattle population. Bovine 
coronavirus can act as a respiratoiy pathogen (Storz et a l, 2000) in addition to 
being potentially enteropathogenie for cattle. As such, BCV may influence the 
immune responses to vaccination against the three other respiratoiy pathogens 
(BRSV, P1V3 and BH Vl) assessed later in the current study.
Sera were tested quantitatively by solid-phase antibody capture ELISA specific 
for total BCV-IgG according to the manufacturers guidelines (Svanovir BCV- 
Ab, SVANOVA Biotech, Uppsala, Sweden). Technical methodology was 
according to the manufacturer’s instructions without modification and is 
described in detail later (Chapter 3 -  section 3.2.2).
2.4 Resuits
Only five calves had detectable levels o f BVDV antibody above relative optical 
density (ROD) =10% with no discernible patterns based on sex, year-of-birth, 
breed-cross, age, dam-age, dam or sire.
However, mean levels o f BCV IgG were high (Table 2.2). Antibody to BCV was 
detected evenly across all groups except the male calves in cohort 2001 (Figure 
2.7). Female calves had higher levels o f BCV antibody than male calves (t-test; p 
<0 .0 0 1 ) across all cohorts but there was no evidence of breed-cross effects 
(ANOVA; p >0.1).
BCV-IgG
T rait mean variance
(ROD)
median
(ROD)
dQ skewness
Day 77 BCV overall 121.7 3436.0 129.9 58.8 -0.5
Day 77 BCV females 155.5 1531.9 146.5 58.7 0.3
Day 77 BCV males 90.7 3176.0 104.3 103.2 -0.2
Table 2.2 Levels of BCV-IgG on Day 77 relative to P1V3/BHV1 vaccination. BRSV 
vaccine administered on Day 0 and Day 21. dQ (interquartile range); ROD (relative 
optical density). All data is non-transfcrmed and presented as overall and grouped on sex.
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Figure 2.7 Levels of BCV-IgG antibody, grouped on year-of-birth (1998 to 2001) 
and sex (male (M) and female (F)). Results are log transformed relative optical 
density (ROD) data.
Figure 2.8(a) shows how levels of BCV antibody largely tend to be almost 
constant among all age-groups and sexes, a pattern common when virus is 
actively circulating within a population. Such high levels of antibody against 
BCV indicate that the virus was widely disseminated across the four cohorts of 
the Robogen herd. However in one sub-group: the male calves of cohort 2001, 
levels o f BCV antibody were much lower. Therefore, within this specific sub­
group, there is much less evidence o f active BCV infection, emphasizing the 
unpredictability of field viral infections. In this sub-group, antibody levels 
against BCV tended to be lower in older calves (Figure 2.8(b)), a pattern 
consistent with declining levels o f maternally-derived antibody.
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Figure 2.8 Levels of BCV-IgG antibody, grouped on age. Results shown for (a) 2001 males 
only and (b) all other remaining calves. Age-group I ~ 60-81 days, age-group II ~ 82-103 
days, age-group III -  104-125 days, age-group IV -  126-147 days and age-group V ~ 148- 
169 days. Results are log transformed relative optical density (ROD) data.
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2 . 5  Discussion
It has been demonstrated that the Robogen cattle population used in this study, 
although an intensely investigated experimental herd, shares many features in 
common with commercial UK cattle units. Data were collected across four 
different years, to reduce one-off seasonal effects. Within the study, both dairy 
and beef calf-production systems were examined. The population studied was 
large and calves were tested over a 1 0 0 -day age range, to allow comprehensive 
assessment of the important variable, age. All o f these features contributed to the 
broad scope of the study, making it suitable for detailed assessment o f the most 
important variables controlling antibody responses to vaccination in young cattle.
Male calves are larger than female calves at birth (McDermott et a l, 1992). For 
Holstein calves this sex effect was quantified as 8,5% (Kertz et a l, 1997) which 
closely reflects the pattern seen in the current study. Primiparous Holstein cows 
have smaller calves than Holstein multiparous cows partially because first-parity 
cows have shorter gestation lengths than later-parity cows (Johanson and Berger,
2003). In the current study, dam-age positively influenced calf birth-weight until 
four years of dam-age. Kertz et al (1997) made a very similar finding in Holstein 
calves with a 7-8% increase per-year of dam-age, the effect persisting up to the 
fourth parity. A study of beef breeds including Charolais cattle also came to the 
same conclusion (Van Vleck and Cundiff, 1998). The subject is comprehensively 
reviewed by Rumph and Van Vleck (2004). Other research regarding birth 
weights in calves has identified influential areas on the bovine genome such as 
QTL on BTA2 (Grosz and MacNeil, 2001) and BTA23 (Elo et a l, 1999).
'7
The Robogen herd operated under normal commercial levels of biosecurity and 
was not pathogen-free. Screening for viral pathogens was not exhaustive.
Adenoviruses, rhinoviruses, reoviruses, enteroviruses, bovine parvoviruses and 
other bovine herpesviruses are not unusual isolates on UK cattle farms (Stott et 
al, 1980). Undoubtedly, there will be other pathogens which have remained 
unreported here. There was however evidence of the virtual absence of one 
pathogen, BVDV, and the confirmed presence of another pathogen, BCV, two of 
the more prevalent bovine infections in the UK. Both of these have been
6 6
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. . .demonstrated previously as components of the bovine respiratory disease
complex.
'
Low levels of herd seroprevalence indicate virtually no active circulation of 
BVDV within the test population. Those BVDV-specific antibodies detected in 
this study are probably o f colostral origin, most likely due to birth-dam exposure 
to the virus, prior to joining the Robogen herd. Another possibility is low-level 
horizontal transmission of pestivirus from the adjoining Blythbank sheep flock.
There may be potential risks in over-interpretation o f the BCV results as the 
antibody levels were due to field infection without standardisation of timing, 
inoculate dose, route or content. However, they do act as a useful comparison 
with antibody kinetic patterns obtained in the respiratory vaccine experiment 
described in later chapters. In addition, they demonstrate that the Robogen herd 
operated under pressure from multiple bovine pathogens, representative of 
typical UK farming conditions, and therefore any results from later chapters 
should be applicable to commercial production environments.
Chapter 3
Antibody to bovine respiratory syncytial virus
6 8
i69
3.1 Introduction
3.1.1 Background
Bovine Respiratory Syncytial Virus (BRSV) is a major cause of respiratory 
disease in both dairy and beef cattle worldwide, acting either as a primary 
pathogen or synergistically with other agents (Larsen, 2000). Bovine Respiratory 
Syncytial Virus appears to be endemic in most areas of intensive cattle 
production (Uttenthal et a l, 1996) with morbidity ranging from 80 to 100 percent 
and mortality up to 10 per cent (Bryson et a l, 1978). Bovine Respiratory 
Syncytial Virus was found to be the virus most commonly implicated in 
outbreaks of bovine respiratoiy disease in animals under one year old in the UK 
(Veterinary Investigation Diagnosis Analysis, 2002). Recent research has shown 
UK isolates to be more closely related to US variants than those from continental 
Europe (Nettleton et a l, 2003). In Northern Europe, BRSV outbreaks tend to be 
seasonal, occurring most frequently in early winter (van der Poel et a l, 1993).
The peak incidence o f severe disease occurs commonly in young animals, less 
than six months old, often in the presence of maternally-derived antibody (Patel 
and Didlick, 2004). Poor immunogenicity (Larsen et a l, 2001) and silent re­
infections among seropositive adults (van der Poel et a l, 1993) may explain 
annual resurgences on “closed” daily farms. It has been proposed that immunity 
is more transient in the upper respiratoiy tract than in the lungs (Stott and Taylor, 
1985). Within any herd, passive and active BRSV antibody levels in calves are 
dictated by a seasonally periodic BRSV recirculation among the adult bovine 
population (van der Poel et a l, 1997). Bovine Respiratoiy Syncytial Virus often 
leads to severe disease in young beef and dairy calves (Verhoeff and van 
Nieuwstadt, 1984) with clinical signs rarely seen at less than two weeks old, 
most severe between one and five months old and virtually absent in cattle over 
nine months (Larsen, 2000). Signs of BRSV disease appear between two and five 
days post-infection and persist for up to eight days (Belknap et a l, 1991). 
Typically these include coughing, lacrimation, nasal discharge, depression, 
anorexia, pyrexia and tachypnoea often progressing to dyspnoea and interstitial 
pneumonia (Biyson et a l, 1978).
_
Vaccination is a common control measure, with modified live vaccines 
considered the safest and most efficacious (Ellis et a l,  1995; West et a l, 1999), 
stimulating both mucosal and systemic, humoral and CMI responses (Sandbulte 
and Roth, 2002), Rispoval RS (Pfizer Animal Health, Surrey, UK) a vaccine used 
commonly in Europe, based on the RB-94 strain of BRSV (a 1969 Belgian 
isolate) has been successfully employed commercially since 1978 (Zygraich,
1982). Within any given population, however, all BRSV vaccination regimes 
induce a broad spectrum o f antibody responses in individual animals (Stewart 
and Gershwin, 1990; Kubota et a l, 1992; Outteridge, 1993). Although 
vaccination does limit clinical disease, it seems not to suppress transmission and 
recirculation of wild-type BRSV (Piazza et a l, 1993; Schrijver et a l, 1997). 
Neutralizing antibody, induced by either vaccination or natural infection, is 
critical for subsequent protection against BRSV (West et a l, 1999a). Specific 
BRSV antibody, in acute or convalescent sera therefore provides useful indirect 
evidence of infection and vaccination. The use of serum antibody levels as a 
correlate of vaccine-induced protection has been discussed previously (Plotkin, 
2001), with the suggestion that for BRSV, antibody may be more important in 
the prevention of infection than clearance of the virus (Mclnnes et a l, 1999). The 
development of a BRSV-specific ELISA (Kimman et a l, 1987b; Langedijk et 
al, 1996) has permitted quantitative, repeatable, evaluation of isotype-specifie 
antibody responses to both BRSV vaccination and natural infection in cattle 
(Elvander et a l, 1995; Hazari et a l, 2002). These studies have identified a 
number of factors which influence the level of immune response generated, such 
as inoculate content and infection site (Kimman et a l, 1989), maternally-derived 
antibody (Uttenthal et a l, 2000) and calf age (Thomas et a l, 1986).
3.1.2 Genetic Factors
In addition to non-genetic effects, there is growing evidence of a predetermined 
association between genotype and immunological response to both infection and 
to vaccination. In humans, significant genetic control of vaccine-induced 
antibody responses has been reported for the viral diseases hepatitis B (Poland 
and Jacobson, 1998), measles, mumps and rubella (Tan et a l, 2001). Similar 
evidence extends to the responses of humans to the human equivalent of BRSV,
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human Respiratory Syncytial Virus (hRSV), where polymorphisms in human 
cytokine genes have been demonstrated to modulate both immune response and 
disease severity (Gentile et a l, 2003; Hoebee et a l, 2004). The severity of the 
bronchiolitis caused by hRSV infection is influenced by polymorphisms in the 
IL-10 gene (Wilson et a l, 2005) and a genetic locus controlling susceptibility to
viral bronchiolitis has been identified near the human IL- 8  gene (Hull et a l,
2004). The CC chemokines -  RANTES (regulated on activation, normal T-cell 
expressed and secreted) and macrophage inflammatoiy protein (M lP)-la and 
their associated receptor CCR5 have been implicated as determining the severity 
o f bronchiolitis caused by hRSV (Hull et a l, 2003). Bovine homologues of the 
human CCR5 receptor have been identified though as yet are unmapped. Stark et 
al (2002) also described 15-fold differences in susceptibility to hRSV challenge 
between strains of inbred miee. Also in mice, hRSV post-vaccination 
eosinophilia was found to be influenced by MHC haplotype (Hussell et a l, 
1998).
Although there is no comparable evidence published regarding BRSV
specifically, the influence o f genetics on endogenous serum antibody in cattle has
been established (Burton et a l, 1989b; Lie, 1979; Mazengera et a l, 1985).
Cumulatively, these findings and others reviewed by Glass (2004) strongly imply 
.that a significant component of variation in protective immunity dependent on 
vaccine-induced antibody is genetically determined.
The proposed hypothesis is that in a sufficiently large, fully pedigreed 
population, genetic influences on immune responses are detectable and the size 
of this genetic component will be computable. In the current study, a 
commercially available live BRSV vaccine was used on a juvenile crossbred 
bovine population and the specific IgG antibody responses were measured by 
ELISA. Subsequent analysis allowed the separation of heritable factors, such as 
additive and maternal genetic effects, from non-transmissible factors, such as 
year-of-biith, age and sex effects. Accurate compartmentalisation o f the observed 
variation permits their respective contributions to the overall immune response to 
be assessed and quantified.
_
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3,2 Methods
3.2.1 Vaccination and sampling
The study population was the Robogen herd. This experimental population and 
the vaccination protocol are described in detail in Chapter 2, section 2.2.3. Blood 
samples were collected on Days -28 and -14 pre-vaccination; Day 0, the day of 
vaccination and Days 14, 35 and 49 post-vaccination, providing six longitudinal 
samples per calf.
ROD (%) = COD serum sample x 100 [EQ3.I]
COD positive control
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3.2.2 ELISA for detection o f total BRSV-specific IgG antibody
Sera were tested quantitatively by solid-phase antibody capture ELISA specific 
for total BRSV-IgG according to the manufacturer’s guidelines (SVANOVA 
Biotech, Uppsala, Sweden). Briefly, samples were added at a dilution o f 1/25 in 
PBS-Tween buffer (0.01 M pH 7.4 phosphate buffered saline (PBS) containing 
0.05% Tween 20) to each of two wells, one coated with viral antigen and the 
other with control antigen, to make a final volume of 100 pi. Common positive 
and negative control sera were included on eaeh 96-well microtitration plate also 
at a dilution of 1/25. Each plate was shaken, sealed and incubated for one hour at 
37°C, then washed three times with PBS-Tween buffer. After the third wash, 
each plate was tapped diy and 1 0 0  pi of horse-radish peroxidase-conjugated anti- 
bovine IgG added to each well. Eaeh plate was then incubated for a further hour 
at 37°C and washed as previously described. One hundred pi of substrate 
chromogen solution (3 ’,3 ’,5 ’,5 ’-tetramethyIbenzidine and hydrogen peroxide) 
were added to each well and the plate was incubated at room temperature for ten 
minutes after which the reaction was stopped by adding 50 pi o f 2  M H2 SO4 per 
well. After shaking, the optical density (OD) of each well was measured 
immediately at 450 nm on a MRX microplate plate reader (Dynex Technologies, 
Chantilly, USA). The corrected optical density (COD) value for each sample and 
the assay control sera were calculated by subtraction of the OD value of each 
control antigen-coated well from that o f the corresponding viral antigen-coated 
well, and the relative optical density (ROD) value for each sample calculated as a 
percentage o f the highly positive control serum on a per-plate basis:
3.2.4 Serum neutralisation test for detection o f BRSV antibody
For validation and comparison, serum antibody levels specific to BRSV were 
determined independently (Biobest Laboratories Ltd, Pentlands Science Park, 
UK) using another in vitro method in addition to the ELISA, the serum 
neutralisation test (SNT; (Gillette, 1983)). A subset of 30 sera, five selected from 
each of the six sampling days, were analysed by SNT. Sera were chosen to 
represent the range o f BRSV-IgG responses on each sampling day. Correlations 
between SNT results and the corresponding ELISA results were calculated.
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Samples were tested in duplicate and repeated if these pairs of ROD values were 
>10% discordant. The intra-plate and inter-plate repeatabilities for the BRSV- 
specific IgG ELISA were 97.6% and 98.9%, respectively.
3.2.3 ELISA for detection o f BRSV-specific IgG i antibody
Total BRSV-IgG^ levels were tested using a modified form of the above assay. 
All dilutions were as described above but 100 pi of 1/10,000 horse-radish 
peroxidase-conjugated anti-bovine IgG% (Acris Antibodies GniBH, 
Hiddenhausen, Germany) was used as the secondary antibody. Following assay 
optimisation by cross-titration, samples were again included at a dilution of 1/25 
in PBS-Tween buffer. Levels of BRSV-IgGz antibody were tested for Days 0, 14, 
35 and 49 and the corresponding ROD values, calculated as above. The intra­
plate and inter-plate repeatabilities for the BRSV-specific IgGi ELISA were 
98.7% and 97.2%, respectively. This assay did not discriminate between 
allotypes IgG]a and IgG2b (Williams, 1990)
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3.3 Statistical Methods
3.3.1 Data preparation
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Means, medians, variance and interquartile range for all traits were calculated 
using Genstat 7.0 (VSN International Ltd, Herts, UK). The same software was 
used to ealculate skewness (a measure of distribution symmetiy. Appendix A .l) 
for each trait, with normality set as a skewness of 0.0. All data collected on total 
BRSV-IgG and BRSV-IgG2 antibody levels was subsequently normalised by loge 
transformation.
Deviations (A) in antibody levels between all days post-vaccination (Days 14, 35 
and 49) and the day of vaccination (Day 0) were calculated for both antibody 
isotypes - so typically for Day 35:
AMgG (DO to D35) = Day 35 BRSV-IgG - Day 0 BRSV-IgG [EQ 3.2]
The total area under both BRSV-IgG antibody curves was calculated pre­
vaccination (between Days -28, -14 and 0) and post-vaccination (between Days 
0, 14, 35 and 49), inclusive. The trapezoidal rule (Appendix A.2) was used to 
calculate a good working approximate of this summary trait (Abramowitz and 
Stegun, 1972). So typieally:
3-day-area />IgG(prevac) = area under IgG curve for Days -28, -14 and 0 [EQ 3.3]
3.3.2 Non-regressive statistical methods
Depending on the number of factor levels, either unpaired Students t-test (if 2
levels) or one-way analysis of variance (ANOVA; (if > 3 levels)) were used to
compare factor effects. Tests were confirmed as slgnifieant if p <0.05 and highly 
. . .significant if p <0.001. Pearson product moment correlations between 
combinations of factors and variâtes were evaluated for levels of total BRSV-IgG 
and BRSV-IgG2 on all sampling days and r values calculated. Excel 2003 
(Microsoft Corp., Seattle, USA) was used for collation and preparation of data, 
Genstat 7.0 (VSN International Ltd, Herts, UK) was used for statistical analysis,
3.3.4 Univariate mixed linear regression
Mixed linear models were fitted to the data using Residual Maximum Likelihood 
(REML) methods, with Genstat procedures (Genstat 7.0, VSN International Ltd). 
The impact of a number of explanatory factors was evaluated and the remaining 
variation decomposed into variances of either transmissible or environmental
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as stated and ASREML (VSN International Ltd, Herts, UK) used for statistical i
analysis, as stated.
3.3.3 Logistic regression
By introducing a binary coding system whereby A6 IgG (DO to D14), AMgG (DO 
to D35) and A6 IgG (DO to D49) were converted into either 1 (positive A) or 0 
(negative A), a variate suitable for analysis by logistic regression was generated.
Linear binomial models with these binaiy variâtes as the response variable (y) 
and the level of Day 0 BRSV-IgG antibody as the explanatory variable (% ) were
fitted to the data using a logit link function, (log -- - -- ) and the associatedv - p )
model parameters (a and (3) estimated by logistic regression methods (Genstat 
7.0).
Using
y = [EQ3.4]
where p  is the probability of binaiy 1, (i.e. a positive A); x  is the population 
mean level of Day 0 BRSV-IgG antibody. Assuming that when p  =0.5, a positive 
or negative antibody response was equally likely, it was possible to provide an 
empirical estimate o f the threshold at which pre-existing BRSV antibody begins 
to block the BRSV vaccine response. This mechanistic approach is exploratory in 
nature, greatly simplifying the modelling o f this relationship. No other relevant 
factors were included at this stage. If the first threshold {p =0.5) can also be 
envisaged as the point at which 50% of the calves showed a positive antibody 
response, a second useful threshold may be estimated when p  =0.9 or when a 
positive vaccine response may be expected in 90% of the population.
where phenotypic variance cr  ^ was estimated as + a l , as defined above.
The basic model was extended for post-vaccination Days 14, 35 and 49 by
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origin. The fixed effects in the model, with appropriate degrees of freedom (df), 
were breed-cross (BCH, BH, F2; 2df), sex (male, female; Idf), year-of-birth 
(1998, 1999, 2000, 2001; 3df), dam-age (2, 3, 4, 5, 6 , 7; 5df) and age at first 
sampling (continuous variate), with calf sire included as a random effect. As 
male and female calves were reared separately and under different management, 
the effect sex incorporates management and environmental components, in 
addition to its physiological effect. To improve model clarity, the fixed effect 
breed-cross was further resolved into Holstein and recombination-loss fractions 
in accordance with: breed-cross BCH = (0.25 Holstein, 0.50 recombination-
loss)', breed-cross F2 = (0.50 Holstein, 1.0 recombination-loss) and breed-cross >■:
BH (0.75 Holstein, 0.50 recombination-loss), Holstein represents the expected 
genetic contribution of the Holstein cattle breed, while recombination-loss 
represents the expected fractional loss in the phenotype of progeny, arising from 
the non-productive recombination o f genetic loci at fertilisation which previously 
interacted in either of the two parents (Fries et a l, 2002).
Thus the linear model was:
Yijklmiip ^  p + tti + pj + 5k + TTi 47m + 8 (Sijklninp- s) 4- Ujjklmn + eyklmnp [EQ 3.5] 
where
Yijkimnp - observation of phenotypic trait, 
p - population mean,
Ui - effect (fixed) of sex i {i = 1 ,2 ),
Pj - effect (fixed) of Holstein fraction j  (j = 1,2,3),
6 k - effect (fixed) of recombination-loss fraction k { k = \  ,2,3),
7Ü1 - effect (fixed) of dam-age / (/ = 2,3,4,5,6,7),
Ym - effect (fixed) o f year-of-birth m {m = 1,2,3,4), 
e(sijkimnp- s) - effect (fixed) of sampling age Sijkimnp(age of calf ijklmnp) 
expressed as a deviation from the population mean age s,
Uijkimn - direct heritable effect (random) of sire n ~ N(0, l a l  ), 
eykimnp - residual error (random)p  -  N(0, l a l  ).
Where both uykimn and eykimnp were assumed to have multivariate normal 
distributions with means 0  and (co)variances l a l ,  and l a l , respectively.
Estimates of direct heritability (h^) were calculated using:
9 a^IT = 4 ^  [EQ 3.6]
I
adding the appropriate level of pre-existing BRSV-IgG antibody on the day of 
vaccination (Day 0 BRSV) as a covariate {q).
The significances of the fixed effects and their interactions were estimated by the 
generalised Wald test. Only those interactions achieving statistical significance 
(p <0.05) were retained in the final best-fit model. The significance o f random 
effects in the model was determined using log-likelihood ratio tests. The 
robustness o f each model produced was verified by examining the linearity of 
standardised deviance residuals against normal order statistics (Belsley et a l, 
1980) as exemplified in Appendix A.5.
3.3.5 Bivariate mixed linear regression
To evaluate heritable maternal effects, a two step approach was adopted. To 
account for the potential scale o f variation between male and female calves kept 
in different environments, a bivariate mixed linear analysis was made using 
ASREML procedures (ASREML, VSN International Ltd) for each sampling day 
with male and female responses treated as separate traits (Gilmour et a l, 2000). 
However given the limitations imposed by the number of observations, these 
analyses assumed that the fractions of variance explained by maternal or additive 
variance were the same in each sex/environment and that maternal and additive 
effects were perfectly and equally correlated across both sexes. Although such 
assumptions would be implicitly made if  the BRSV-IgG responses o f both sexes 
were analysed as the same trait, the above approach gave an opportunity for 
homogeneity of variances across the sex/environment boundary to be tested.
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Thus the bivariate linear model was:
Y ijklmnp “  gj 4" ay + (3ik 4- yj| 4- 8 j (Sijkimnp“  s) 4- Uyklm 4" ayklmn 4" eykimnp [EQ 3.7] 
where
Yijkiinnp - observation of phenotypic trait,
Pi - effect (fixed) of sex i (i = 1 ,2 ),
ay - effect (fixed) of year-of-birth j  for sex / (/’ = 1,2,3,4),
pik - effect (fixed) o f cross k for sex z (A= 1,2,3)
7 ii - effect (fixed) o f embiyo transfer I for sex i (1 = 1 ,2 )
Gi (sykimnp “  s) - effect (fixed) of 8 i, regression coefficient for sex i on sampling 
age Sykimnp expressed as a deviation from the population mean 
age s.
Ujjklmn - maternal effect (random) o f birth-dam m ~ multivariate N(0,I 
with a^m(/) constrained to be m^a^p(z) for sex /, 
aykimn - additivc effect (random) o f calf n ~ multivariate N(0, A o^a(z)), 
with a^ aCO constrained to be h^o%(z) for sex i, 
eyk im np - residual error (random)p  ~ N(0, l a l  (i)).
Where o^p(z) was the phenotypic variance for sex i, I is the identity matrix and A 
is the additive genetic relationship matrix, calculated from the pedigree traced 
back to the purebred founder sires.
The constraints on the variance components were achieved by fixing the 
maternal and additive genetic correlations for the effect in males and in females 
to be both 0.999 and by constraining the additive and maternal transmissible 
variance components in each sex to have identical linear relationships with the 
residual variance for that sex e.g. o^m( 0  -  ci, = 0  :: o^a( 0  -  C2 , o \( /)  = 0  
where C| and C2 were the same constants for both sexes. This approach 
necessitated multiple runs to find the maximum likelihood, made by searching 
across a grid of values for ci and ci, and the maximum located to an accuracy of 
±0.005. The validity o f the assumption o f equal direct heritable and maternal 
heritable fractions of variance was tested. The magnitude of phenotypic 
variances and components for the two sexes/environments were found to be 
sufficiently similar to allow pooling. Subsequent models therefore dropped 
dependence of the variance components on sex i.
The second step examined the correlations of the different components across the 
different periods using multi-trait linear models. For reasons made clear in the 
results this was done in several stages: joint analysis of BRSV-IgG levels on pre­
vaccination Days -28, -14, and 0; joint analysis of BRSV-IgG levels on post-
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vaccination Days 14, 35 and 49; joint analysis of PRE and BRSV-IgG levels on 
Day 14, (where PRE is the mean of the three observations on Days -28, -14 and 
0); and joint analysis of PRE with BRSV-IgG levels on Days 35 and 49.
The linear models then fitted were:
Y hijklm np= g h i +Cthij + P h ik  + T h il + T h i (Shijklm np “  § )  +U hijktm  +  ah ijk lm n +  Ghijklmnp [EQ 3 . 8 ]
where the model terms differ from those o f the previous model only by the 
addition of subscript/, denoting each trait h. The variance covariance matrices for 
the distributions of Uhykim, ahykimn and Chykimnp were then direct products Vm®I, 
Va®A and Ve®I where V„i was the (co)variance matrix for the maternal 
transmissible components across traits, with Va and Ve similarly defined for the 
additive transmissible and residual effects across traits.
3.4 Results
3.4.1 Descriptive analysis
Substantial variation in the levels o f total BRSV-IgG and BRSV-IgGa antibody 
were demonstrated in this population o f young cattle of mixed age, sex, breed 
and management histoiy (Table 3.1). Generally, a steady reduction in mean and 
median levels of pre-existing BRSV-IgG occurred throughout the population in 
the four-week pre-vaccination period. There was no detectable difference (t-test, 
p >0.1) between mean A6IgG(D-28 to D-14) and A61gG(D-14 to DO) suggesting 
that pre-vaccination, the rate of decay may be constant. Both measures of spread; 
variance and interquartile range also tended to decline pre-vaccination, as 
increasing numbers of calves approached undetectably low levels o f pre-existing 
BRSV-IgG. For similar reasons, the distribution of BRSV-IgG became 
progressively more skewed with the later pre-vaccination samples.
More complex patterns were apparent in the levels o f BRSV-IgG and BRSV- 
IgG] post-vaccination. Vaccine efficacy was good - on post-vaccination Days 14, 
35 and 49, respectively 64.8%, 80.6% and 75.1% of calves had increased levels 
of BRSV-IgG above Day 0 levels. The equivalent percentages for increases in 
levels of BRSV-IgG] were 71.0%, 87.6% and 83.4% on Days 14, 35 and 49, 
respectively. Overall mean levels of both BRSV-IgG and BRSV-IgG] antibodies
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increased, 6.4-fold and 5.4-fold, respectively, between Day 0 and Day 35 (Figure 
3.1(a+b)). Both BRSV-IgG variance and interquartile range dropped on the 
earliest post-vaccination sampling day (Day 14) then increased again on Days 35 
and 49. The distribution o f BRSV-IgG levels approached normality on Day 35 
but had returned to a more skewed pattern by Day 49. BRSV-IgG] variance and 
interquartile range were mueh higher on post-vaccination Days 35 and 49, than 
the earlier Days 0 and 14. Post-vaccination, BRSV-IgG] levels were 6 .8 -fold, 
4.7-fold, 3.2-fold and 2.5-fold lower than BRSV-IgG levels on Days 0, 14, 35 
and 49, respectively. The disti'ibution o f BRSV-IgG] levels remained markedly 
skewed throughout the study.
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Trait
(a) total
(ROD)
m ean
BRSV-IgG
variance
(ROD)
median
(ROD)
dQ sk ew n ess
Day -28 />IgG 26.9 774.7 16.9 39.3 1 .1
Day -14 MgG 20.4 636.2 1 0 .2 25.8 1.5
Day 0 6IgG 13.8 417.6 4.8 16.7 2 . 2
Day 14 />IgG 2 0 . 0 238.6 16.1 16.0 2 . 0
Day 35 6IgG 38.9 365.3 37.5 27.6 0.5
Day 49 WgG 31.3 419.4 27.1 29.4 0.9
A6IgG(D-28 to D-14) -6 . 6 67.1 -4.8 1 0 .6 0.5 1
A6IgG(D-14 to DO) -6.5 78.9 -3.4 9.3 1.9
A61gG(D0 to D14) 6 . 2 245.1 5.3 21.7 -0 .1
A6IgG(D14 to D35) 18.7 468.7 17.6 38.5 0 . 2
AAIgG(D35 to D49) -7.7 226.1 -7.1 1 1 .8 1.4
3-day-area AIgG (prevac) 81 9213 42 106 1 .0 I,
3-day-area AIgG (postvao 192 7947 178 106 1 .0
1
:■ I
(b) BRSV-IgG] ' ;
(ROD) (ROD) (ROD) •;
Trait mean variance median dQ sk ew ness ■?
Day 0 AIgG] 2.2 6 . 6 1.3 2 . 2 2.7
Day 14 AlgG] 4.5 16.7 3.4 4.4 2 . 0
Day 35 61gG] 1 2 .6 115.4 9.7 12.7 1.9 ÇDay 49 61gG] 13.1 175.0 9.5 13.6 2.3 %
A6IgG](D0 to D14) 2.4 2 0 . 0 1.5 4.5 1.5
A6IgG](D14 to D35) 8 . 0 93.9 5.3 1 1 .0 1.9 iA61gG](D35 to D49) 0 . 6 92.7 -1 .0 5.1 4.2
3-day-area AIgG] (postvac) 58.0 1858.9 47.4 52.5 1.7
Table 3.1 Levels of (a) total BRSV-IgG on Days -28 to 49 and (b) BRSV-IgG] on Days 0 to 
49, relative to first vaccination, BRSV vaccine administered on Day 0 and Day 21. BRSV- 
IgG] levels not measured before Day 0. dQ (interquartile range); ROD (relative optical 
density). Values based on non-transformed ROD data.
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Figure 3.1 Antibody levels of (a) BRSV-IgG on Days -28 to 49 and (b) BRSV-IgG] on 
Days 0 to 49, relative to first vaccination. Median (central horizontal line), quartiles 
(outer horizontal lines), and range (outer vertical lines) shown. BRSV vaccine 
administered on Day 0 and Day 2 1 , BRSV-IgG] levels not measured before Day 0. 
Values are log transformed ROD data.
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3.4.1.1 BRSV-IgG and BRSV-IgG] antibody half-lives
Based on the regression coefficients for Days -28, -14 and 0, the half-life of total 
BRSV-IgG was estimated as 24.7 days (95% confidence interval: 22.4 -  27.0 
days). Based on the regression coefficient for Day 0, the antibody half-life of 
BRSV-IgG] was longer, estimated to range between 52 and 93 days.
3.4.1.2 BRSV-IgG and BRSV-IgG] antibody correlations
Pre-vaccination, BRSV-IgG levels for each sampling day were strongly 
correlated with BRSV-IgG levels for previous sampling days with {r =0.958) 
between Day -14 and Day 0, {r =0.928) between Day -28 and Day -14 and (r 
=0.908) between Day -28 and Day 0. BRSV-specific IgG] levels were measured 
on only one pre-vaccination day (Day 0).
The strongest post-vaccination correlations were found between the same 
antibody isotype collected on consecutive sampling days (Figure 3.2) with 
slightly weaker correlations for Day 49 BRSV-IgG than the other BRSV-IgG and 
BRSV-IgG] sampling days. Moderate correlations (r =0.560; r =0.526) were 
found between serum levels of Day 35 BRSV-IgG and BRSV-IgG] on Day 35 
and 49, respectively (Table 3.2). Other correlations between various isotypes and 
post-vaccination sampling day pairings were weak (r <0.250). All reported 
correlations are p <0 .0 0 1 .
The raw data for levels (untransformed) of BRSV-IgG on Days -28 to 49 and 
BRSV-IgG] on Days 0 to 49, relative to vaccination, are shown in Appendices 
A.3 and A.4, respectively.
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Table 3.2 Pearson correlations between levels of total BRSV-IgG and BRSV-IgG2 on 
Days 14, 35 and 49, relative to first vaccination (p <0.001). Analysis based on log 
transformed ROD data. BRSV-IgG2 levels not measured before Day 0.
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Figure 3.2 Correlations (p<0.001) between levels of total BRSV-IgG and BRSV-IgG2, 7
on Days 35 and 49, relative to first vaccination. BRSV vaccine administered on Day 0 ■1and Day 21. 3RSV“IgG2 levels not measured before Day 0. All values are log
transformed relative optical density (ROD) data. ■i:
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igG 1
D ay 35 AIgG 0 . 2 2 2 1
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Mean AMgG(D14 to D35) were ~3,0-fold greater than mean A^lgG(DO to D14); 
a difference consistent with a transient lag period before full antibody production 
is attained. The mean AZ?IgG(D35 to D49) was negative, demonstrating a drop in 
total BRSV-IgG to this point. The correlation between AMgG(D14 to D35) and 
A6IgG(D0 to D14) was low (r =+0,176) but positive. That between AMgG(D35 
to D49) and AHgG(D14 to D35), was again low but negative (r =-0.186).
3.4.1.3 BRSV-specific serum neutralisation test
Pearson correlation coefficients between results from the BRSV-IgG and BRSV- 
IgG2 ELISA and those obtained using BRSV-specific SNT were high, calculated 
to be 0.66 and 0.84, respectively (p <0.001).
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3.4.2 Analysis o f fixed effects
3.4.2.1 Sex / Management
Sex influenced levels of BRSV-IgG on all sampling days (REML; p <0.005) 
except post-vaccination Day 14. When taken over the entire sampling period, 
antibody patterns for male and female calves were similar. Figure 3.3(a) shows 
BRSV-IgG antibody responses when grouped on sex. Pre-vaccination, female ■;calves had higher levels o f BRSV-IgG than male calves (t-test, p <0.001) with
mean (antilog) levels of BRSV-IgG in the female calves being 1.9-fold, 2.0-fold
.and 2.1-fold greater than the corresponding levels of IgG in the male calves, on 
Days -28, Day -14 and Day 0, respectively (Figure 3.3(a)). An equivalent 
comparison for BRSV-IgGz antibody on Day 0 , showed no significant difference 
between sexes (t-test; p > 0 . 1 ).
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Post-vaccination on Days 35 and Day 49, levels of BRSV-IgG in the female 
calves were 1 .2 -fold (antilog) higher than those of the male calves on each day 
(t-test; p <0.001). On Day 14 post-vaccination, there was no significant 
difference in levels o f BRSV-IgG between the sexes (t-test; p >0.1). By Day 35, 
post-vaccination, female calves had higher (1.2-fold) levels of BRSV-IgGz 
antibody than the male calves (t-test; p <0.001). On the other post-vaccination 
days, sex did not influence levels o f BRSV-IgGz (t-test; p >0.1). BRSV-IgG 
variance fell 1.27-fold (antilog) at the vaccination event, although it appeared to 
be relatively stable before and after vaccination. There was no evidence of 
differences in variance based on sex^ at any stage during the study (Figure 
3.3(b)). Table 3.3 shows that pre-vaccination, sex was a significant factor (two- 
way interaction) for levels of BRSV-IgG, at a relatively stable level. Sex was not 
included in REML models for early Day 14, post-vaccination but once again 
featured (again as two-way interactions) on Days 35 and 49. Sex appeared to be 
important for levels of BRSV-IgGz on Days 35 and 49 (Table 3.4).
'
(a)
4.0 n
3.5-
3.0-
?  2.5-
% 2 .0 - 
>
00 1.5-
0.5-
0.0 -28 0 35 49-14 14
Day relative to  vaccination
4.01
3.5-
3.0-
^  2.5- 
% 2 .0 - 
m 1.5-
0.5-
0.0
-28 35-14 0 14 49
Day relative to vaccination
Figure 3.3 Levels of total BRSV-IgG (black) and BRSV-lgGa (blue) from Day -28 to 
Day 49, relative to vaccination. BRSV-IgG; levels not measured before Day 0. BRSV 
vaccine administered on Day 0 and Day 21. Means (a) and variances (b) presented. 
Values are log transformed relative optical densities (ROD%) and grouped on sex: female 
(O) and male (□)
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BRSV-IgG by sex i:
Day
-28
-14
0
14
35
49
REM L term
sex.year-of-birth
sex.dam-age
sex.dam-age
sex.Day 0-BRSV 
sex.year-of-birth
sex.year-of-birth
W ald
statistic
8.22
12.82
11.25
8.55
9.35
17.14
d.f. P  value
0.042
0.025
0.047
0.003
0.025
< 0.001
Table 3,3 Data analyses using REML models. Significant inclusions of the fixed effect sex, 
either as main effects or interactions for levels of BRSV-IgG on Days -28 to 49, relative to 
vaccination. BRSV vaccine administered on Day 0, Values are log transformed ROD data. 
Day 0-BRSV (level of BRSV-IgG on Day 0)
Day
0
14
35
49
REML term
sex
sex
W ald
statistic
1 8 .4 4
9 .0 7
BRSV-IgG2  by sex
d.f. P  value
1 < 0.001
1 0 .0 0 3
Table 3.4 Data analyses using REML models. Significant inclusions of the fixed effect sex, 
either as main effects or interactions for levels of BRSV-IgG; on Days 0  to 49, relative to 
vaccination. BRSV vaccine administered on Day 0. Values are log transformed ROD data.
3.4.2.2 Year-of-birth
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Figure 3.4(a) shows mean BRSV-IgG and BRSV-IgGa antibody responses when 
grouped onyear-of-birth. The effect of year-of-birth was unremarkable until Day 
35 post-vaccination. At this point year-of-birth became significant (REML; p 
<0 .0 0 1 ), due largely to higher levels in year 2 0 0 0  compared to the other three 
years. Mean BRSV-IgG levels in year 2000 were 1.3-fbld (antilog) and 1.6-fbld 
(antilog) the mean BRSV-IgG level of the other three years on Days 35 and 49, 
respectively. Year-of-birth was significantly associated with BRSV-IgG2 levels 
on all three post-vaccination days, due largely to lower levels (0 .8 -fold; antilog)
in 2001 compared to the mean BRSV-IgG; level for the other three years. Over
the 4-year duration of the experiment, mean post-vaccination levels of BRSV- !
IgG antibody in the male group tended to gradually increase from cohort 1998 to
cohort 2001, with overall 2001 levels being 1.6 -fold (antilog) those of 1998. In
contrast, mean post-vaccination levels of BRSV-IgG in the female group,
gradually decreased over the same 4-year period, with overall 2001 levels being
half those o f 1998.
Although general patterns of BRSV-IgG variability were veiy similar between 
year-of-birth cohorts, the first cohorts, 1998 and 1999, tended to have the highest 
pre-vaccination variances while the later cohorts, 2 0 0 0  and 2 0 0 1 , tended to have 
the lowest. This pattern of divergence may be stochastic or indicative of 
differences in the circulation of field BRSV infections between cohorts. There 
was a mean 1.2-fold (antilog) decrease in BRSV-IgG variance from Day 0 to 
Day 14 post-vaccination and post-vaccination BRSV-IgG variance was lower in 
2000 than the other three cohorts (Figure 3.4(b)). Year-of-birth featured for 
levels of BRSV-IgG on all days (as two-way interactions) except Day 14, post- 
vaccination (Table 3.5). Year-of-birth was significant on all sampling days for 
levels of BRSV-IgG;, apparently becoming more important for later days (Table 
3.6).
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Figure 3.4 Levels of total BRSV-IgG (black) and BRSV-IgG2 (blue) from Day -28 to Day 
49, relative to vaccination. BRSV vaccine administered on Day 0 and Day 21. BRSV-IgG; 
levels not measured before Day 0. Means (a) and variances (b) presented. Values are log 
transformed relative optical densities (ROD) and grouped on year-of-birth: 1998 (O ), 
1999 (□ ), 2000 ( A ) and 2001(V).
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BRSV-IgG by year-of-birth
Pay
-28
-14
0
14
35
49
REML term
W ald
statistic
year-of-birth. sex
year-of-birth.Holstein
y ear- of-b irth .Holstein 
year-of-biith.age
year-of-birth. Day 0-BRSV 
year-of-birth.sex
year-of-birth. sex
8.22
17.26
18.11
9.58
14.15
9.35
17.14
d.f. P  value
0.042
< 0.001
< 0.001
0.022
0.003
0.025
< 0.001
Ï
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Table 3.5 Data analyses using REML models. Significant inclusions of the fixed effect year-of- 
birth, either as main effects or interactions for levels of total BRSV-IgG on Days -28 to 49, 
relative to vaccination. BRSV vaccine administered on Day 0. Values are log transformed 
relative optical density (ROD) data. Day 0-BRSV (level of BRSV-IgG on Day 0)
BRSV-IgG2 by year-of-birth
Pay
0
14
35
49
REML term
W ald
statistic d.f. P  value
year-of-birth.age 1 1 . 2 0 3 0 . 0 1 1
year-of-birth 9.56 3 0.023
year-of-birth 1 2 .2 1 3 0.007
year-of-birth 41.16 3 < 0 . 0 0 1
year-of-birth 57.95 3 < 0 . 0 0 1
Table 3.6 Data analyses using REML models. Significant inclusions of the fixed effect year-of- 
birth, either as main effects or interactions for levels of total BRSV-IgG; on Days 0  to 49, 
relative to vaccination. BRSV vaccine administered on Day 0. Values are log transformed ROD 
data. I
___
3.4.2.3 Age
Figure 3.5 shows total BRSV-IgG and BRSV-IgG; antibody levels when 
grouped on the factor age. For Days -28,-14, 0 and 14, levels of BRSV-IgG for 
all age-groups were significantly different from each other (ANOVA, p <0.001). 
However on post-vaccination Days 35 and 49, these differences were minimal, 
with the highest values being only 1.06-fold (ANOVA; p <0.01) and 1.07-fold 
(ANOVA; p <0.05) greater than the lowest, respectively.
Before and including the day o f vaccination (Day 0), increasing age was 
associated with a steady decrease in the level o f both BRSV-IgG and BRSV-IgG; 
i.e. younger calves have higher levels of antibody, older calves have lower levels 
of antibody. On Day 14 post-vaccination, the youngest calves (age-groups I and 
II) have highest levels of BRSV-IgG, age-group III calves have the lowest levels 
of BRSV-IgG, while older calves (age-groups IV and V) have mid-range levels 
of BRSV-IgG. A similar pattern was found for Day 14 levels of BRSV-IgG;. By 
Day 35 post-vaccination, older calves generally had higher levels o f BRSV-IgG 
than younger calves although age-group III had again the lowest levels of BRSV- 
IgG antibody. By Day 49 post-vaccination, increasing age was associated with an 
increase in the levels o f both BRSV-IgG and BRSV-IgG; antibodies: the inverse 
to that found pre-vaccination.
After REML models were fitted, age at first vaccination was found to influence 
(REML; p <0.001) levels o f both subclasses of BRSV-IgG, on all pre­
vaccination days. On Days -28, -14 and 0, pre-vaccination, calf age had a 
negative effect on levels of antibody. Post-vaccination, age combined with pre­
existing Day 0 levels o f BRSV-IgG was found to significantly influence (REML; 
p <0.005) levels of antibody on Days 14, 35 and 49, the effect being negative for 
all three days but 2.3-fold (antilog) stronger on Day 14 than on Day 35 or 49.
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Figure 3.5 Levels of total BRSV-IgG (black) and BRSV-IgG] (blue) in a population of 
463 calves from Day -28 to Day 49, relative to first vaccination. Vaccine administered on 
Day 0 and Day 21. BRSV-IgG] levels were not measured pre-vaccination. Mean (a) and 
variance (b) presented. Results are log transformed ROD data and presented grouped on 
age: Group I~ 60-81 days (o). Group II ~ 82-103 days (□), Group 111 ~ 104-125 days (A), 
Group IV ~ 126-147 days (V) and Group V ~ 148-169 days (*)
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Deviations in levels of BRSV-IgG between days; AôIgG(DO to D14) and 
A^IgG(DO to 035) tended to increase with increasing age. For A6IgG(D0 to 
014), age-group V showed a mean deviation of (ROD =+13.3%) compared to a 
mean deviation of (ROD =-5.9%) for age-group I (Figure 3.6(a)). While for 
A6IgG(O0 to 035), age-group V showed a mean increase o f (ROD =+35.4%) 
compared to a mean decrease of (ROD =-8.9%) for age-group I (Figure 3.6(b)).
Age was important for levels o f BRSV-IgG, pre-vaccination and early post­
vaccination (up to Day 14), its significance appeared to decline for the later post- 
vaccination days (Table 3.7). Age was only significant on Days 0 and 14 for 
levels of BRSV-IgG2 (Table 3.8).
’C
By Day 35 post-vaccination, differences in levels of BRSV-IgG based on age 
were small, although levels of BRSV-IgG remained lowest in calves aged 104- 
125 days. By Day 49, older calves had the highest levels of BRSV-IgG, in an 
almost perfect inverse of the pre-vaccination scenario.
To summarise: Pre-vaccination, older calves have lower levels o f BRSV-IgG 
(and less markedly, lower BRSV-IgG2). Early post-vaccination (Day 14), calves 
younger than 103 days continued to have the highest levels o f BRSV-IgG but 
showed the smallest response (A) to vaccination. Calves aged 104-125 days 
although they do respond moderately well to BRSV vaccination, do so from a 
lower starting point than the younger animals and therefore have lower peak 
levels of BRSV-IgG on Day 35. Calves older than 125 days, have marginally 
lower peak levels of BRSV-IgG on Day 35 than younger calves. To arrive at ,those peak levels however, these older calves show much greater antibody 
responses (A), the effect apparently positively associated with age.
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Figure 3.6 Deviation in level of BRSV-IgG on (a) A6IgG(D0 to D14) and (b) 
AôIgG(DO to D35). Median (central horizontal line), quartiles (outer horizontal lines), 
and range (outer vertical lines) shown. Values are non-transforined relative optical 
density (ROD) data and presented grouped on age: age-group I -  60-81 days, age- 
group II ~ 82-103 days, age-group III -  104-125 days, age-group IV ~ 126-147 days 
and age-group V ~ 148-169 days.
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BRSV-IgG by age
Day REM L term
W ald
statistic d.f. P  value
-28 age 85.36 1 < 0 . 0 0 1
-14 age 99.70 1 < 0 . 0 0 1
0 age. year-of-birth 9.58 3 0 . 0 2 2
14 age.Day 0-BRSV 82.41 1 < 0 . 0 0 1age 9.84 1 0 . 0 0 2
35 age.Day 0-BRSV 5.79 3 0.016
49
Table 3.7 Data analyses using REML models. Significant inclusions of the fixed 
effect age, either as main effects or interactions for levels of BRSV-IgG on Days -28 
to 49, relative to vaccination. Vaccine administered on Days 0 and 21. Values are log 
transformed ROD data. Day 0-BRSV (level of BRSV-IgG on Day 0)
Pay REM L term
BRSV-IgG2  by age
Wald
statistic d.f. P  value
0 age.year-of-birth 1 1 . 2 0 3 0 . 0 1 1
14 age.Day 0-BRSV age
21.49
12.93
1
1
< 0 . 0 0 1
< 0 . 0 0 1
35 - - -
49 _
Table 3.8 Data analyses using REML models. Significant inclusions of the fixed 
effect age, either as main effects or interactions for levels of BRSV-IgGz on Days 
0 to 49, relative to vaccination. Vaccine administered on Days 0 and 21. Values are 
log transformed ROD data. Day 0-BRSV (level of BRSV-IgG on Day 0)
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/A3,4.2.4 Pre-existing antibody
I"In general, levels of pre-existing BRSV-IgG antibody on Day 0 suppressed 
subsequent humoral responses to vaccination. These effects were most apparent 
early post-vaccination. Figure 3.7 shows the BRSV-IgG deviation induced 
between Day 0 and Day 14 (A6IgG(D0 to D14)) against the level o f pre-existing 
BRSV-IgG at vaccination.
Regression coefficients when levels of pre-existing antibody were included in 
REML models for induced BRSV-IgG and BRSV-IgG2 levels on Days 0 to 49 are 
shown in Table 3.9. Across both sexes, pre-existing Day 0 levels o f BRSV-IgG 
were negatively correlated with vaccine induced levels of BRSV-IgG on Days 35 
and 49, but not those of BRSV-IgGs on the same days. Day 14 levels of BRSV- 
IgG were negatively associated with induced levels of BRSV-IgG on Days 35 
and 49 in the female group but positively associated with corresponding Days in 
the male group. Day 14 levels o f BRSV-IgGa were positively associated with 
induced levels of BRSV-IgGz antibody on Day 35 and Day 49, in both sexes.
Using logistic regression, it was possible to develop binomial models 
(parameters: a  and (3 detailed in Table 3.10) and therefore calculate and graph the 
probability that the Day 0 level o f pre-existing BRSV-IgG was associated with a 
positive deviation in BRSV-IgG. This process was performed for A6IgG(D28 to 
D42), AZ)IgG(D28 to D63) and A6IgG(D28 to D77). Consequently estimates 
were obtained o f the 50% {p =0.5) and 90% {p =0.9) threshold levels were 
estimated and plotted for BRSV-IgG antibody (Figure 3.8).
For BRSV, the 50% inhibitory threshold on Day 0 was 11.7% for Day 42 
responses, 25.9% for Day 63 responses, and 19.8% for Day 77 responses. For 
BRSV, the 90% inhibitory thresholds on Day 0 were 3.8%, 12.8% and 9.5% for 
Days 42, 63 and 77, respectively.
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Figure 3.7 Deviations in level o f total BRSV-IgG - AAIgG(DO to DI4) against level o f 
pre-existing Day 0 BRSV-lgG. Best fit regression line (solid). Zero threshold (A^IgG =0) 
(dashed). A/>IgG(DO to D14) values are untransformed. Day 0 BRSV-lgG are log 
transformed ROD data.
Induced IgG a n tib o d y  on D ay
14 35 49
W) C e oIf
«
49
35
14
F - 0.92 (0.21) -0.42 (0.07) -0.48 (0.08) F
M - n.s. -0.18(0.08)' -0.28 (0.08) M
F 0.90 (0.05) - -0.21 (0.04) -0.23 (0.04) F
M 0.77 (0.05) - 0.24 (0.06) 0.23 (0.07) M
F 0.32(0.08)0.35 (0.07) - 0.87 (0.04) F
M 0.48 (0.07)0.45 (0.06) - 0.85 (0.05) M
F n.s. n.s. 0.32 (0.06) - F
M n.s. n.s. 0.L5 (0.06)2 - M
14
35
49
M "0
§.TO" «ÎÏ3 (M
49 35 14 0
Induced lgG 2 antibody on Day
Table 3.9 REML analysis based on log transformed ROD data
Above diagonal (black): Regression coefficients (standard error) when level o f pre-existing 
BRSV-lgG on Days 0 to 49 is included in REML models for BRSV-lgG on Days 0 to 49. 
Below diagonal (blue): Regression coefficients (standard error) when level o f pre-existing 
BRSV-lgGz on Days 0 to 49 is included in REML models for BRSV-lgGzon Days 0 to 49. 
Results presented grouped on sex: female (F), male (M). All associations have p <0.001 
except '(p =0.019), ^(p =0.022) and n.s. (p >0.1)
98
îE2S.
Logistic reg ression  model 
Day 14 Day 35 Day 49
a 4.82 10.08 8.97
(0.46) (1.19) (1.01)
P -1.96 -3.09 -3.00
(0.18) (0.37) (0.34)
Table 3.10 Estimated parameters a  and P for levels o f total BRSV-lgG on Days 14, 35 and 
49 against levels o f pre-existing Day 0 BRSV-IgG. Means (standard error) presented, (p 
<0.001) for all regression coefficients. Logistic regression based on log transformed ROD 
data.
0.9
0 .8 -
0.7-
0.6 -
.aI 0.5-
0 . 0.4-
0.3-
0 2 -
0 .0 -
1 0 1 2 3 5 6 74
Day 0 BRSV-lgG log(%)
Figure 3.8 Probability o f positive total BRSV-lgG antibody response on Days 14, 35 and 
49 against level o f Day 0-BRSV. Day 0 BRSV-lgG levels are log transformed. Lines 
shown for A6lgG(D0 to D14)~black, A6lgG(D0 to D35)~blue and A6lgG(D0 to 
D49)~red. p  =0.5 (green dashed), p  =0.9 (green solid). Logistic regression based on log 
transformed ROD data.
99
3.4.3 Analysis o f genetic effects
3.4.3.1 Cross-breeding effects - Holstein
Holstein influenced levels of BRSV-IgG antibody (REML; p <0.001) on pre­
vaccination Days -28, -14 and Day 0 (the day of vaccination), but had no 
significant effect on BRSV-IgG levels, in the post-vaccination period. BH calves 
with greater proportions o f Holstein genes {Holstein = 0.75) had the highest pre­
vaccination levels of BRSV-IgG with mean ROD values of 19.7%, 12.2% and 
7.6% on Days -28, -14 and Day 0, respectively (Figure 3.9). F2 calves with 
intermediate proportions o f Holstein genes {Holstein = 0.50) had pre-vaccination 
levels of BRSV-IgG with mean ROD values of 13.1%, 8.4% and 5.2% on Days - 
28, -14 and Day 0, respectively. BCH calves with the lowest proportions of 
Holstein genes {Holstein ~ 0.25) had the lowest pre-vaccination levels of BRSV- 
IgG with mean ROD values o f 8 .6 %, 5.9% and 4.0% on Days -28, -14 and Day 
0 , respectively. BRSV-IgG2 antibody levels were much lower but a similar 
pattern existed. On Day 0, calves with proportions Holstein = 0.75, 0.50 and 0.25 
had mean BRSV-lgG2 ROD values of 2.7%, 1.7% and 1.5%, respectively.
Prevaccination, breed-cross BH calves had on average 1.5-fold (antilog) higher 
levels of BRSV-IgG than F2 calves, which in turn had 1.4-fold (antilog) higher 
levels than BCH calves. On Day 0, BRSV-IgG2 levels in the BH calves were on 
average 1.4-fold (antilog) those o f the BCH or F2 calves. Neither breed-cross nor 
Holstein influenced levels of BRSV-IgG or BRSV-IgG2 in the post-vaccination 
period. This finding was confirmed by REML modelling (REML; p >0.1), so that 
levels of BRSV-IgG and BRSV-IgG2 were influenced by the factor Holstein, only 
pre-vaccination (Tables 3.11 and 3.12)
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Figure 3.9 Levels o f total BRSV-lgG (black) and BRSV-lgGz (blue) from Day -28 
to Day 49, relative to vaccination. BRSV vaccine administered on Day 0 and Day 
21. Means (a) and variances (b) presented. BRSV-lgG: levels not measured before 
Day 0. Values are log transformed relative optical densities (ROD) and presented 
grouped on Holstein: 0.25 (O), 0.50 (□) and 0.75 (A ).
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BRSV-IgG by Holstein
Day REML term
Wald
statistic d.f. P  value
Holstein.year-of-birth
Holstein.year-of-birth
Holstein.year-of-birth
10.25 3
17.26 3
16.35 3
0.017
< 0.001
< 0.001
-28
-14
0
14
35
49
Table 3,11 Significant inclusions of the fixed effect Holstein, either as main effects or 
interactions for levels of total BRSV-IgG on Days -28 to 49, relative to vaccination. 
BRSV vaccine administered on Day 28. Values are log transformed relative optical 
density (ROD) data. Data analyses using REML models.
BRSV-IgG2  by Holstein
Day REML term
W ald
statistic d.f. P value
0 Holstein 5.57 1 0.018
14 - - -
35 - - -
49 -
Table 3.12 Significant inclusions of the fixed effect Holstein, either as main effects or 
interactions for levels of BRSV-lgG: on Days 0 to 49, relative to vaccination. BRSV 
vaccine administered on Day 28. Values are log transformed ROD data. Data analyses 
using REML models.
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3.4 3.2 Cross-breeding effects -  recombination loss
Figure 3.10 show s that there w as no evidence in this study that recom bination- 
loss significantly  influenced levels o f  B R SV -lgG  and BRSV -IgG ] on any o f  the 
sam pling days (R EM L; p >0.1).
4.0 n
3.5-
3.0-
0.5-
0.0 0 35 49-28 -14 14
Day relative to vaccination
Figure 3.10 Levels of total BRSV-lgG (black) and BRSV-lgG] (blue) from Day -28 
to Day 49, relative to vaccination. BRSV vaccine administered on Day 0 and Day 
21. Means presented. BRSV-lgG] levels not measured before Day 0. Values are log 
transformed relative optical density (ROD) data and presented grouped on 
proportion recombination-loss: 0.5 (O) and 1.0 (□)
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3.4.33 Sire effects
To maximise the potential power and experimental objectivity of the test, all 
available results were used, without stratification, to evaluate genetic effects 
(Table 3.13). Trait heritabilities and log-likelihood statistics for inclusion of sire 
on all sampling days up to and including the day of vaccination (Day 0) were 
relatively constant and of a lower order than those found on the later sampling 
days. Post-vaccination, the contribution of sire became much more significant on 
Days 14 and 35 before returning to lower levels on Day 49. Over this period, 
estimates of sire heritability, i f  (±s.e.) peaked at 0.16 (±0 .1 1 ) and 0.29 (±0.17) on 
Days 14 and 35, respectively. The Day 35 i f  value is robust - restricting the 
analysis by removing the upper or lower ten per cent of the dataset causes the 
value to change only slightly to 0.32 (±0.19) and 0.26 (±0.16), respectively. The 
i f  (±s.e.) values associated with the deviation in levels of antibody: A6IgG(D0 to 
D14), AHgG(DO to D35) and A6IgG(D0 to D49) were greater than those for total 
antibody levels, with values of 0.20 (±0.15), 0.52 (±0.26) and 0.17 (±0.14), 
respectively. Although heritable effects were detectable using area under the 
curve as an alternative phenotypic trait, there was no evidence that using these 
summary traits e.g. 3-day-area 6 IgG(prevac), provided any additional information.
On a natural logarithm scale, BRSV-IgG phenotypic variance (op^) was much 
larger (4.2-fold; antilog) over the pre-vaccination period than the post- 
vaccination period. On the same scale, BRSV-IgG] Op was approximately twice 
(antilog) that of BRSV-IgG Op^  over the post-vaccination period.
On all three post-vaccination days, the progeny of one sire (ROl) were 
consistently associated with the highest levels o f BRSV-IgG, while the progeny 
of another sire (R11) were consistently associated with the lowest levels (Figure 
3.11). The progeny of these two sires had very similar pre-vaccination levels of 
BRSV-IgG, with a mean 0.98-fold (antilog) difference over the three days. The 
ratios of the mean (antilog) levels o f BRSV-IgG antibody (highest/lowest) 
between these two sires were 1,82, 1.67 and 1.75 on Days 14, 35 and 49, 
respectively. The sire with progeny with the highest (R05) pre-vaccination level 
of BRSV-IgG and the sire with progeny with the lowest (H27) pre-vaccination 
level of BRSV-IgG had intermediate responses to vaccination between the two 
extreme sires previously outlined.
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BRSV-IgG
Table 3.13 Trait heritabilities h^(standard error), total phenotypic variances (op^ ) on 
natural logarithm scale and sire log-likelihood ratio shown. Statistics for absolute 
levels, area-under-curve and deviations (A) between Day 0 and Days 14, 35 and 49 
post-vaccination, for both total BRSV-lgG and BRSV-IgG]. 
n.s. (p >0.1). Estimates produced using REML.
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overall log-likelihood 1trait overall h on log scale ratio for sire
Day -28 MgG 0 . 1 0 (0.09) 1.46 n.s.
' S':
1
Day-14 MgG 0 . 1 2 (0.09) 1.53 n.s. 'I
Day 0 blgG 0 . 1 0 (0.08) 1.44 n.s. '7$
Day 14 blgG 0.16 (0 .1 1 ) 0.38 < 0 . 0 1
Day 35 ^IgG 0.29 (0.17) 0.26 < 0 . 0 0 0 1
Day 49 61gG 0 . 1 1 (0.09) 0.41 0.06 1
3-day-area MgG (prevae) 0 . 1 0 (0.09) - <0.05
3-day-area AIgG (postvac) 0.23 (0.14) - < 0 . 0 0 1 -•V
BRSV-IgG] :
Day 0 6IgG] 0.14 (0 .1 2 ) 0.67 n.s.
Day 14 AIgG] n.s. 0.76 n.s. Ï
Day 35 MgG] 0.14 (0 .1 1 ) 0.75 <0.05
Day 49 6IgG] 0.09 (0.09) 1.03 n.s. :
3-day-area MgG] (postvac) 0.14 (0 .1 1 ) - <0.05
A BRSV-IgG J:7■ 4
A6IgG(D0 to D14) 0 . 2 0 (0.15) 0.80 <0.05
A6IgG(D0 to D35) 0.52 (0.26) 0.49 < 0 . 0 0 0 1 1
A6IgG(D0 to D49) 0.17 (0.14) 0.60 <0.05 :ï i
A6IgG](DG to D14) n.s. 1.23 n.s.
1A61gG](D0 to D35) 0.36 (0.20) 1.07 < 0 . 0 0 0 1 . :
A61gG](D0 to D49) 0 . 2 1 (0.15) 1.04 < 0 . 0 1
g
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Figure 3.11 Levels of total BRSV-lgG from Day -28 to Day 49, relative to first 
vaccination. BRSV vaccine administered on Day 0 and Day 21. BRSV-lgGz not shown. 
Values are log transformed relative optical densities (ROD) and presented, grouped on 
sire: 4 FO Charolais (red) and 8 FI Holstein/Charolais (black). Note y-axis begins at 1.0.
No consistent pattern was apparent for mean levels o f  B R SV -lgG ] antibody, 
when grouped on sire.
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3.4.3 3 Maternai effects
3.4,3.3.1 Dam-age
Due to the availability  o f  three pre-vaccination sam pling points, an opportunity  
presented to study any persistent dam  effects in the results. D am s aged four, five 
and six years old had calves w ith very sim ilar levels o f  B R SV -lgG  (A N O V A ; p 
>0.1). Together, dam s aged 4-6 years old had offspring w ith significantly 
d ifferent levels o f  total B RSV -IgG  than dam s aged tw o, three and seven 
(A N O V A ; p <0.05) on all three pre-vaccination days (Figure 3.12). O lder dam s 
have calves with h igher levels o f  B R SV -IgG , the effect appearing to stabilise for 
dam s aged betw een 4 and 6 years old. (There are only 3 dam s aged seven years 
or m ore w hich provides a very small sam ple). The age o f  the dam  at calving 
influenced levels o f  B RSV -IgG  pre-vaccination (REM L; p <0.05) present as an 
interaction with sex on Days -14 and 0. H ow ever, the overall effect o f  dam -age  
on BRSV -IgG  appeared to be o f  a low er o rder than that for the factor H olstein.
4.0
3.5
3.0
&  2.5
g  % 2.0
I  1.5
CO
0.5
0.0
Day relative to vaccination
Figure 3.12 Levels o f total BRSV-lgG from Day -28 to Day 49, relative to first 
vaccination. BRSV vaccine administered on Day 0 and Day 21. Mean values are log 
transformed relative optical densities (ROD) and presented grouped on dam -age: 2 ( • ) ,  3 
(■), 4 (O ), 5 (□), 6 (A ) and 7 (A) years.
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Post-vaccination, dam-age influenced levels of BRSV-IgG on Day 35 only, as an 
interaction v^ \X\\ year-of-birth (Table 3.14). Dam-age was significant for levels of 
BRSV-IgGz on post-vaccination Day 14 only (Table 3.15)
Day REML term Waldstatistic
BRSV-IgG by dam-age 
d.f. P value
-28
-14
0
14
35
49
dam-age.sex 
dam-age.sex
dam-age.year-of-birth
12.82 5
11.25 5
22.13 11
0.025
0.047
0.023
Table 3.14 Significant inclusions of the fixed effect dam age, either as main effects or 
interactions for levels of total BRSV-lgG on Days -28 to 49, relative to vaccination. BRSV 
vaccine administered on Days 0 and 21. Values are log transformed relative optical density 
(ROD) data. Data analyses using REML models.
Day REML term
Wald
statistic
BRSV-IgG2 by dam-age 
d.f. P value
14 dam-age 19.80 7 0.006
35 - - -
49 - -
Table 3.15 Significant inclusions of the fixed effect dam age, either as main effects or 
interactions for levels of BRSV-IgG2 on Days 0 to 49, relative to vaccination. BRSV 
vaccine administered on Day 0 and 21. Values are log transformed ROD data. Data 
analyses using REML models.
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3.43,3.2 Components of variation at individual time points
Other maternai effects were evaluated using ASREML procedures (ASREML,
VSN International Ltd) instead of Genstat procedures (Genstat 7.0, VSN 
International Ltd) used previously for the sire effects. The ASREML software 
accounts for the Robogen pedigree structure differently than the Genstat 7.0 
software and therefore slight differences between calculated eoeffieients, such as 
additive heritability, were expected and found.
As explored earlier (seetion 3.4.1), mean levels of BRSV-IgG (the phenotype) 
declined exponentially to low values pre-vaccination but then increased rapidly 
with a peak on Day 35 post-vaccination. In contrast, phenotypic variances were 
much larger post-vaccination than pre-vaccination (see section 3.4.3.3), an 
arrangement which appeared to be uniform across all levels of BRSV-IgG when 
segregated on sex^ year-of-birth or breed-cross (sections 3.4.2.1, 3.4.2.2 and 
3.4.3.1)
A clear pattern was observed for the eomponents of the variation determined by 
the timing relative to BRSV vaccination (Table 3.16). Pre-vaccination, there was 
no evidence of additive (h^) heritability (p >0.05) but a strong and consistent 
maternal (m^) transmissibility was observed, explaining 0.33 to 0.35 o f the total
%
phenotypic variance (p <0.001). Post-vaccination, the partition pattern of 
phenotypic variance reversed. Over that period, the maternal variance was 
smaller than the additive variance and statistically significant (p <0.05) on Day 
35 only. In contrast, evidence of additive variation was found on all post­
vaccination days (p <0.05) and as previously established, additive heritability 
was greatest on Day 35 with a value o f 0.285, compared to 0.164 and 0.171 for
Days 35 and 49, respectively. However examination of the component 
.heritabilities, in relation to the total phenotypic variances (Figure 3.13), suggests 
that for the BRSV antibody responses observed, total transmitted phenotypic 
variance is at similar levels post-vaccination to that pre-vaccination.
___
Trait Day relative to first vaccination
tatistic -28 -14 0 14 35 49
h: 0.031 0.061 0.007 0.164 0.285 0.171
[0.000] [0.000] [0.000] [0.018] [0.069] [0.018]
0.352 0.325 0.336 0.016 0.109 0.054
[0.229] [0.204] [0.211] [0.000] [0.000] [0.000]
1.684 1.970 1.857 0.551 0.250 0.482
Op (m) 1.554 1.545 1.454 0.506 0.299 0.503
P(f) 2.85 2.32 1.96 2.75 3.65 3.30(0.181) (0.209) (0.180) (0.130) (0.099) (0.122)
R(m) 2.30 1.89 1.37 2.75 3.46 3.10
(0.169) (0.180) (0.154) (0.122) (0.106) (0.122)
Table 3.16 Components o f overall transmitted variance; additive heritability (h^) and 
maternal transmissibility (m^) for levels o f total BRSV-IgG (log transformed) pre- and post­
vaccination, together with phenotypic variances (op^) and means (p) for female (f) and male 
(m) groups, respectively. BRSV vaccine administered on Day 0 and Day 21. Standard errors 
for the means are given in rounded parentheses, and the lower values o f the 95% support
intervals for 
ASREML.
h and m are given in square parentheses. Estimates produced using
0.5-,
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Figure 3.13 Relationships among variance components over time. Total transmitted 
variance ( ^ )  and it’s components: additive heritability fraction (O) and maternal 
transmissibility fraction (□) for levels o f total BRSV-IgG (log transformed) on Days -28 
to 49, relative to first vaccination. BRSV vaccine administered on Day 0 and Day 21. 
Estimates produced using ASREML.
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3.4,3.3.3 Pre-vaccination traits
The correlations among the maternal components and the residual components 
over the three pre-vaccination observations are shown in Table 3.17. The results 
demonstrate the repeatable nature of the observations in this trial. The component 
attributable to the individual dam was consistent across all three occasions with 
correlations close to 1 (the formal test against zero correlations was p <0.001, 3 
d.f.). The residual variance, which includes variation in the dam effect between 
cohorts, environmental effects on the calf and laboratory technical errors, was 
also highly repeatable across occasions with correlations ranging from 0.79 to 
0.88. It is this residual component that would have been poorly repeatable if 
wildtype BRSV infections were widespread in the pre-vaccination period. The 
high repeatability in the individual components of variation resulted in 
phenotypic correlations ranging from 0.86 to 0.93.
'i:
Day relative to first vaceination
-28 -14 0
I -28-14
o |
0.883 (0.012) 0.789(0.020)
0.996 -  0.800(0.021)
0.986 0.992
Table 3.17 The maternal and residual correlations for pre-vaccination levels of total 
BRSV-IgG on Days -28, -14 and 0 (log transformed). Maternal correlations are below the 
diagonal, residual correlations above. Results presented as means (standard error). 
Estimates produced using ASREML. *No standard errors available from ASREML due to 
proximity of estimates to positive definite boundary ( 1 )
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3.4.3.3.4 Post-vaccination traits
Post-vaccination, the patterns differed as shown in Table 3.18. Whilst there was 
evidence of positive genetic correlations (rg) across Days 14, 35 and 49 (p <0.01, 
all rg = 0, 3 df), the residual correlations were more variable: in particular. Day 
14 was poorly correlated with later observations (IgG production can take up to 
18 days for peak production and in this study calves received a booster 
vaccination on Day 21), whilst the residual correlation of Day 35 to 49 was 
moderate to high. Day 14 would seem to represent a transitional antibody level 
whereas Day 35 and 49 seem to represent the more mature antibody response. 
This pattern was also reflected in a low phenotypic correlation of Day 14 with 
later days (0.21 and 0.17 for Days 35 and 49, respectively) but a high phenotypic 
correlation between Day 35 and Day 49.
I
g
14
35
49
Day relative to first vaccination 
14 35 49
0.055 (0.061) 0.026 (0.056)
0.760 -  0.666 (0.039)
0.896 0.966
f
;
■
Table 3.18 Genetic and residual correlations for post-vaccination levels of total BRSV- 
IgG (log transformed). Genetic correlations are below the diagonal, residual correlations 
above. Results presented as means (standard error). Estimates produced using ASREML* 
No standard errors available û'om ASREML due to proximity of estimates to positive 
definite boundaiy Î
1 1 2
I
:l
"A
1Day relative to first vaceination 
PRE 35 49
PREîi «
| iI 49
Table 3.19 Maternal and residual correlations for levels of total BRSV-IgG (log 
transformed) pre-vaccination mean (PRE) and post-vaccination Days 35 and 49. 
Maternal correlations are below the diagonal, residual correlations above. Estimates 
produced using ASREML. Results presented as means (standard error).
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3.4.33.5 Combined pre- and post-vaccination traits
In the light of the results obtained above, demonstrating a high repeatability 
(strong correlations) among observations pre-vaccination, and justified further in 
the Discussion, the observation for Days -28, -14 and 0 were averaged and 
treated as a single trait (PRE). Furthermore to overcome the convergence 
problems of estimating variance components on the limited numbers, the 
relationship of PRE with Day 14 and with Days 35 and 49 were tested in separate 
analyses.
The pre-vaccination variance identified included a maternal component but no 
additive genetic components, whereas by Day 14 the variance included additive 
genetic but no maternal component. Therefore the only relevant correlation (±se) 
which arose when Day 14 and PRE were tested is from the residual effects, 
which were 0.047 (±0.059; p >0.05), with the overall phenotypic correlation 
being smaller i.e. 0.034 (±0.043).
The relationships of Day 35 and Day 49 with PRE were clearer. The inclusion of 
PRE in the multi-trait analysis allowed better identifieation o f maternal effects 
for levels of BRSV-IgG on Days 35 and 49. Correlations for the residual and 
maternal components are shown in Table 3.19. The results for the genetic 
components were veiy similar to those described above (i.e. the heritabilities as 
shown in Table 3.16 (p i09), and the genetic correlation between Day 35 and Day 
49 as shown in Table 3.18). The relationships between the maternal components 
for PRE and Days 35 and 49 were both negative and although standard errors 
were large, the formal test of each correlation was statistically significant (each p #
<0.05, 1 df).
-0.258 (0.071) -0.312(0.064)
-0.474 (0.236) -  0.658 (0.054)
-0.690 (0.453) 0.772 (0.287)
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3.5 Discussion
Muggli et a l (1987) found no difference between levels o f antibody induced in male 
and female beef calves, vaccinated against the virus, BHVl. In the current study, 
sex/management exerted mueh stronger effects pre-vaccination than post-vaccination, 
probably due to a combination o f group-specific pathogen exposure and the disparate 
calf-rearing systems used, effectively daiiy and suckler regimes.
Many environmental factors such as housing, nutrition, weaning, transportation and 
field infections may also influence levels o f IgG in juvenile cattle (Franklin el a l, 
2003; Mackenzie et a l, 1997; Norheim and Simensen, 1985; Quigley et a l, 1995; 
Rajala and Castren, 1995) and may contribute to the variability hQtwQQn year-of-birth 
cohorts. Although the impact of physiological sex alone remains unknown, it is 
striking how, despite these external pressures, the post-vaccination BRSV-IgG 
antibody patterns of both sex/management groups were very similar in magnitude and 
frequency.
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This study demonstrated that serum levels o f BRSV-IgG antibody are heritable. It 
appears to be the largest data-set available, to date, that provides evidence that 
antibody levels in cattle following vaccination against a specific viral agent are f
substantially influenced by both additive and maternal genetic factors, in addition to 
other environmental effects.
Respiratoiy disease caused by BRSV, is largely a condition of young cattle. Although 
it complicates the analysis, it is crucial that responses to BRSV vaccination should be 
studied in early life. This is particularly important over the period when levels of 
maternally-derived passive antibody subside in calves, which when young may be 
only partially immunocompetent. Epidemiologically, this window of vulnerability has 
veiy important implications for developing strategies to optimise BRSV vaccination 
and prevent clinical disease in young cattle.
The design of this experiment confounds management effects with those of 
physiological sex. Vertheyli (2001) reviews sex-based differences in humoral 
immunity in humans and mice but the majority of previous research in cattle suggests 
that management is the larger determinant o f levels of IgG antibody. Management 
practices but not sex had significant effects on antibody titres to foreign antigens
A(human erythrocytes and ovalbumin) in dairy calves (Burton et a l, 1989a), while
a.
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A
levels were four-fold lower in calves aged less than 5 weeks old compared to those 
aged over 32 weeks old and also that older calves had higher circulating lymphocyte 
counts than younger calves. Those cellular findings may explain much higher levels 
of antibody responses found by those authors in older calves when compared to 
younger age groups. Age-associated responses have also been described previously 
for immunisation of cattle against antigens such as human serum albumin (Lie, 1979), 
keyhole limpet haemocyanin (Pollock et al., 1994), BRSV and Mycoplasma spp. 
(Martin et a l, 1999). Scholium and Marshall (1985) reported that three times as many 
6 -month old calves as 3-month old calves, responded to vaccination against 
leptospiral bacterins. In that study, older groups had significantly higher antibody 
titres than younger ones. In Holstein calves from BVDV-immunised dams, the median 
ages by which BVDV-specific colostral antibodies declined to negligible levels were 
141 and 114 days, respectively (Munoz-Zanzi et a l, 2002). In that study, subsequent 
antibody responses to BVDV vaccination were strongly influenced by peak levels of 
absorbed colostral antibody. Again in Holstein calves, Hodgins and Shewen (1998) 
reported an age-related unresponsiveness to immunisation SLgomsi Pasteurella spp.
The relationship between age, level o f maternally derived antibody and BRSV 
vaccine responses has been discussed previously (Kimman et a l, 1987b; Kimman et 
a l, 1988; Muggli-Cockett et a l, 1992). In human infants, a paradigm was proposed 
where immaturity of the immune system {age) negatively affected primarily 
antibodies directed against the liRSV F-glycoprotein, while pre-existing maternal 
antibody negatively affected primarily antibodies directed against the hRSV G- 
glycoprotein (Murphy et a l, 1986). The late decline in levels o f BRSV-IgG despite a 
booster vaccination may reflect consumption, increased catabolism or a down- 
regulation of the synthesis of specific IgG. The summaiy trait, area under the curve, 
has been used previously by other authors (Grell et a l, 2005; Nielsen et a l, 2001) for 
evaluation of antibody response. In the current study, genetic effects were more 
apparent when evaluated for antibody levels on individual sampling days. 
Cross-breeding influenced pre-vaccination levels o f antibody; animals with a higher 
proportion of Holstein genes had greater levels o f BRSV-specific IgG antibody than 
animals with higher proportions o f Charolais genes. This dissimilarity may be due 
either to calf-breed or birth-dam factors. Breed-associated differences in antibody 
responses reported previously, such as higher antibody responses in Angus compared 
to Simmental calves (Engle et a l, 1999), focussed on broad contrasts between breeds.
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Using the Robogen population there was no evidence for interbreed differences 
between Holstein and Charolais cattle breeds with regard to IgG antibody responses to 
BRSV vaccination. As only twelve different sires were used it is likely that a subset 
rather than the full repertoire o f bovine alleles for humoral response may have been 
represented.
Whereas non-specific bovine respiratoiy disease was shown to have low heritabilities 
in housed and grazing eattle (Muggli-Cockett et a l, 1992), a variety of novel antigens 
such as human serum albumin, human erythrocytes and ovalbumin have induced 
antibody responses with heritabilities o f 0.31 to 0.56 (Lie, 1979); 0.51 and 0.87 
(Burton et a l, 1989a) and 0.50 (Wagter et a l, 2000) in cattle. Detilleux et ah (1994) 
described mean heritabilities o f between 0.55 to 0.84, 0.24 to 0.63 and up to 0.43 for 
basal levels of IgM, IgG2 and IgGi, respectively. Newman et ah (1996) identified 
significant effects of both sire and MHC BoLA type on levels of IgG antibody, 
induced by immunisation against the bacterium Brucella abortus in mixed-breed beef 
heifers. Furthermore, Garcia-Briones et al (2000) described associations between 
allelic variability in specific BoLA genes and the humoral response o f Hereford steers, 
to vaccination against foot-and-mouth disease. As in the latter two studies, by 
concentrating on antibody responses linked to pathogens, which are a present threat to 
cattle production systems, the current study is intended to demonstrate how farm 
animal genetics can influence individual animal immunity to infectious agents. If 
indicators of immunity such as BRSV-specific total IgG have h  ^ of -0.3 (obtained 
under pathogen and management conditions typical of UK commercial farms) it is a 
sufficiently heritable trait for practical incorporation into selective breeding 
programmes. This is within-breed variation based on sire variance, independent of 
other multi-breed effects such as heterosis. This report shows that such an approach is 
both robust and highly relevant to contemporary problems “in the field” such as BRD.
Calves are born agammaglobulinaemic. Until the maturation of the immune system at 
approximately three months old, the level o f serum antibody depends entirely on 
absorption of passive antibody, from colostrum ingested at birth (Matte et a l, 1982).
..i
Initial post-absorption levels o f maternally-derived passive antibody (MDPA) in
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neonatal calves are governed by the pathogen experience of the dam, colostrum 
quality, volume and efficiency of the intestinal absorptive process (Abel Francisco 
and Quigley, 1993). Thereafter, levels of serum MDPA decay exponentially due to 
increasing animal size and antibody catabolism. The effects of maternally inherited
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immunity are accepted to be most important in neonatal animals and decline as 
animals mature (Grindstaff et a l, 2003). However, early bovine life is typically beset 
by infectious diseases, such as BRSV respiratoiy disease, so the impact of these 
maternal factors on long term productivity is significant (Belknap et a l, 1991; Wells 
et a l, 1996). Moreover, as passive immunity diminishes and is superseded by an 
endogenous immune response, the transitionary period marks a window of specific 
vulnerability and elevated susceptibility to infectious disease.
Extrinsic factors (season, climate, nutrition, etc) which control MDPA have been 
systematically investigated in cattle (Besser and Gay, 1994; Jaster, 2005). Genetic 
control however has been reported much more unevenly. Muggli et a l (1984) found 
associations between serum levels of non-specific MDPA and dystocia (p<0.05), calf- J
age (p<0.05), dam-age (p<0.05) and calf-breed (p<0.01). In that study, heritabilities 
(±se) for sire and maternal effects were estimated as 0.09 (±0.09) and 0.27 (±0.17), 
respectively. Gilbert et a l (1998) reported that line-of-sire and the degree of 
inbreeding of the dam influenced serum levels o f IgGi in 36-hour old beef-breed 
calves. Those authors found calf-sex, calf-sire, sire-line or dam-age as non-significant 
determinants. In a study of crossbreeding between Angus and Brahma calves, Vann et 
al (1995) reported that crossbred calves had higher levels of colostral antibody than 
purebred calves. Neither antibody-class or calf-breed appeared to have any effect on 
efficiency of absorption in that experiment. More recently, haplotypes expressing 
specific Fc antibody receptors (P-2-microglobulin), which mediate intestinal 
transmission of IgG, have been associated with failure of MDPA transfer in calves A
(Clawson et al, 2004; Laegreid et a l, 2002).
An indirect heritability (i.e. maternal) is when the genotype o f one individual 
influences the phenotype of another individual. In contrast, a direct heritability (i.e. 
additive) is when the genotype of one individual influences its own phenotype.
Ideally, both indirect (maternal genes) and direct (progeny genes) heritable effects 
could be used jointly to beneficially modify immunity to infection, especially in 
younger cattle. These results show that the pattern o f variation in antibody responses 
to BRSV vaccination is dynamic but clearly defined. Pre-vaccination, approximately 
1/3 of the observed variation is maternal, attributable to the dam and repeatable across 
calvings without additive genetic variation. Post-vaccination, the dominant 
component of the heritable variance becomes additive rather than maternal. The 
evidence for repeatable maternal variation comes from utilising the Robogen herd
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structure in which the same dams calved into the same farming environment over
several calving seasons, the average number o f progeny per dam being - 2 . 2 2  over the 
duration of the study.
Whether or not the maternal component is inherited is fundamental to understanding 
the genetics of vaccine response. The results show that the maternal transmissible 
component is substantial pre-vaccination and that antibody levels pre-vaccination are 
negatively correlated with antibody levels achieved post-vaccination. Different 
possibilities exist:
(i) The repeatable maternal component may be entirely due to the life history of the 
dam, i.e. previous exposure events. Then with no inheritance the opportunities for 
selection are limited and can be interpreted at their face value which emphasizes the 
role of farm management and husbandry.
(ii) They may be inherited so that the dam’s maternal effect and the ca lf s additive A
genetic effect are positively correlated, in which case high maternal protection in early 
life leads to greater inhibition o f vaccine response in her progeny. However the same 
progeny will benefit positively from additive immune function genes in mounting an 
endogenous antibody response, so the tendency is to reduce the overall genetic 
variation observed in the vaccine response, effectively masking the amount of genetic 
variation present.
(iii) They may be inherited so that the dam’s maternal effect and the c a lf  s additive 
genetic effect are negatively correlated. In this case, high maternal protection in 
neonatal life will suppress the potential response to vaccination. This is further 
compounded by the additive genetics inherited from the dam, also leading to a 
reduced vaccine response. This doubly negative outcome will tend to increase the 
overall genetic variation observed in the vaccine response, amplifying the amount of 
genetic variation apparent.
Exploration of the association between phenotypic responses to vaccination and 
animal genetics permits vaccine development to encompass vaccine responses in their 
entirety, to include host-vaccine interactions, in contrast to simply focussing on the 
attributes of the vaccine alone. Moreover, although management is important for 
controlling disease in domestic animals, an individual’s genetic background also |
makes a sizeable contribution to vaccine response. Identification of animals with sub- 
optimal antibody responses should allow vaccine development to focus on lower
responder groups, increasing overall herd efficacies for vaccines. In a wider sense,
ÀA
119 I
A:
,, 'r
A
Chapter 3
with almost a third o f variation accounted for by genetics, this study stresses the 
necessity for all vaccine studies to utilize as genetically diverse and genetically 
defined a test population as possible (Ovsyannikova et a l, 2004a). Although it may 
be presumed that the commercial vaccine has been optimised in terms of inoculate 
dose and content, genetic variability remains detectable, thus emphasizing its 
importance.
One o f the most useful extensions to the current study would be to link the antibody 
phenotypic responses observed to protection from clinical disease. The size of the 
study (n=463), and the time and the resources available for this segment of the 
project, precluded the type of clinical assessments and bioassays required for a 
complete evaluation of disease protection. Such deficiencies affect all experiments 
based on indicator traits although the moderately high correlation (-0.7) between the 
SNT and ELISA results does help bridge this gap. Much greater resources are 
necessary in order to overcome the difficulties in objective assessment of challenge 
studies. More calves from a larger number of sires, using more cattle breeds and an 
experimental blocking design to permit the isolation of effects based on physiological 
sex alone, would have improved the clarity of the results. Altering the design of the 
study to facilitate the observation of the more transient antibody isotypes such as IgM 
and IgA and the inclusion of a respiratoiy cellular immune component would have 
broadened the overall scope of the conclusions. Another useful addition would be to 
enlarge the study to include both cellular and humoral type mucosal responses to 
BRSV vaccination.
Mammalian systemic antibody responses to vaccination are complex polygenic traits 
modified by environmental and host genetic factors. Recognising and understanding 
how host genotype controls such immunological responses will enhance the 
effectiveness of current and future generations of vaccines. This research verifies that 
immune responses to viral vaccines in cattle are heritable and makes progress towards 
the eventual identification o f bovine genetic markers relevant to optimal antibody 
production following vaccination.
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Antibody to bovine parainfluenza-3 virus and 
bovine herpesvirus-1
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4.1 Introduction
Bovine parainfluenza-3 virus (PIV3) and bovine herpesvirus 1 (BHVl) are 
common respiratory pathogens of eattle. In calves, PIV3 infection is usually mild 
or silent (Allan et al, 1978), and often a component of mixed-infection 
respiratory disease (Adair, 1986; Bryson et a l, 1979a; Rosenquist and Dobson, 
1974). In contrast, BHVl infection can present as rhinotracheitis, 
meningoencephalitis, conjunctivitis, vulvovaginitis, abortion or neonatal 
systemic infection (Dungworth, 1992; Gibbs and Rweyemamu, 1977; Tikoo et 
a l, 1995). Parainfluenza-3 virus is almost ubiquitous among the British cattle 
population with average overall herd prevalences of -97%  (McCullough et a l, 
1987) and with -13%  of all British calves being seropositive (Adair et a l, 2000). 
Parainfluenza-3 virus was detected in 49% of Northern Ireland BRD outbreaks 
with conflrmed virus involvement (Graham et a l, 1998b). The prevalence of 
BHVl in European cattle has been reported as between 26-35% in Italy, 20-38% 
in Poland and 16-64% in Hungary (Castrucci et a l, 2002). In the UK, between
January and October 2004, 106 incidents o f BHVl-associated disease were 
confirmed by the Veterinary Laboratory Agency, eighty of which presented 
primarily as respiratory disease (Holliman et a l, 2005).
Parainfluenza-3-virus-related disease is most common among calves aged two to 
twelve weeks old (Dungworth, 1992). Pyrexia, coughing, tachypnoea, nasal 
discharge, and depression are frequent clinical findings (Bryson et a l, 1979b). In 
comparison, BHVl infection typically occurs in older animals (Babiuk et al., |
1996) with common clinical signs including pyrexia, coughing, conjunctivitis, 
lacrimation, rhinitis, nasal discharges, snoring, and inappetance (Edwards et a l,
1991). In common with other alphaherpesviruses, BHVl causes life-long 
infection of the sensoiy neiwe ganglia with the potential for periodic reactivation 
and virus shedding with associated epizooties (Pastoret et a l, 1982). Concurrent ti"infections with BHVl and PIV3 demonstrate delayed and lower specific 
antibody responses, higher serum cortisol levels and more exaggerated clinical 
signs than animals incubating either virus singly (Ghram et a l, 1989).
Vaccination is widely used for the control of both viruses with intranasal 
temperature-sensitive vaccines providing rapid, long-lasting immunity with 
useful mucosal action (Burroughs et a l, 1982; Martin et a l, 1983). Vaccination
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against BHVl reduces the period of virus shedding, and both peak and total 
amounts of virus shed (Kerkhofs et a l, 2003). Parainfluenza-3 virus (strain RLB 
103) and BHVl (strain RLB 106) vaccine strains are chemically-altered,
■■■■genetically-stable mutants, incapable of replication above 39°C (Zygraich et al,
1974a; Zygraich et al, 1974b). Modified-live forms of these two viruses have 
been combined commercially for intranasal vaccination since 1976 (Todd, 1976).
Specifically, immunisation with Imuresp RP (Pfizer Animal Health, Sandwich,
UK) gave significant protection against PIV3 challenge (Bryson et a l, 1999), 
and both clinical signs and lung pathology were found to be reduced in 
challenged vaccinates. In addition, Imuresp RP induced BHV1 antibody (Lucas 
et al, 1982), preventing clinical disease and significantly reducing BHVl virus 
shedding (Fairbanks et a l,  2004). A PIV3-specific seroconversion rate of 82% 
was reported 10 weeks after a single intranasal PIV3/BHV1 vaccination (Durham 
et a l, 1991), while seroconversion rates of 87-94% were described for intranasal 
BHVl monovalent vaccines. In another study, 93% of animals seroconverted to 
BHVl and 100% of animals seroconverted to P1V3 following multivalent 
intranasal vaccination (Weiblen et a l, 1982).
No single laboratoiy test allows perfect assessment of immunocompetence due to 
the complexity of the mammalian immune system. However, it is accepted that 
specific antibody production is correlated with degrees of protection (Plotkin,
2001). Detection o f serum antibody level is therefore an objective, reliable and 
useful means of determining the activation of the immune system, although it can 
never encompass the full extent and efficacy of the overall immune response 
(Perino and Hunsaker, 1997). Testing for antibody using commercial BHVl and 
PIV3 ELISAs has undergone extensive validation (Graham et a l, 1997) and has 
been proved a robust and reliable method of detecting the major antibody isotype 
IgGi. A BHVl ELISA was found to be almost 100-fold more sensitive for 
diagnostic purposes than testing by virus neutralisation, the latter being specific 
only for antibodies which functionally neutralise BHVl in vitro (Dubeski et a l,
1996).
To date, most research into BHVl and PIV3 vaccine responses has either been 
small scale or alternatively deliberately designed to minimise or exclude fixed 
effects such as age, breed, sex and management (Ahl and Straub, 1985; van der 
Poel et a l, 1995; Zygraich et a l, 1975a). The host genetics behind immune
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responses to the two viruses also remains relatively unexplored. Differences in
allelic frequencies in host interferon genotype were linked to the severity o f A
BHVl "induced disease (Ryan and Womack, 1997). Wimmers et a l (2004) found
associations between levels of specific IgG antibody and BF, DRB and DQB %
porcine genotypes following vaccination against another important animal
alphaherpesvirus, Aujeszkys Disease (AD) virus. Further, quantitative trait loci
on chromosomes 9 and 11 have been demonstrated to correlate with clinical
signs (neurological signs and pyrexia) in pigs which were experimentally A
infected with AD virus, thereby linking host genotype to disease phenotype 
(Reiner e ta l,  2002).
The current study is one of the first to systematically address the many complex 
factors which control the humoral response to PIV3/BHV1 vaccination in cattle.
A large juvenile crossbred bovine population of known parentage was 
immunised with a commercially available PIV3/BHVl vaccine. Statistical 
models were developed, thoroughly investigating the effect o f environmental 
factors such as year-of-birth, age and sex effects on vaccine response 
phenotypes. By integrating accurate pedigree records with these models, genetic 
effects should be detectable and discernible from the environmental effects and 
the relative contribution o f the two sources of variation should be computable.
VAS
4 . 2  Methods
4.2.1 Vaccination and sampling
The study population was the Robogen herd. This experimental population and 
the vaccination protocol are described in detail in Chapter 2, section 2.2.3. Blood 
samples were collected by jugular venepuncture on Day 0, the day of 
vaccination, and Days 14, 28, 42, 63 and 77 post-vaccination, providing six 
samples per calf.
4.2.2 ELISA for detection o f PIV3- and B H V l-IgG  antibody
Sera were tested quantitatively by solid-phase antibody capture ELISA specific 
for total PIV3-IgG and total BHVl-IgG according to the manufacturer’s "Àguidelines (SVANOVA Biotech, Uppsala, Sweden). Briefly, samples were added 
at a dilution of 1/25 in PBS-Tween buffer (0.01 M pH 7.4 phosphate buffered 
saline (PBS) containing 0.05% Tween 20) to each of two wells, one coated with 
viral antigen and the other with control antigen, to a final volume of 1 0 0  pi.
Positive and negative control sera were included on each 96-well microtitration 
plate at a dilution of 1/25. Each plate was shaken, sealed and incubated for one 
hour at 37°C, then washed three times with PBS-Tween buffer. After the third 
wash, each plate was tapped dry and 1 0 0  pi o f horse-radish peroxidase- 
conjugated anti-bovine IgG added to each well. Each plate was then incubated 
for a further hour at 37°C and washed as previously described. One hundred pi of j/'substrate solution (3 ’,3’,5’,5’-tetramethylbenzidine and hydrogen peroxide) were 
added to each well and the plate was incubated at room temperature for ten 
minutes after which the reaction was stopped by adding 50 pi of 2 M H2 SO4 per 
well. After shaking, the optical density (OD) of each well was measured 
immediately at 450 nm on a MRX microplate plate reader (Dynex Technologies,
Chantilly, USA). The corrected optical density (COD) value for each sample and 
the assay control sera were calculated by subtraction of the OD value of each 
control antigen-coated well from that o f the corresponding viral antigen-coated 
well, and the relative optical density (ROD) value for each sample calculated as a 
percentage o f a highly positive control serum on a per-plate basis;
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■;A=:
ROD (%) = COD serum sample x 100 [EQ4.I]
COD positive control
Samples were tested in duplicate and repeated if paired means were >10% 
discordant. The inter-plate repeatabilities for the PIV3-IgG ELISA and BHVl- 
IgG ELISA were 97.1% and 96.6%, respectively (p <0.001).
4.2.3 Serum ueutralisation test for detection o f PIV3 and B H V l 
antibody
The serum neutralisation test (SNT) is a well established in-vilro technique for 
determining specific antibody levels (Gillette, 1983). For assay validation and 
comparison, serum antibody levels specific to PIV3 and BHVl were determined 
independently (Biobest Laboratories Ltd, Pentlands Science Park, UK) using the 
SNT, in addition to the ELISA. A panel of thirty sera, five selected from the six 
sampling days, were analysed, chosen to represent the range o f PIV3-IgG and 
BHVl-IgG responses on each sampling day. Correlations between SNT results 
and the corresponding ELISA results were calculated.
4.3 Statistical Methods
4.3.1 Data preparation
Means, medians, variance and interquartile range for all traits were calculated 
using Genstat 7.0 (VSN International Ltd, Herts, UK). The same software was 
used to calculate skewness (a measure of distribution symmetry) for each trait, 
with normality set as a skewness of 0.0. The data collected on PIV3-IgG and 
BHVl-IgG antibody levels were normalised by log transformation.
Deviations (A) in antibody levels between days post-vaccination (Days 14, 28, 
42, 63 and 77) and the day o f vaccination (Day 0) were calculated for both 
viruses - so typically for Day 14:
A/;IgG(DO to D14) = Day 14 PIV3-IgG - Day 0 PIV3-IgG [EQ 4.2]
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and
A/IgG(DO to D14) = Day 14 BHVl-IgG - Day 0 BHVl-IgG [E Q  4 .3 ]
4.3.2 Non-regressive statistical methods
Depending on the number of factor levels, either unpaired Students t-test (2 
factors) or one-way analysis of variance (ANOVA; >3 factors) were used to 
compare factor effects. Tests were confirmed as significant if p <0.05 and highly 
significant if p <0.001. Pearson product moment correlations between 
combinations of factors and variâtes were evaluated for levels of PIV3-IgG and 
BHVl-IgG on all sampling days and r values calculated. Excel 2003 (Microsoft 
Corp., Seattle, USA) was used for collation and preparation of data and Genstat 
7.0 (VSN International Ltd, UK) was used throughout for the statistical analysis 
of results, unless otherwise stated.
4.3.3 Logistic regression
By introducing a binary coding system whereby ApIgG(D0 to D14), AplgG(DO 
to D28) and A/?IgG(DO to D42) were converted into either: 1 (positive A) or 0 
(negative A) a variate suitable for analysis by logistic regression was generated. 
Linear binomial models with these binary variâtes as the response variable (y) 
and the level of Day 0 BRSV-IgG antibody as the explanatory variable (%) were
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When overall antibody profiles had linear patterns, it was possible to calculate a 
summaiy trait, the 6 -day-average, taken as the arithmetic mean of the ROD 
values on all six sampling days.
For both PIV3-IgG and BHVl-IgG profiles, the total area under the antibody 
curve was calculated between Days 0 and 77, inclusive. The trapezoidal rule was 
used to provide a good working approximate of this second alternative summaiy 
trait (Abramowitz and Stegun, 1972).
So typically:
6 -day-area /ilgG  = area under PIV3-IgG curve from Day 0 to Day 77 [ E Q  4 .4 ]
n ^fitted to the data using a logit link function, (logj ) and the associated
i - f ,
model parameters (a and P) estimated.
Using
y =
where p  is the probability of binary 1, (i.e. a positive A); x  is the population 
mean level of Day 0 PlV3-IgG antibody. Assuming that when p  -0 .5 , a positive 
or negative antibody response was equally likely, it was possible to provide an 
empirical estimate of the threshold at which pre-existing PIV3 antibody begins to 
block PIV3 vaccine response. If this first threshold is envisaged as the point at 
which 50% of the calves showed a positive response, a second useful threshold 
may be estimated a tp  =0.9 when a positive vaccine response may be expected in 
90% of the population.
This analysis was then repeated exactly as above but using AdgG(D0 to D28), 
A/lgG(DO to D42) and A/IgG(D0 to D63) to obtain threshold values at which 
BHVl-IgG begins to exert a suppressive effect.
4.3.4 Univariate mixed linear regression
Mixed linear models were fitted to the data using Residual Maximum Likelihood 
(REML) methods, with Genstat procedures (Genstat 7.0, VSN International Ltd). 
The impact of a number of explanatoiy factors was evaluated and the remaining 
variation decomposed into variances of either direct heritable or environmental 
origin. The fixed effects in the model, with appropriate degrees o f freedom (df), 
were breed-cross (BCH, BH, F2; 2df), sex (male, female; Idf), year-of-birth 
(1998, 1999, 2000, 2001; 3df), dam-age (2, 3, 4, 5, 6 , 7; 5df) and age at first 
sampling (continuous variate), with calf sire included as a random effect. As 
male and female calves were reared separately and under different management, 
the effect sex incorporates management and environmental components, in 
addition to its physiological effect. To improve model clarity, the fixed effect 
breed-cross was further resolved into Holstein and recombination-loss fractions 
in accordance with: breed-cross BCH = (0.25 Holstein, 0.50 recombination- 
lossy, breed-cross F2 = (0.50 Holstein, 1.0 recombination-loss) and breed-cross
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iBH = (0.75 Holstein, 0.50 recombination-loss). Holstein represents the expected 
genetic contribution of the Holstein cattle breed, while recombination-loss 
represents the expected fractional loss in phenotypic traits in progeny, arising 
from non-productive reeombinations of genetic loci at fertilisation which 
previously interacted in either of the two parental breeds (Fries et a l, 2002).
Thus the linear model was:
T ijk m n p  ~  p  ±  OCj +  P j +  § k  ±  ÎTi +  Ym ±  c(S ijk lm np" s )  +  Ujjklmn eÿk ln in p  [E Q  4 .6 ]
where
Yijkimnp " obseiwation of phenotypic trait, 
p - population mean, 
tti - effoct (fixed) of sex / (/ = 1 ,2 ),
Pj - effect (fixed) of Holstein ffactiony (j = 1,2,3),
6 k - effect (fixed) of recombination-loss fraction k { k = \  ,2,3),
7Ci - effect (fixed) o f dam-age / (/ = 2,3,4,5,6,7) ;
Ym - effect (fixed) of year-of-birth m {m = 1,2,3,4),
B(sijk]mnp- s) - effect (fixcd) of Sampling age spinmp (age o f calf ijklmnp) 
expressed as a deviation from the population mean age s,
Uijkimn " direct heritable effect (random) of sire « ~ N (0,1 erf ), 
eijkimnp “ residual error (random) p  ~ N (0 ,1  erf ).
Both Ujjklmn and eijkimnp were assumed to have multivariate normal distributions 
with means 0 and (co)variances I c f , and I  erf , respectively. Estimates of direct
heritability (li^) were calculated using: h  ^= 4 - ^  [EQ 4.7]
where phenotypic variance erf was estimated as erf -  erf +er f , as defined above.
The basic model was extended for post-vaccination Days 14, 28, 42, 63 and 77 
by adding the appropriate level of pre-existing PlV3-IgG or BHVl-IgG antibody 
on the day o f vaccination (Day 0) as co variâtes {qj and q2).
The significances of the fixed effects and their interactions were estimated by the 
generalised Wald test. Only those interactions achieving statistical significance 
(p <0.05) were retained in the final best-fit model. The significance of random 
effects in the model was determined using log-likelihood ratio tests. The 
robustness o f each model produced was verified by examining the linearity of 
standardised deviance residuals against normal order statistics (Belsley et a l,
1980).
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4.4 Results
4.4.1 Descriptive analysis
Due to the large numbers of calves with low levels of specific antibody, the 
distributions of both the PIV3-IgG and BHVl-IgG raw data are right-skewed 
(Table 4.1(a+b)). Both datasets better approximated normality after log 
transformation. The multivalent BHVl/PI V3 vaccination occurred in the 
presence of high levels of pre-existing antibody to both viruses. Overall Day 0 
IgG mean levels against BHVl and PIV3, were quite similar (ROD =35.7%) and 
(ROD =39.6%), respectively (Table 4.1 (a+b)). But at individual calf level, there 
was strong evidence that the pre-vaccination Day 0 level of PlV3-IgG was 
consistently higher than the equivalent level o f BHVl-IgG on Day 0 (t-test; p 
<0.001) and the subsequent pathogen-specific IgG response profiles showed 
many dissimilarities between responses to BHVl and PIV3.
Generally, overall mean levels of PIV3-IgG were high throughout the study yet 
these tended to show a moderate and progressive increase, to Day 77 (Figure 
4.1(a)). Post-vaccination, overall mean PIV3-IgG levels declined 1.07-fold 
(antilog) between Day 0 and Day 14 then increased between Days 28 and 77 
(Table 4.1(a)). Day 63 and Day 77 PIV3-IgG levels (antilogs) were 1.66-fold (t- 
test; p<0.001) and 1.62-fold (t-test; p<0.001) those of Day 0, respectively. 
Differences (A) between consecutive sampling days were most significant for 
ApIgG(DI4 to D28) and ApIgG(D28 to D42) (t-test; p <0.001) and dropped in 
magnitude by A/?IgG(D63 to D77) (Table 4.1(a)). Overall Day 28 had the 
minimum PlV3-IgG variance being 2.24-fold smaller than that on Day 0, the day 
with the maximum value. The PIV3-IgG variance was 1.58-fold smaller on Day 
77 compared to that o f Day 0. However, the interquartile range (dQ) decreased to 
Day 28 before increasing steadily to Day 77. The summary trait, 6 -day-area 
plgG, had a much more normal distribution than most of the other traits 
examined.
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(a) PIV3-lgG
T rait
(ROD)
m ean variance
(ROD)
median
(ROD)
dQ skew ness
Day OpIgG 39.6 1082.0 29.9 46.2 0.9
Day 14 plgG 37.0 988.8 26.0 37.0 1.3
Day 28 plgG 42.7 677.7 36.8 27.7 1.4
Day 42 plgG 47.0 700.7 41.1 34.0 0.9
Day 63 plgG 52.0 1088.2 42.9 46.6 0.8
Day 77 plgG 54.4 1568.6 40.9 54.8 0.8
AplgG(DO to DI4) -2.6 228.8 -3.8 14.2 1.0
AplgG(D14 to D28) 5.8 284.4 5.1 19.5 0.0
AplgG(D28 to D42) 4.1 386.9 3.1 20.1 0.4
AplgG(D42 to D63) 4.7 809.4 0.0 22.1 1.5
/^IgG (D 63 to D77) 1.9 569.6 -2.3 15.7 2.0
6-day-area plgG 446.0 4360353 572.0 2920.0 0.0
(b) BHV1-lgG
(ROD) (ROD) (ROD)
Trait m ean variance m edian dQ skew ness
Day 0 /IgG 35.7 1096.6 26.6 55.6 0.7
Day 14 /IgG 28.0 850.2 17.0 44.3 1.0
Day 28 /IgG 23.6 474.3 17.0 29.9 1.3
Day 42 /IgG 19.2 326.6 14.7 23.3 1.5
Day 63 /IgG 15.0 264.3 9.2 18.7 1.6
Day 77 /IgG 12.3 243.3 6.3 15.5 2.2
A/lgG(DO to DI4) -7.7 147.3 -5.6 14.5 0.1
A /lgG (D I4to  D28) -4.2 239.7 -3.6 14.9 -0.2
A/lgG(D28 to D42) -4.5 146.4 -3.0 12.5 -0.3
A/lgG(D42 to D63) -4.2 118.8 -2.8 10.4 -0.6
A/lgG(D63 to D77) -4.2 65.3 -1.5 6.1 1.1
6-day-area /IgG -1087.0 2897664 -1161.0 2380.0 0.0
6-day-average /IgG 2.4 2.4 1.0 1.4 -0.2
Table 4.1 Means, variance, medians, interquartile ranges and skewness for levels o f P1V3- 
IgG (a) and BHVl-IgG (b) on Days 0 to 77, relative to vaccination. Also descriptive 
statistics for ApIgG and A/IgG, 6-day-area /IgG, 6-day-area p\gG  and 6-day-average 
/IgG on Days 0 to 77. BHVl/PI V3 vaccine administered on Day 0. Values based on non­
transformed relative optical density data. dQ  (interquartile range), ROD (relative optical 
density).
131
Overall mean levels o f BHVl-IgG tended to decline gradually and continuously 
from Day 0 to Day 77, with the mean Day 77 BHVl-IgG level 2.7-fold (antilog) 
lower than that of Day 0 (Figure 4.1 (b)). The rate o f decrease remained 
relatively constant at (~1.2-foId) between consecutive days. The variance also 
steadily decreased from Day 0 to Day 77 as more calves reached undetectably 
low levels o f BHVl-IgG. The BHVl-IgG variance was 2.60-fold smaller on Day 
77 compared to Day 0, the day with the maximum variance. In line with the 
decreasing mean and variance, the interquartile range (dQ) decreased for later 
sampling days. Once again, the summary trait, 6 -day-area /IgG, was much more 
normally distributed than most of the other traits examined.
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Figure 4.1 Levels of (a) PlV3-lgG and (b) BHVl-IgG on Days 0, 14, 28, 42, 63 and 77, 
relative to vaccination. BHV1/PIV3 vaccine administered on Day 0. Median (central 
horizontal line), quartiles (outer horizontal lines), and range (outer vertical lines) shown. 
Values are log transformed relative optical density data.
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4.4.1.3 PIV3- and BHVl-specific serum neutralisation tests
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4.4.1.1 PIV3-and BHVl-IgG antibody half-lives
Based on the regression coefficients from REML analysis on Day 0, the half-life 
of PlV3-IgG was estimated as 32,2 days (95% confidence interval; 29.4 to 35.6 
days). Using a similar method for BHVl-IgG, the antibody half-life was 
estimated as 25.8 days (95% confidence interval: 19.8 to 37.2 days).
4.4.1.2 PIV3- and BHVl-IgG antibody correlations
Correlations between levels o f PIV3-IgG and BHVl-IgG are shown graphically 
in Figure 4.2. Table 4.2 shows that intra-virus correlations between the first three 
samplings days (Day 0, 14 and 28) were high (r >0.600). Inter-virus (PIV3 and 
BH Vl) correlations on these three days tended to be lower but those between 
Day 0 PIV3-IgG and Day 0 and Day 14 BHVl-IgG were still moderately high (r 
>0.500). All other inter-virus correlations between days were low (r <0.250) 
except those between Day 14 PIV3-IgG and Day 14 BHVl-IgG (r =0.520), 
between Day 14 PIV3-IgG and Day 28 BHVl-IgG {r =0.410) and between Day 
28 PIV3-IgG and Day 14 BHVl-IgG (/' =0.346). All reported correlation 
significances were p < 0 .0 0 1 .
The raw data for levels (untransformed) of total PIV3-IgG and BHVl-IgG on
Days 0 to 77, relative to vaccination are shown in Appendices B.I and B.2, îy
respectively.
The Pearson correlation coefficient between results from the BHVl-IgG ELISA 
and those obtained using BHVl-specific serum neutralisation test (SNT) was 
high, calculated as 0.72 (p <0.001). The equivalent Pearson correlation 
coefficient between results from the PIV3-IgG ELISA and those obtained using 
PIV3-specific SNT was even higher, calculated as 0.78 (p <0.001).
*  ^  X X
DO PIV3 D14 PIV3 D28 PIV3 DO BHV1 D14 BHV1
Figure 4.2 Matrix scatter plots showing correlations between levels o f PlV3-lgG and BHVl- 
IgG on Days 0 and 28, relative to vaccination. BHVI/PIV3 vaccine administered on Day 0. 
All values are log transformed relative optical density data.
Day 0 PIV3 1
Day 14 PIV3 0.855 1
Day 28 PIV3 0.609 0.728 1
Day 0 BHV1 0.542 0.481 0.302 1
Day 14 BHV1 0.560 0.520 0.346 0.895 1
Day 28 BHV1 0.440 0.410 0.335 0.652 0.743 1
Day 0 Day 14 Day 28 Day 0 Day 14 Day 28
PIV3 PIV3 PIV3 BHV1 BHV1 BHV1
Table 4.2 Correlations between levels o f PIV3-lgG and BHVI-IgG on Days 0 and 28 (p 
<0.001). BHVI/PIV3 vaccine administered on Day 0. Values were calculated using log 
transformed relative optical density data.
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4.4.2 Analysis o f fixed effects 
4.4.2.1 Sex / Management
Mean levels of PIV3-IgG in female calves were 1.69-foid, 1.69-fold, 1.35-fold 
and 1.24-fold (all back-transformed) higher than those of male calves (t-test; p 
<0.001) on Days 0, 14, 28 and 42, respectively (Figure 4.3(a)). By Day 63, there 
was no difference in levels of PIV3-IgG between sexes (t-test; p >0.05) and on 
Day 77, the male calves that had 1.34-fold higher levels of PIV3-IgG than the 
female calves (t-test; p <0.001). For both sexes, the PIV3-IgG variance followed 
a very similar pattern between Day 0 and Day 28, a sharp ~2.2-fold decline. 
Female PlV3-IgG variance remained virtually constant between Days 42 and 77 
while the male PIV3-IgG variance increased to 1.18-fold and 1.43-fold (antilog) 
that of the female group on Days 63 and 77, respectively (t-test; p <0.001). Table
4.3 shows the significance attached when the effect, sex, is included in the 
REML models developed for PIV3-IgG on Days 0 to 77. Sex is highly significant 
across all sampling days either as a main effect or as a two-way interaction, the 
effect apparently strongest on Day 77.
In general, BHVl-IgG responses to vaccination were weak. In contrast to PIV3- 
IgG, the ratios (back-transformed) of mean levels of BHVl-IgG in the female 
calves to those of the male calves remained relatively constant (see Figure 
4.3(b)) being 1.34, 1.43, 1.29, 1.29 and 1.35 on Days 0, 14, 28, 42 and 63, 
respectively (t-test; p <0.05). Although on Day 77, female calves continued to 
have higher mean levels of BHVl-IgG compared to the male calves, the 
difference was not significant (t-test; p >0.05). Bovine herpesvirus 1 vaccination I :appeared to only marginally affect mean levels of BHVl-IgG in either sex; 
overall mean Day 28 BHVl-IgG levels are only 1.17-fold mean Day 14 BHVl- 
IgG levels. However despite the small change in means between Day 14 and Day 
28, the overall BHVl-IgG variance declined 3.09-fold over the same period. The 
male BHVl-IgG variance was lower, on average ~0.8 -fold than the female 
BHVl-IgG variance up to and including Day 42 but on Days 63 and 77, it was 
the male BHVl-IgG variance which was ~1.5-fold higher than the female group.
The variances of both sexes rose steadily from the low levels attained on Day 28.
Table 4.4 shows the significance attached when the effect,
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Figure 4.3 Levels of PIV3-lgG (a) and BHVl-IgG (b) from Days 0 to 77, relative to 
vaccination. BHV1/P1V3 vaccine administered on Day 0. Values are log transformed 
ROD data and presented grouped on sex: female(O), male (□). Mean (black) and 
variance (blue) of data presented.
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1
PIV3-IgG by sex
Day REM L term W aldstatistic d.f. P  value
0 sex.year-of~birth 31.3 3 < 0 . 0 0 1
14 sexsex.Holstein
17.4
8.5
I
I
< 0 . 0 0 1
0.003
28 sex.year-of-birth sex. age
27.0
9.1
3
1
< 0 . 0 0 1
0.003
42
sex
sex. Day 0-PIV3 
sex.Holstein
10.5
7.9
7.3
1
1
1
0 . 0 0 1
0.005
0.007
63 sex.year-of-birth 65.6 3 < 0 . 0 0 1
77 sex.year-of-birth 1 1 1 .1 3 < 0 . 0 0 1
Table 4.3 Significant inclusions of the fixed effect sex, either as main effects or interactions 
for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. BHV1/PIV3 vaccine 
administered on Day 0. Values are log transformed ROD data. Day 0-PIV3 (level of P1V3- 
IgG on Day 0). Data analyses using REML models.
BHVl~JgG by sex
Day REM L term Waldstatistic d.f. P  value
0 sex 5.0 1 0.026
14 sex.Day 0-BHVl 4.0 1 0.045
28 sex.Day 0-BHVl 7.8 1 0.004
42
sex.Day 0-BHVl 
sex. year-of-birth 
sex.recombination-loss
1 1 .0
7.9
7.5
1
1
< 0 . 0 0 1
0.048
0.006
63
sex. Day 0-BHVl
sex.year-of-birth
sex. recombination-loss
21.3
18.8
8.3
1
1
< 0 . 0 0 1
< 0 . 0 0 1
0.004
77 sex. Day 0-BHVl sex.year-of-biith
15.9
14.4
1
3
< 0 . 0 0 1
0 . 0 0 2
Table 4.4 Significant inclusions of the fixed effect sex, either as main effects or 
interactions for levels of BHVl-IgG on Days 0 to 77, relative to vaccination. BHV1/PIV3 
vaccine administered on Day 0. Values are log transformed ROD data. Day 0-BHVl (level 
of BHVl-IgG on Day 0). Data analyses using REML models.
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ï '
sex, is included in the REML models developed for Days 0 to 77 BHVl-IgG. Sex
is less significant early post-vaccination than on later sampling days, commonly 
present as two-way interaction with either year~of~birth or Day 0-BHVL 
Altogether, sex seems to be o f a lower order of significance for BHVl-IgG than 
forPIV3-IgG.
4.4.2.2 Year-of-birth
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There are clear differences in mean levels o f PIV3-IgG. based on year-of-birth 
(Figure 4.4(a)). In cohort 1999, the mean level of PIV3-IgG remains relatively 
constant over the six sampling days with a highest/lowest ratio of only 1.43 
(back-transformed) whereas mean levels o f PIV3-IgG in cohort 2001 show a 
relatively linear increase over the six sampling days with a highest/lowest ratio of 
2.78. The mean PIV3-IgG profiles for cohorts 1998 and 2000 show features 
intermediate between the former two. Despite the disparities in the mean levels 
o f PIV3-IgG between cohorts, PIV3-IgG variances follow very similar patterns 
over 1998, 1999, 2000 and 2001, generally falling to Day 28 and remaining at 
that level until Day 77. Table 4.5 shows the significance attached when the 
QfÏQct, year-of-birth, is included in the REML models developed for PIV3-IgG on 
Days 0 to 77. Year-of-birth is highly significant either as a main effect or a two- 
way interaction with sex or age for all sampling days except Day 42 and appears 
to be more important for the later sampling days.
In general, BHVl-IgG responses to vaccination were weak. Apart from Day 0 
(ANOVA; p <0.01), the day o f vaccination, there were no significant differences 
(ANOVA; p >0.05) between mean levels of BHVl-IgG based on year-of-birth 
(Figure 4.4(b)). Mean BHVl-IgG levels based on year-of-birth are minimal on 
Day 28 as all four cohorts tend to converge to ROD -14% . Although only small 
changes are detectable in the mean BHVl-IgG levels based on year-of-birth over 
the six sampling days, vaccination is associated with a sharp decline in BHVl- 
IgG variance in all four years until Day 28 or Day 42, followed by a more 
gradual increase to Day 77. BHVl-IgG variance profiles, grouped on year-of- 
birth, converged on Day 28 with a highest/lowest ratio of only 1.24 (antilog) 
compared to an average ratio of 1.71 for the other five sampling days. Table 4.6 
shows the significance attached when the effect, year-of-birth, is
I
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Figure 4.4 Levels o f PlV3-IgG (a) and BHVl-IgG (b) from Days 0 to 77, relative 
to vaccination. BHV1/P1V3 vaccine administered on Day 0. Values are log 
transformed ROD data and presented grouped on year-of-birth: 1998 (O ), 
1999(0), 2000(A) and 2001 (V ) .  Mean (black) and variance (blue) of data 
presented.
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Table 4.6 Significant inclusions of the fixed effect year-of-birth, either as main effect or 
interactions for levels of BHVl-IgG on Days 0 to 77, relative to vaccination. BHV1/PIV3 
vaccine administered on Day 0. Values are log transformed ROD data. Day 0-BHVl (level 
of BHVl-IgG on Day 0). Data analyses using REML models.
PIV3~IgG by year-of-birth
Day REML term Waldstatistic d.f. P  value
0 year-of-birth.sex 31.3 3 < 0 . 0 0 1
14 year-of-birth 38.2 3 < 0 . 0 0 1
28 year-of-birth.sexyear-of-birth.age 27.015.4 33 < 0 . 0 0 1< 0 . 0 0 1
42 year-of-birth 7.6 3 0.05
63 y ear- of-b irth.sex year-of-birth.age 65.620.4 33 < 0 . 0 0 1< 0 . 0 0 1
77 year-of-birth.sexyear-of-birth.age 1 1 1 .122.5 33
< 0 . 0 0 1
< 0 . 0 0 1
Table 4.5 Significant inclusions of the fixed effect year-of-birth, either as main effect or 
interactions for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. BHV1/PIV3 
vaccine administered on Day 0. Values are log transformed ROD data. Data analyses using 
REML models.
Day
0
14
28
42
63
77
REML term
BHVl-IgG by year-of-birth
Wald
statistic d.f. P  value
year-of-birth.age 14.9 3 0 . 0 0 2
year-of-birth 11.5 3 0.009
year-of-birth 7.8 3 0.050
year-of-birth.Day 0-BHVl 15.3 3 0 . 0 0 2
year-of-birth.Day 0-BHVl 13.6 3 0.004
year-of-birth.sex 7.9 3 0.048
year-of-birth.Day 0-BHVl 10.3 3 0.016
year-of-birth.sex 18.8 3 < 0 . 0 0 1
year-of-birth.recombination-loss 8 .1 3 0.044
year-of-birth.sex 14.4 3 0 . 0 0 2
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included in the REML models developed for Days 0 to 77 BHVl-IgG. Overall, 
although the effect of year-of-birth seems to be constant across sampling days, it 
has a much lower order of significance than that shown for PIV3-IgO.
4.4.2.3 Pre-existing PIV3-IgG antibody
In general, levels of pre-existing PIV3-IgG antibody on Day 0 {Day 0-PIV3) 
suppressed subsequent humoral responses to vaccination. These effects were 
most apparent early post-vaccination. Figure 4.5 shows the PIV3-IgG deviation 
induced by Day 14 (AjcIgG(DO to D14)). Smaller Day 0-PIV3 values tend to have 
positive A/?IgG while larger Day 0-PIV3 values tend to have negative A^IgG. 
Regression coefficients when levels of pre-existing PIV3-IgG antibody (q) were 
included in REML models for induced PIV3-IgG on Days 14 to 77 are shown in 
Table 4.7. Levels of PIV3-IgG on Days 14, 28, 42 were positively associated 
with pre-existing Day 0-PlV3^ the effect decreasing with later samples. By Day 
63, the effect was still significant but negative and became still more strongly 
negative by Day 49. Table 4.8 shows the significance attached when the effect. 
Day 0-PIV3, is included in the REML models developed for Days 14 to 77. The 
main effect is most strongly significant early post-vaccination on Days 14 and 
28, declining on Days 42, 63 and 77.
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Figure 4.5 Deviations in PIV3-IgG level — ApIgG(DO to D14) against Day 0 level of 
PIV3-IgG. Best-fit regression line shown (dashed). ApIgG(DO to D14) values are 
untransforined ROD data. Day 0 PIV3-IgG are log transformed ROD data.
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induced PIV3-IgG antibody
I
Table 4.7 Regression coefficients when Day 0 level of pre-existing PIV3-IgG (q) is 
included in models for PIV3-IgG level on Days 14 to 77. Mean values (standard errors) 
are presented on log scale. Data analysis using REML models (EQ 4.6).
PIV3-IgG by Day 0 PIV3-IgG
Day REML term Waldstatistic d.f. P value
0 - - - -
14 Day 0-PIV3 Day 0-PIV3.age 798.012.4 11
< 0 . 0 0 1
< 0 . 0 0 1
28 Day 0-P1V3 Day 0-PIV3.age 128.013.4 11 < 0 . 0 0 1< 0 . 0 0 1
42 Day 0-PIV3.sex 7.9 1 0.005
63 Day 0-PIV3 8.3 1 0.004
77 Day 0-PIV3.year-of-birth 14.1 3 0.003
Table 4.8 Significant inclusions of the fixed effect pre-existing plgG, either as main effect 
or interactions, for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. 
BHVI/PIV3 vaccine administered on Day 0. Values are log transformed ROD data. Data 
analyses using REML models (EQ 4.6). Day 0-PIV3 (level of PlV3-IgG on Day 0).
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D14 D28 D42 D63 D77
I
0.65 0.26 0.14 -0.09 -0.29
(s.e.) (0 .0 2 ) (0 .0 2 ) (0.04) (0.03) (0.08) ÎI:
1
I
3-7
7■I
I
vast
Using logistic regression, it was possible to develop binomial models (with 
parameters a and (3, as detailed in Table 4.9 and therefore calculate and graph the 
probability (p) that Day 0-PIV3 antibody were associated with a positive 
deviation in PIV3-IgG. This process was performed for A/?IgG(DO to D14), 
ApIgG(DO to D28) and A/?IgG(DO to D42). Consequently estimates were 
obtained of the 50% (p =0.5) and 90% (p =0.9) threshold levels for Day 0-PIV3 
antibody for each of Days 14, 28 and 42 (Figure 4.6).
For Day 0 PIV3-IgG, the 50% inhibitoiy threshold was 14.3% for Day 14 
responses, 35.2% for Day 28 responses, and 35.3% for Day 42 responses. For 
Day 0 PIV3-IgG, the 90% inhibitoiy thresholds on Day 0 were 1.5%, 11.6% and 
14.3% for responses on Days 14, 28 and 42, respectively. Days 28 and 42 have 
similar 50% and 90% thresholds, while those for Day 14 were much lower, 
perhaps reflecting the transitionaiy state of antibody production at this point.
ÎÏ&
induced APIV3-IgG
(DO to D14) (DO to D28) (DO to D42)
a 2.59 7.04 8 . 6 6
(0.36) (0 .6 6 ) (0.81)
P -0.98 -1.97 -2.43(0 .1 1 ) (0.18) (0 .2 2 )
Table 4.9 Estimated parameters (a and p) for deviation ApIgGi on Days 14, 28 and 42 
against level of pre-existing PIV3-IgG on Day 0. Mean values (standard errors) are 
presented, p <0.001 for all regression coefficients. Data analysis using logistic regression 
models (EQ 4.5).
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Figure 4.6 Data analysis using logistic regression models (EQ 4.5).
Probability of positive PlV3-IgG antibody response on Days 28, 42 and 63: 
(A/7lgG(D0 to D28: black), AplgG(DO to D42: blue), AplgG(DO to D63: red) 
against Day 0 PIV3-IgG level. A/7lgG values are untransformed. Day 0 PIV3-IgG 
level is log transformed, p  =0.5 (green dashed); p  =0.9 (green solid).
There was evidence that post-vaccination levels o f  B H V l-IgG  on D ays 0, 14, 
and 28, w ere influenced by D ay 0-PIV3  (R EM L; p <0.001), w ith correlations r  = 
0.541, 0.558 and 0.439, respectively (all p <0.001).
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4.4.2.4 Pre-existing BHVl-IgG antibody
During the study, changes in levels of BHVl-IgG following vaccination were 
generally much lower than those for PIV3~IgG but it was still possible to use a 
logistic regression approach to estimate the threshold level at which suppression 
of antibody responses occurs. Figure 4.7 shows the deviation in levels of BHV1 - 
IgG induced between Day 0 and Day 63, (AdgG(DO to D63)), relative to the Day 
0 level of pre-existing BHVl-IgG (Day 0-BHVl). Again, lower Day 0-BHVl 
tends to result in positive AflgG while higher Day 0-BHVl tends to result in 
negative A/lgG.
Regression coefficients when levels of pre-existing BHVl-IgG antibody {q) were 
included in REML models for induced BHVl-IgG on Days 14 to 77 are shown in 
Table 4.10. Levels o f BHVl-IgG on Days 14, 28 and 42 were positively 
associated with pre-existing Day 0 levels of BHVl-IgG. BHVl-IgG levels on 
Days 63 and 77 were negatively associated with Day 0-BHVL Table 4.11 shows 
the attached significance when the effect Day 0-BHVl is included in the REML 
models developed for Days 14 to 77. There is a two-way interaction of Day 0- 
BHVl with age which features on every sampling day and another two-way 
interaction of Day 0-BHVl with sex on four out o f five of the post-vaccination 
sampling days.
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Figure 4.7 Deviations in levels of BHVl-IgG -  ((A/IgG(DO to D63)) against level of 
Day 0 BHVl-IgG. Best-fit regression line shown (dashed). A/IgG values are 
untransformed. Day 0 BHVl-IgG are log tiansfbrmed ROD data.
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iS
induced BH Vl-IgG antibody
D14 D28 D42 D63 D77
q 0.84 0.49 0.30 -0.16 -0.83(s.e.) (0.03) (0.09) (0 . 1 1 ) (0.07) (0.14)
Table 4.10 Regression coefficients when Day 0 level of pre-existing BHVl-IgG 
{q) is included in models for BHVl-IgG level on Days 14 to 77. Mean values 
(standard errors) are presented on log scale. Data analysis using REML models 
(EQ4.6)
BHVl-IgG by Day 0 iIgG antibody
Day
0
14
28
42
63
77
Table 4.11 Significant inclusions of the fixed effect pre-existing /IgGi, either as main 
effect or interaction, for levels of BHVl-IgG on Days 0 to 77, relative to vaccination. 
BHV1/PIV3 vaccine administered on Day 0. Values are log transformed ROD data. Day 
0-BHVl (level of BHVl-IgG on Day 0). Data analyses using REML models (EQ 4.6).
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REML term Waldstatistic d.f. P  value
Day 0-BHVl.age 8 .8 1 0.003
J-
1Day 0-BHVl.age 21.7 1 < 0 . 0 0 1
Day 0-BHVl.year-of-bii-th 15.3 0 . 0 0 2
Day 0-BHV1 .sex 7.9 1 0.004 1
Day 0-BHVl.age 42.6 1 < 0 . 0 0 1
Day 0-BHV 1 .year-of-birth 13.6 0.004
Day 0-BHVl.sex 1 1 .0 1 < 0 . 0 0 1
Day 0-BHVl.Holstein 5.7 1 0.017
Day 0-BHVl.age 35.9 1 < 0 . 0 0 1 ■f
Day 0-BHVl.sex 21.3 1 < 0 . 0 0 1 ÎDay 0-BHVl.recombination-loss 14.1 1 < 0 . 0 0 1Day 0-BHVl.year-of-birth 10.3 0.016 àDay 0-BHVl.Holstein 6.9 1 0.009
Day 0-BHVl.age 31.4 1 < 0 . 0 0 1
Day 0-BHVl.sex 15.9 1 < 0 . 0 0 1
Day 0-BHVl.Holstein 1 2 .2 1 < 0 . 0 0 1 . ..
Day 0-BHVl.recombination-loss 5.5 1 0.019 ..
Parameters (a and P) for the binomial models developed using logistic 
regression, are detailed in Table 4.12. Threshold levels of pre-existing Day 0- 
BHVl at which positive or negative effects were equally likely {p =0.5) are 
shown in Figure 4.8. For BHVl, the threshold was 4.1% for Day 14 responses, 
5.6% for Day 28 responses and 5.3% for Day 42 responses. Threshold levels of 
pre-existing antibody were estimated at {p =0.9) at which 90% of calves were 
expected to respond with an increased antibody response. For BHVl antibody 
responses on Days 14, 28 and 42, these values were 0.9%, 1.4% and 1.3%, 
respectively.
Î
i
111
induced AiTgG
(DO to D28) (DO to D42) (DO to D63)
a 2.67 2.05 2.64
(0.44) (0.41) (0.37)
P -1.55 -1.46 -1.59(0.17) (0.16) (0.15)
Table 4.12 Estimated parameters (a and p) for deviation A/lgG on Days 14, 28 and 42 
against level of pre-existing BHVl-IgG on Day 0. Mean values (standard errors) are 
presented. p<0.001 for all regression coefficients. Data analysis using logistic 
regression models (EQ 4.5).
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Figure 4.8 Probability o f positive BHVl-IgG antibody response on Days 28, 42 and 63 
(A/?IgG(DG to D28: black), ApIgG(DO to D42: blue), A/?lgG(D0 to D63: red) against 
Day 0 BHVl-IgG level. A/IgG values are untransformed, Day 0 BHVl-IgG level is log 
transformed, p  = 0.5 (green dashed); p  = 0.9 (green solid). Data analysis using logistic 
regression models (EQ 4.5).
There was no evidence that pre-existing  levels o f  B H V l-IgG  had a significant 
effect on post-vaccination levels o f  PIV 3-IgG  (REM L; p >0.1).
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4.4,2.5 Age at first vaccination
There is a clear relationship between caif age and the level of pre-existing PIV3 
antibody on Day 0. Older animals have lower levels of PIV3-IgG, with an almost 
constant ~1.4-fold (antilog) increment between consecutive age-groups (Figure 
4.9(a)). Although all age-groups showed some increase in mean levels of PIV3- 
IgG between Days 14 and 28, for age-groups 1, II and III, this increase was both 
small and transient, peaking at only ~1.2-fold. However in older calves (age- 
groups IV and V), levels of PIY3-IgG increased 1.54-fold and 1.58-fold, 
respectively between Days 14 and 28, and continued to increase until Day 77, 
post-vaccination. Mean PIV3-IgG levels in age-groups IV and V were different 
on Day 0 (t-test; p <0.05) only, with no detectable differences between the two 
age-groups on the other five sampling days (t-test; p >0.1). Table 4.13 shows the 
significance attached when age is included in the REML models developed for 
PIV3- IgG Days 0 to 77. The strongest effect of age is on Day 0 but age persists 
as part of two-way interactions for all sampling days except Day 42.
In general, BHVl-IgG responses to vaccination in this study were weak. A 
pattern similar to Day 0 PIV3-IgG is apparent for Day 0 BHVl-IgG  levels but 
with more variation in increments between age-groups and age-group IV, not 
age-group V, having the lowest levels of Day 0 BHVl-IgG  (Figure 4.9(b)). There 
were no detectable increases in mean levels o f BHVl-IgG in the youngest calves 
(age-groups 1 and 11), post-vaccination. Between Days 14 and 28, age-groups III 
and V did show small positive deviations in levels of BHVl-IgG but it was age- 
group IV, the second oldest set o f calves, which had lowest levels of Day 0 
BHVl-IgG and correspondingly the largest increase in levels o f BHVl-IgG 
between Days 14 and 28 post-vaccination. Age-group V had higher levels of Day 
0 BHVl-IgG and only intermediate increases in levels of BHVl-IgG post­
vaccination. Table 4.14 shows the significance attached when age is included in 
the REML models developed for BHVl Days 0 to 77. The strongest effect o f age 
is on Days 42, 63 and 77 as an interaction with Day 0-BHVl but age is present as 
a main effect or two-way interaction on all sampling days.
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Figure 4.9 Levels o f PIV3-IgG (a) and BHVl-IgG (b) from Days 0 to 77, relative to 
vaccination. Vaccine administered on Day 0. Results are log transformed ROD data and 
presented grouped on age: group I ~ 60-81 days (o), group II ~ 82-103 days (□), group 
III ~ 104-125 days (A ), group IV ~ 126-147 days (V ) and group V ~ 148-169 days (•) .
ISO
ID ay
0
14
28
42
63
77
M odel term
age
age.Day 0-PIV3
age.Day 0-PIV3
age.year-of-birth
age.sex
age.year-of-birth
age.year-of-birth
PIV3~IgG by age
Wald
statistic d.f.
74.7
12.4
13.4
15.4 
9.1
20.4
22.5
P  value
< 0.001
< 0.001
< 0.001
0.002
0.003
< 0.001
< 0.001
Table 4.13 Significant inclusions of the fixed effect age, either as main effect or 
interactions, for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. Vaccine 
administered on Day 0. Values are log transformed ROD data. Day 0-PIV3 (level of PIV3- 
IgG on Day 0). Data analyses using REML models (EQ 4.6).
1
I
BHVl-IgG by age
Day
0
14
28
42
63
77
Model term
age.year-of-birth
age
age.Day 0-BHV I
age.Day 0-BHVl 
age
age.Day 0-BHV I 
age.Day 0-BHVl 
age.Day 0-BHV 1
Wald
statistic d.f.
14.9
9.0
8.8
2 1 . 7
1 1 . 7
42.6
35.9 
31.4
P value
0.002
0.003
0.003
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
s.
Table 4.14 Significant inclusions of the fixed effect age, either as main effect or interactions 
for levels of BHVl-IgG on Days 0 to 77, relative to vaccination. Vaccine administered on 
Day 0. Values are log transformed ROD data. Day 0-BHVl (level of BHVl-IgG on Day 0). 
Data analyses using REML models (EQ 4.6). ;
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4.4.2.Ô Dam-age
Dam s o f  all ages had calves with very sim ilar levels o f  PIV 3-IgG  (A N O V A ; p 
>0.1) on all sam pling days except Day 77 (A N O V A ; p <0.01). On Day 77, there 
w ere small increm ental rises in levels o f  PIV3-IgG  associated w ith dam -age  
(Figure 4.10). On Day 63, the order was the sam e although the actual differences 
w ere even lower. N ote that as there are only three dam s aged seven years old, 
this group is small and statistically  unreliable. Table 4.15 show s the significance 
attached w hen dam -age  is included in the REM L m odels developed for PIV3 
Days 0 to 77. The effect is only significant on Day 42 post-vaccination, present 
as tw o-w ay interaction W \\h year-o f-b irth .
4.001
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Figure 4.10 Levels of PIV3-lgG from Day 0 to Day 77, relative to vaccination. PIV3/BHVI 
vaccine administered on Day 0. Mean values are log transformed relative optical density 
(ROD)and presented grouped on dam-age: 2 ( • ) ,  3 (■), 4 (O ), 5(D), 6 (A ) and 7 (A ) years. 
Note y-axis begins at 2.00.
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D ay R E M L  term
PIV3~IgG by dam-age 
W ald
statistic d.f. P  value
dam-age.year-of-birth
dam-age.recombination-loss.
30.29
14.29
10
4
< 0.001
0.006
0
14
28
42
63
77
Table 4.15 Significant inclusions of the fixed effect dam-age, either as main effects or 
interactions, for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. 
FIV3/BHV1 vaccine administered on Day 0. Values are log transformed relative 
optical density (ROD) data. Data analyses using REML models.
Dams of all ages had calves with very similar levels of BHVl-IgG (ANOVA; 
p>0.1) on all sampling days except Day 42 (ANOVA; p <0.05). There was no 
obvious pattern in levels of BHVl-IgG when grouped on dam-age (Figure 4.11). 
Table 4.16 shows the significanee attached when dam-age is included in the 
REML models developed for BHVl Days 0 to 77. The effect is only significant 
early post-vaccination on Days 14 and 28, present as two-way interactions with 
year-of-birth and Day 0-BHVf respectively.
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Figure 4.11 Levels o f BHVl-IgG from Day 0 to Day 77, relative to vaccination. 
PIV3/BHVI vaccine administered on Day 0. Mean values are log transformed relative 
optical density (ROD) data and presented grouped on dam-age: 2 ( • ) ,  3 (■), 4 (O ), 5(D), 
6 (A ) and 7 (A ) years.
D ay
BHVl-IgG by dam-age
REML term
Wald
statistic d.f. P  v a lu e
0
14
28
42
63
77
dam-age.year-of-birth 
dam-age.Day 0-BHVl
21.34
22.55
10
5
0.019
< 0.001
Table 4.16 Data analyses using REML models. Significant inclusions o f the fixed effect 
dam  age, either as main effects or interactions for levels o f BH V l-IgG  on Days 0 to 77, 
relative to vaccination. PIV3/BHV1 vaccine administered on Day 0. Values are log 
transformed ROD data. Day 0-BHVl (level o f BHVl-IgG on Day 0)
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4.4.3 Analysis of genetic effects 
4.4.3.1 Crossbreeding effect - Holstein
On Days 0 and 14, calves with greater proportions of Holstein genes {Holstein =
0.75) have 1.19-foId higher levels of PIV3-IgG than calves with a lower 
proportion of Holstein genes, {Holstein = 0.5) which in turn had 1.21-fold higher 
levels of PIV3-IgG than calves with Holstein = 0.25. Figure 4.12(a) shows that 
between Day 28 and Day 77, mean levels o f PIV3-IgG based on Holstein were
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not significantly different (ANOVA; p >0.05). All three profiles for PIV3-IgG 
variance followed very similar patterns when grouped on Holstein = 0.25, 0.50 
and 0.75, however, ranked in the opposite order (0.75 > 0.50 > 0.25) to that 
found with the PIV3-IgG mean profiles. Table 4.17 shows the significance 
attached when Holstein is included in the REML models developed for PIV3 
Days 0 to 77. Holstein is significant only on Days 14 and 42 as a two-way 
interaction with sex.
In contrast to PIV3, calves with greater proportions of Holstein genes {Holstein = 
0.75) had lower levels of BHVl-IgG than calves with a lower proportion of 
Holstein genes {Holstein = 0.25 or 0.50) on Days 0, 14, 28 and 42, relative to 
vaccination (p <0.05). There were negligible differences (t-test; p >0,1) between 
levels of BHVl-IgG in calves with either Holstein = 0.25 or 0.50 on any of the 
six sampling days (Figure 4.12(b)). Mean BHVl-IgG levels grouped on Holstein 
(0.25, 0.50 and 0.75) tend to converge on Day 63 and Day 77 post-vaccination. 
The BFIVl-IgG variance profiles o f all three Holstein groups broadly follow 
similar patterns although for Holstein = 0,25 calves, the Day 77 variance is 3,60- 
fold (antilog) that of Day 28. For Holstein = 0.50 and = 0.75 calves, the Day 77 
BHVl-IgG variances are only 1.92-fold (antilog) and 1.35-fold (antilog) the 
respective Day 28 BHVl-IgG values. Table 4.18 shows the significance attached 
when Holstein is included in the REML models developed for BHVl Days 0 to 
77. Holstein is significant on all sampling days except Day 14, either as a main 
effect or as an two-way interaction with Day 0-BHVL Its influence seems to be 
highest on Day 0 and Day 77, declining on the intervening sampling days, Day 
14 to Day 63. The three profiles for BHVl-IgG variance followed very similar 
patterns when grouped on Holstein = 0.25, 0.50 and 0.75, however again, ranked
in the opposite order (0.75 > 0.50 >  0.25) to that found with the B H V l-IgG  mean 
profiles.
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Figure 4.12 Levels o f PIV3-lgG (a) and BHVl-IgG (b) from Days 0 to 77, relative to 
vaccination. Vaccine administered on Day 0. Values are log transformed and presented 
grouped on Holstein: 0.25 (O  ), 0.50 (□) and 0.75(A). Mean (black) and variance (blue) of 
data presented.
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D ay
PIV3-IgG by Holstein
R E M L  term Waldstatistic d.f. P value
14 Holstein.sex 8.5 1 0.003
28 “ - -
42 Holstein.sex 7.3 1 0.007
63 - - -
77 - -
Table 4.17 Significant inclusions of the fixed effect Holstein, either as main effect or 
interactions for levels of PIV3-IgG on Days 0 to 77, relative to vaccination. BHV1/PIV3 
vaccine administered on Day 0. Values are log transformed relative optical density (ROD) 
data. Data analyses using REML models (EQ 4.6).
Day REML term Waldstatistic
BHVl~IgG by Holstein 
d.f. P value
0
14
28
42
63
77
Holstein
Holstein
Holstein.Day 0-BHVl 
Holstein.Day 0-BHVl 
Holstein.Day 0-BHVl
12.3
6.2
5.7
6.9
12.2
< 0.001
0.013
0.017
0.009
< 0.001
Table 4.18 Significant inclusions of the fixed effect Holstein, either as main effects or 
interactions for levels of BHVl-IgG on Days 0 to 77, relative to vaccination. Vaccine 
administered on Day 0. Values are log transformed ROD data. Day 0-BHVl (level of 
BHVl-IgG on Day 0). Data analyses using REML models (EQ 4.6).
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4.4 3.2 Crossbreeding effect - recombination-loss
As Figure 4.13 (a,b) show s, there w ere no significant d ifferences (REM L; p 
>0.1) betw een mean levels o f  PIV 3-IgG  and B H V l-IgG  w hen grouped on 
recom bination-loss  on any o f  the six sam pling days tested.
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Figure 4.13 Levels of PIV3-lgG (a) and BHVl-IgG (b) from Days 0 to 77, relative to 
vaccination. Vaccine administered on Day 0. Values are log transformed relative optical 
density (ROD) data and presented, grouped on recombination-loss: 0.5 (O ) and 1.0 (□). 
Mean (black) and variance (blue) o f data presented.
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4.4.3.3 Sire effects
Generally mean levels of PIV3-IgG, based on sire, increased from Day 0 to 
between Days 14 and 42 and then remained at that higher level until Day 77 
(Figure 4.14). There was a 3.36-fold difference between the half-sib group with 
the highest (sire = R05) and lowest (sire = H I47) Day 0 PIV3-IgG level but only 
a 1.95-fold difference between the half-sib group with the highest (sire = R19) 
and lowest (sire = H25) Day 77 PIV3-IgG level. Half-sib group R02 had the 
largest Day 0 to Day 77 deviation, (ApIgG(DO to D77)), a 2.52-fold increase, 
while half-sib group R05 had the smallest ApïgG(DO to D77), a 1.29-fold 
decrease. Half-sib group R12 had the smallest increase (1.04-fold) between Days 
14 and 28, while over the same period half-sib group R11 has the largest increase 
(1.43-fold). Half-sib group R21 had the smallest deviation: an actual 1.03-fold 
decrease between Days 28 and 42, while over the same period half-sib group ROl 
had the largest increase (1.24-fold). Although there is only a 1.05-foId difference 
between PIV3-IgG levels of half-sib groups R02 and H25 on Day 14, this had 
increased to 1.56-fold by Day 77.
Overall heritability (hP) for PIV3-IgG level decreased initially post-vaccination 
to negligible levels on Day 14, then rose to 0.30 by Day 28, peaking at 0.31 on 
Day 42 then falling to lower levels on Day 63 and 77 (Table 4.19). The Day 28 
PIV3-IgG h  ^ value was robust, after removing either the upper or lower ten per 
cent of the data - the i f  value moved to 0,38 (±0.22) and 0.24 (±0.15), 
respectively. Similarly, after removing either the upper or lower ten percent of 
the data - the Day 42 PIV3-IgG i f  value changed to 0.40 (±0.22) and 0.29 
(±0.17), respectively. The pattern of PlV3-IgG heritability also differed between 
sexes. In the female calves, PIV3-IgG i f  started high on Day 0, fell on Day 14 
but increased quickly by Day 28 and remained at a high level until Day 77. In 
contrast in the male calves, PlV3-IgG h  ^ started low, increased more slowly to a 
slightly lower peak on Day 42 and Day 63, then declined back to low levels by 
Day 77.
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Figure 4.14 Levels of PlV3-IgG from Days 0 to 77, relative to vaccination. Vaccine 
administered on Day 0. Values are log transformed ROD data and means are 
presented, grouped on sire: 8 FI Holstein/Charolais (black) and 4 FO Charolais 
(blue). Note y-axis begins at 2.00.
The sum m ary trait 6-day-area pIgG  proved useful and representative o f  the 
individual sam pling days, providing representative h^ values for overall PIV3- 
IgG and PIV3-IgG  when grouped on sex.
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PIV3-IgG (both sexes) 
overall ct„ log-likelihood
tra it overall on log scale ratio  for sire
Day 0 /jIgG 0.25 (0.16) 0.31 (0.21) < 0 . 0 0 2
Day 14/;IgG 0.00 (0.05) 0 . 0 0  (0 .0 1 ) n.s.
Day 28 /?IgG 0.30(0.17) 0.12(0.07) < 0 . 0 0 0 1
Day 42 jvIgG 0.31 (0.17) 0.24 (0.14) < 0 . 0 0 0 1
Day 63 /?IgG 0.24 (0.14) 0.24 (0.15) < 0 . 0 0 0 1
Day 77 />IgG 0.17(0.12) 0.16(0.12) < 0.005
[)IgG(D14 to D28) 0.10(0.09) - 0.03
6-day-area /tIgG 0.37 (0.20) - < 0 . 0 0 0 1
P IV 3 -Ig G  (males only)
Day 0 /JigG 0.10(0.15) 0 .1 1  (0.16) n.s.
Day 14 pIgG 0.23 (0.21) 0.05 (0.05) n.s.
Day 28 joIgG 0.15(0.15) 0.05 (0.05) n.s.
Day 42 plgG 0.47 (0.28) 0.32(0.21) <0.0005
Day 63 plgG 0.23 (0.19) 0.24 (0.21) 0.025
Day 77 /?IgG 0.01 (0.09) 0 . 0 1  (0.08) n.s.
6-day-area /?IgG 0.26 (0 .2 0 ) - <0.05
PIV3-IgG (females only)
Day 0 pIgG 0.32 (0.23) 0.36 (0.24) 0.013
Day 14 p lgG 0.15(0.18) 0.04 (0.05) n.s.
Day 28 />IgG 0.44 (0.30) 0.17(0.12) 0.009
Day 42 /?IgG 0.51 (0.31) 0.35 (0.24) 0 . 0 0 2
Day 63 plgG 0.47 (0.28) 0.38 (0.26) 0.0008
Day 77 p\gG 0.54 (0.31) 0.49 (0.32) 0.0008
6 day area /?lgG 0.65 (0.35) - < 0 . 0 0 1
Table 4.19 Additive trait heritabilities (standard error) and total phenotypic variances 
(0 |j^  ) on natural logarithm scale and sire log-likelihood ratios. Statistics for levels of 
PIV3-IgG antibody, and 6 -day-area for PIV3-IgG antibody levels between Days 0 and 
77, post-vaccination. Results presented overall and grouped on sex. n.s. (p >0.1). 
Estimates produced using REML.
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Generally, mean levels of BHVl-IgG based on sire decreased progressively 
between Days 0 and 77 with small, transient increases between Days 14 and 28 
(Figure 4.15). There was a 3.56-fold difference between the half-sib groups R05 
(the highest) and R02 (the lowest) Day 0 BHVl-IgG levels. By Day 77 this had 
increased to a 6.03-fold difference between the highest (sire = H I47) and lowest 
(sire = H25) half-sib groups. Between Days 0 and 77, half-sib group R05 had the 
largest decrease (AROD = -38.2%) while half-sib group R02 had the smallest 
decrease (AROD = -38.2%).
Between Days 0 and 14, half-sib groups H25 and H27 had very similar levels of 
BHVl-lgG but between Days 14 and 28, half-sib group H27 had a positive 
(1.46-fold) BHVl-IgG deviation while half-sib group H25 showed an actual 
(1.20-fold) decrease. Mean Day 0 BHVl-IgG levels for half-sib group H147 
were high but not the highest (sire = R05) and although they did show a small 
increase post-vaccination, they remained relatively constant compared to the 
other half-sib groups tested.
Half-sib group R02 had the smallest decrease (A ROD = -0.7%) between Days 14 
and 28 while half-sib group R12 had the greatest decrease (A ROD = -10.9%). 
Half-sib group R02 also had the lowest mean BHVl-lgG level on Day 0 and the 
most prolonged BHVl-IgG response, remaining above Day 0 levels until after 
Day 63, post-vaccination. Half-sib group R19 had both the highest 6 -day-area 
fIgG and the highest 6 -day-areapIgG in the study. The 6 -day-average ilgG does 
appear to act as a useful summary trait, overall representative o f the individual 
sampling days involved.
As shown in Table 4.20, all heritabilities (h^) for the BHVl-IgG traits (including 
summary traits) analysed were low (< 0.16). In fact, over Days 14, 28 and 42, the 
h  ^ levels dropped to non-significant levels, even below the basal levels on Day 0. 
They apparently returned to those basal levels by Day 77. Such a pattern suggests 
little impact of additive genetics on post-vaccination levels o f BHVl-IgG, as 
detected in the phenotype of the current study.
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Figure 4.15 Levels o f BHVl-IgG from Days 0 to 77, relative to vaccination. Vaccine 
administered on Day 0. Values are log transformed ROD data and means are 
presented, grouped on sire: 8 FI Holstein/Charolais (black) and 4 FO Charolais 
(blue). Note the y-axis begins at 1.0.
63
BHVl-IgG (both sexes)
trait overall h
overall <t,, 
on log scale
log-likelihood  
ratio for sire
0.14(0 .11) 0.09 (0.07) 0.03
n.s. - n.s.
0.04 (0.07) 0.01 (0.02) n.s.
0.08 (0.09) 0.02 (0.02) n.s.
0.11 (0.10) 0.04 (0.04) n.s.
0 .16(0 .13) 0.07 (0.06) 0.04
0.00 (0.00) - n.s.
0.12 (0.10) 0.02 (0.02) 0.06
0.09 (0.09) 0.02 (0.02) n.s.
D ay 0 /TgG 
D ay 14 /IgG  
D ay 28 /IgG  
D ay 42 /IgG  
D ay 63 /IgG  
D ay 77 /IgG
A/IgG(D14 to D28) 
6-day-average /IgG  
6-day-area /IgG
Table 4.20 Additive trait heritabilities h^  (standard error) and total phenotypic variances 
(Op^ ) on natural logarithm scale. Sire log-likelihood ratio statistics for levels of BHVl- 
IgG antibody, ABHVI-IgG deviation between Days 14 and 28, overall 6 -day-average and 
6 -day-area for BHVl-IgG antibody levels between Days 0 and 77, post-vaccination, n.s. 
(p >0.1). Estimates produced using REML.
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4.5 Discussion
Substantial differences in host immunity between the responses to P1V3 and 
BHVl vaccination have been highlighted by the current study of pathogen 
specific IgG antibody levels in a large group of young cattle. The study was also 
able to demonstrate some of the differences in the epidemiology of the two 
viruses. The antibody profiles observed for PIV3 post-vaccination are 
characteristic o f secondary-type immune responses, suggesting previous 
exposure to the virus. This is in contrast with the antibody profiles observed 
following BHVl vaceination, a pattern o f low response to this vaccine 
commented on previously by Patel et al (2005). Those authors also described 
extremely low rates of seroconversion to this BHVl vaccine although it still 
retained protective efficacy as determined by virus shedding following challenge.
Initial levels of pre-existing antibody to both viruses prior to vaccination were 
veiy similar and it is impossible to distinguish passive (originating from 
colostrum) from active (induced by naturally occurring infection) IgG antibody 
by ELISA alone. However over the 77-day course, the mean PlV3-IgG profile 
was consistent with an anamnestic antibody response occurring against a 
background of high levels of PIV3 antibody. This effect was most pronounced in 
the male calves, which had freely mixed with the adult bovine population from 
birth. Anamestic antibody responses tend to be higher, more rapid and more 
sustained than primary antibody responses (Graham et a l, 1999). In contrast, the 
mean BHVl-IgG profile obtained in the current study is typical o f the largely 
inhibitoiy effect o f high levels o f pre-existing BHVl antibody on responses to 
BHVl vaccination (Menanteau-Horta e /a /., 1985).
Bovine herpesvirus 1, in common with many other herpesvirus, causes true latent 
infections producing high levels o f antibody in the adult herd and consequently 
high levels of maternally-derived passive antibody in the calf population (Brar et 
a l, 1978). Although calves do not always seroconvert after BHVl vaccination 
(Le Jan and Asso, 1981), once infection has occurred antibodies to BHVl remain 
readily detectable for at least three years (Zygraich et a l, 1975a). Passive BHVl 
antibody from colostrum can persist for at least nine months (Brar et a l, 1978).
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Lemaire et al. (2000b) found that using ELISA to detect maternally-derived 
BHVl antibody levels extended the period of detection to between 6  and 10 
months instead of between 5 and 8  months using the SNT. In the current study, 
both the overall antibody profile and apparently short half-life o f the BHVl 
antibody imply that most of this antibody may indeed be colostral in origin. The 
dynamics of PIV3 antibody observed were very different. High pre-vaccination 
antibody levels in the calf population in the current study may well be 
maintained by field PIV3 infections. In this study, vaccination against PIV3 may 
therefore be considered to induce secondary immune responses rather than the 
primary immune responses observed against BRSV vaccination.
Based on the results of this study, there appears to be little difference between 
levels of BHVl-IgG based on sex/management, apart from determining the 
initial level of pre-existing antibody on the day of vaccination. In contrast, the 
antibody profile for PIV3-IgG in the male calves is distinctly different from that 
of the female calves. The disparate responses to these two respective viral 
antigens may be explained thus 1 ) environment/management (and/or ^ex) may 
have a specific antigen-dependent effect on antibody response to vaccination; 2 ) 
en V iron ment/management (and/or sex) may play an indirect role in determining 
antibody responses to vaceination, due to challenge of the calves by naturally 
circulating field virus infections; 3) a combination of 1 ) and 2). The divergent 
antibody responses between specific vaccine components are notable but as sex 
and environment/management are confounded in this experiment, discriminating 
which variable has the greatest significance is not possible. These results 
highlight the importance of farming practices in disease management and 
demonstrate how pathogen-specific microenvironments may co-exist on a single 
farm.
In addition to the inherent variables of location, weather, nutrition and overall 
herd health, many management factors such as weaning, transport, feedlot 
acclimatisation, overcrowding, and marketing can produce stress, trauma and 
malnutrition in young cattle. Buffalo calves maintained with outdoor space 
allowances had higher antibody responses to keyhole limpet hemocyanin (KLH) 
than other calves with more restricted indoor accommodation (Grasso et a i, 
1999). Antibody responses specific to KLH were lower in calves maintained in 
open pens compared to hutch-housing, with increased stress proposed as the
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underlying negative cause (Cummins and Brunner, 1991). In contrast, van 
Reenen et a l (2000) found no differences in antibody responses between group- 
housed and individually-housed 12-week old male Holstein Friesian calves, 
vaccinated against BHVl. A Dutch bulk-milk tank survey found that farm 
epidemiological characteristics, such as herd size, herd density and stock 
purchase rate were important determinants of levels of seropositivity to field 
BHVl (van Wuijckhuise e /a /., 1998).
Post-vaccination BHVl antibody levels were higher in vaccinated crossbred beef 
cattle treated with the antibiotic, florfenicol, than in cattle which did not receive 
florfenicol medication (Hunsaker et a l, 1999). Bovine herpesvirus 1 antibody 
responses to vaccination improved when levamisole was administered one week 
after the vaccine (Babiuk and Misra, 1982), while concurrent BVDV infection 
caused increased virus shedding but no difference in antibody response to BHV1 
vaccination (Edwards et a l, 1986). In the current study, the factors year-of-hirth 
and sex contain much of the non-genetic and environmental variation as outlined 
above, as they include seasonal variation in herd disease, climate, nutrition and 
farm management.
Conflicting results have been recorded for the effect of age on vaccine response. 
An inverse correlation was described previously between calf age and levels of 
maternally-derived passive BHVl antibody (Menanteau-Horta et a l, 1985; Stott 
et a l, 1987). Lapierre et a l (1975) found no evidence of age-related effects in 
eight to seventeen week-old calves vaccinated against BHVl, and in another 
study, calf age was found not to be an important determinant of antibody 
response following PIV3 vaccination (Burroughs et aï., 1982). Although clinical 
disease was more severe and longer lasting in younger calves, age was again 
found not to be important for seroconversion following BHVl infection (Msolla 
et al, 1983). However, severe disease occurred in very young (3 day-old) calves 
following intramuscular administration of a combined PIV3/BHV1 vaccine 
(Bryan et a l, 1994). Non-specific reactions lowered the specificity o f the indirect 
BHVl ELISA between 160 days and 240 days, post-vaccination (Cho et a l, 
2 0 0 2 ) but this is largely beyond the age range of calves in the current study. 
Temperature-sensitive PIV3 and BHVl viruses have been combined in intranasal 
live vaccines for decades (Zygraich et a i,  1975b). However, interferon induced 
by BHVl intranasal vaccination may interfere with the immune responses
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induced by simultaneous exposure to PIV3 virus (Cummins and Rosenquist, 
1982). Furthermore, four month old calves with mixed BHVl/PIV3 infections 
had delayed and depressed antibody responses compared to those with single 
BHVl and PIV3 virus infections (Ghram et a l, 1989). In addition, wild-type 
BHV 1 infection has been reported to depress CMI functions such as chemotaxis, 
cytotoxicity and mitogenic responses (Bielefeldt and Babiuk, 1985) and 
multivalent bacterial polysaccharide vaccines showed immunological 
interference between antigens (Fattom et a l, 1999). Although early levels of IgG 
antibody to both viruses were positively associated, most probably due to some 
common colostral origin, the current study found no evidence of immunologic 
interference between the two viruses based on levels of specific IgG antibody. 
These results are consistent with previous research (Fulton et a l, 1995; Talens et 
a l, 1989; Tollis et a l, 1996).
Although BHVl and P1V3 were components of the same multivalent vaccine, the 
contrasting patterns o f specific-IgG responses induced also stresses how the 
immune system deals with each antigen independently. Calves between 126 and 
169 days old (Group IV) had unusually high IgG responses to BHVl. Possible 
explanations include: 1 ) the pattern may be stochastic in origin but with age- 
group IV containing 142 calves compared to 76 and 159 in age-groups III and V, 
respectively, this would seem unlikely or 2 ) the pattern may relate to levels of 
pre-existing antibody. Pre-vaccination levels o f BHVl antibody were lowest in 
age-group IV, not age-group V as would be expected if all antibody was of 
colostral origin. The reasons for this particular deviance remain unclear and 3) 
there may be a temporary age-associated shift in BHVl-IgG vaccine 
responsiveness between 126 to 147 days. This transient receptiveness is perhaps 
due to the development o f the immune system, disease epidemiology or other 
considerations. The effect was not prolonged, and when age-group IV itself grew 
older (on later sampling days), the pronounced BHVl-IgG response subsided and 
resumed a pattern o f constant antibody decay, comparable to all other age- 
groups.
Previous research has reported that BHVl antibody has a half-life of —21 days 
while PIV3 antibody has a half-life of -30  days (Brar et a l, 1978; Fulton et a l, 
1995). The values obtained from the current study are very similar. The pre­
vaccination level of IgG antibody is accepted to influence the subsequent
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antibody response to vaccination. Pre-existing levels of maternal antibody 
interfered with the BHVl antibody response induced by both infection 
(Bradshaw and Edwards, 1996) and vaccination (Brar el a l, 1978; Lucas et al, 
1982; Menanteau-Horta et a l, 1985) but had little effect on cell-mediated 
immune responses (Lemaire et a l, 2000a). Stott et al (1987) found that younger 
calves, with higher levels o f maternally derived antibody, had lower responses to 
PIV3 vaccination, a finding confirmed by Cummins et a l (1982). Lemaire et al 
(2000b) demonstrated that intranasal BHVl vaccination slowed the decay of 
maternally derived antibody, with the actual response to vaccination inversely 
dependent on the level of BHVl maternally derived antibody. In human infants, 
an inverse correlation was reported between pre-vaccination levels of PIV3 
antibody and post-vaccination PIV3 antibody levels (Karron e ta l,  1996). 
Suppression o f antibody tends to be immunologically specific and it was reported 
that, although pre-existing passive BHVl antibody completely prevented 
seroconversion following vaccination (Brar et al, 1978), the calves were 
sensitized to BHVl virus. Maternally derived antibody inhibited or prevented 
seroconversion following experimental exposure to BHVl (Bradshaw and 
Edwards, 1996; Brar et a l, 1978; Le Jan and Asso, 1981). It is unlikely that this 
suppression is absolute however and in the current study nominal threshold 
values were estimated for suppression o f PIV3 and BHVl vaccine responses. 
Threshold antibody titres above which inhibition of antibody responses occurs 
have been previously described are 1:4 for BHVl and 1:128 for PIV3 (Zygraich 
et al, 1975b), Fulton et a l (1995) also estimated threshold titres of 1:20 for 
BETVl and 1:32 for PIV3 before seroconversion was inhibited. In contrast Ellis et 
al (1996) suggested that some low level BHVl antibody production did occur 
following live vaccine immunisation, despite high levels of colostral antibody. 
The results from the current study confirm just such a weak response. Antibody 
half-lives were extended for both BHVl and PIV3 in 3-month old beef calves 
following vaccination (Fulton et a l, 1995). Furthermore, despite immunological 
immaturity and the blocking effect o f passive antibody, intranasal BHVl 
vaccination at four days old extended the detectable period as measured by both 
blocking and indirect ELISA (Lemaire et a l, 2000a), It is probable that stronger 
responses would be evident if mucosal levels of BHVl antibody had been 
investigated in the current study.
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The design of practical vaceination programmes must aceoiint for the variety of 
responses occurring which in turn depends on the prevailing type of 
immunological preconditioning: either passive or active. In the present study pre­
vaccination PIV3 antibody levels were higher than BHVl antibody levels. 
However vaccination stimulated strong PIV3 responses but weak BHVl 
responses. In another study, maternally-derived BHVl antibody declined from a 
peak titre of 1:32 to undetectable levels by day 170 in mixed-sex beef calves 
(Menanteau-Horta et a l, 1985). The same authors found that calves vaccinated at 
84 days of age appeared not to seroconvert, with antibody levels continuing to 
decline. Calves given BVDV vaccine concurrently, however, did seroconvert 
despite BHVl antibody levels being lower than those for BVDV. The effect of 
pre-existing antibody level on subsequent antibody response is therefore 
compelling and has clinical importance in disease management schemes for 
young cattle.
Few researchers have investigated genetic control of BHV1/PIV3 infection or 
vaccination. Despite this, some genetic effect on responses to vaccination should 
be anticipated. Major histoeompatability complex (B) haplotypes influence 
vaccinal immunity against the chicken alphaherpesvirus: Marek’s disease virus, 
as reviewed by Bacon et a l (2001). Also in poultry, Sacco et a l (1994b) 
described both higher antibody responses to Newcastle Disease vaccine (caused 
by a paramyxovirus like PIV3) in turkey lines selected for increased body weight 
and elevated antibody levels in female rather than male birds. A peak heritability 
of 0.47 was described for sire-based genetic effects controlling homologous 
antibody titres against strains of foot-and-mouth virus in adult bulls (Samina et 
al 1998.). In addition, cattle-breed significantly affected both rapidity and 
magnitude of antibody (IgG) responses in seven-month-old Angus and 
Simmental heifers following intramuscular administration of pig eiythrocytes 
(Engle e ta l,  1999).
More specifically, using 111 Holstein-Friesian adult cows selected for milk fat 
production, Sinclair et al (1999) found no evidence of genetic control of 
antibody responses to intranasal BFIVl vaccination. In that study, 26% of cows 
were recorded as non-responders to the vaccine but animal age, exposure histoiy 
and limited genetic variability may also have impacted upon the results. 
Differences based on breed-cross were recorded for responses to the BHVl
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component of a live multivalent vaccine but not the P1V3 component by Burton 
et a l (1994). That study was small and primarily designed to demonstrate the 
immunomodulatory effects of chromium. Breed-cross did however significantly 
determine post-vaccination antibody levels to BHVl (killed vaccine) in seven- 
month-old crossbred calves (Cole et a l, 2001). Genetically predetermined 
variability in immune responses to BHVl vaccination was suggested by Zhu et 
al (1996) and following experimental observation, the Guernsey breed was 
postulated as having increased resistance to BHVl infection (Bielefeldt and 
Babiuk, 1985).
Immune responses do not occur in isolation from other metabolic processes and 
genetic variation may reflect individual ability to absorb and metabolise 
nutrients. Vitamin-B supplementation boosted antibody responses to BHVl 
vaccination in stressed calves (Dubeski et a l, 1996), while cattle augmented with 
zinc had higher antibody responses to BHVl vaccination than control animals 
(Spears et a l, 1991). A complex of minerals, including zinc, cobalt and copper, 
increased responses to vaccination against both PIV3 and BHVl (George et al, 
1997). Selenium-deficient calves had lower secondaiy responses to BHVl than 
selenium-adequate animals (Reffett et a l, 1988). Copper supplementation 
increased antibody production to erythrocytes in stressed steers but decreased the 
level of antibody in non-stressed animals (Ward and Spears, 1999). In vaccinated 
120 day-old Holstein calves, plasma pH was negatively correlated with levels of 
both PIV3 and BHVl antibody while increased levels of plasma B- 
hydroxybutyrate were associated with lower antibody levels to BHVl (Donovan 
e ta l,  2003).
Unfortunately, due to the large number of non-responders and weak responders 
to BHVl vaccination, the phenotype generated by the current study was not 
suitable to allow meaningful analysis for heritable effects. The corresponding 
antibody responses to PIV3 did however indicate strong sire-based genetic 
effects. Due to the complicating effect of colostral immunity antibody, present 
for both viruses, it is difficult to determine if this difference in responses is 
pathogen (virus) specific or distorted due to stronger immunological suppression 
by BHVl passive antibody.
The PlV3-IgG heritability estimates (h^) were obtained against high background 
levels of P1V3 antibody and are consistent with a seeondaiy-type antibody
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response. A distinction therefore can be drawn between this phenotype and those 
phenotypic responses obtained when calves were vaccinated against BRSV 
(primary-type antibody response - Chapter 3). The peak h  ^ for PIV3-IgG is 
appreciably higher than that obtained for the primary immune response registered 
against BRSV vaccination. It is however striking that progeny of sire ROl whieh 
had the highest levels of BRSV antibody (Chapter 3) were found to have the 
second highest levels of PIV3 antibody. Further evaluation is required to 
determine if these secondary-type PIV3 immune responses are amplified Ifversions of primary responses or if they operate via (partially or completely) 
independent genetic mechanisms. With -50%  of variation in PIV3-IgG responses 
heritable, even in the face o f circulating field virus infections, effective disease 
control programmes should now take account of immunogenetic effects. These 
PIV3 results substantiate those obtained for BRSV, suggesting that selection for 
increased vaccine response to these two viruses in cattle is likely to yield real 
welfare and production benefits in the future.
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Chapter 5
Linking antibody phenotype to cattle genotype
t
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5.1 Introduction
I
Immunological traits such as antibody and cellular responses to viral infection are 
under complex regulation, controlled by both patent environmental factors and 
concealed genetic components (Lofthouse and Kemp, 2002). It is these types of 
immune traits that mediate resistance to BRD but have proved difficult to decipher 
and improve for several reasons (Soller and Andersson, 1998). Such functional 
traits tend to respond poorly to selective breeding using conventional techniques 
as they often have low heritabilities. There are many practical difficulties in 
obtaining firm data to substantiate selection for relevant immune traits and 
protection against clinical disease. In addition, modern farming practices to date, 
have tended to concentrate exclusively on production traits. However, recently 
there has been an adjustment towards more balanced breeding goals, with immune 
function traits explicitly included in total merit indices (Mark, 2004).
The emergence of precise genetic linkage maps composed of many microsatellite 
markers has facilitated quantitative trait loci-inapping in cattle. Quantitative trait 
loci are chromosomal segments, obeying Mendelian inheritance, which exert 
predictable effects on quantitative phenotypic traits (Hui Liu, 1998). Their 
detection uses phenotypic, pedigree and genetic marker information to dissect 
those allelic mutations underlying the particular phenotypic trait. Quantitative trait 
loci are most beneficial when traits are difficult or expensive to measure, when 
traits are poorly heritable, when each individual phenotype has limited 
informativeness and when it is difficult to clearly assign polygenic cause. Searches 
for QTL may even be performed without prior knowledge of the physiological or 
biochemical functions of the loci involved. Once QTL have been recognised, 
additional markers can be selected to saturate the prospective segment of 
chromosome to finely localize the position, the eventual aim being identification 
o f single gene function through bioinformatic and other technologies.
Mapping of QTL is a well established, effective technique in cattle populations, 
with most research emphasis on production traits. To date, attributes successfully 
linked to QTL include milk yield (Casas and Cundiff, 2003), milk composition 
(Plante et a l, 2001), reproduction (Casas et a l, 2004; Cruickshank et a l, 2004), 
birthweight (Grosz and MacNeil, 2001), and growth and carcase traits (Stone et
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a l, 1999). Selective breeding aims at providing animals with the most favourable 
sets of genes for production, conformation and functional traits. Marker assisted 
selection directed by QTL should enhance the rate of genetic progress towards 
cattle optimised for modern farming requirements.
To date, QTL searches for immune function have tended to concentrate on those 
species which have highly structured breeding programmes, large litter sizes, short 
generation intervals and particularly intensive farming practices. In pigs, the 
heritability (±se) of serum antibody levels following vaccination against AD was 
estimated as 0.42 (±0.13) and differences based on pig-breed have also been 
described (Rothschild et a l, 1984). Swine Leukocyte Antigen (MHC equivalent) 
loci have been associated with this antibody response against AD virus (Mallard et 
al, 1989; Wimmers et a l, 2004), and QTL have been identified for AD resistance 
(Reiner et a l, 2002). In addition, QTL for antibody responses were detected in 
pigs against Escherichia coli antigens (Edfors-Lilja et a l, 1998). Similarly in 
chickens, the heritability of antibody response has been established against 
Escherichia coli and Newcastle Disease virus (Leitner et a l, 1994; Yunis et al, 
2002b), and in turkeys against Pasteurella multocida and Newcastle Disease virus 
(Sacco et a l, 1994a). Quantitative trait loci for antibody responses were detected 
in chickens against exogenous antigens such as sheep erythrocytes (Siwek et a l, 
2003b) and keyhole limpet hemocyanin (Siwek et a l, 2003a). Polygenic 
quantitative control o f antibody responses has been also confirmed by other 
studies in mice (De Souza et a l, 2004; Puel et a l, 1995), chickens (Siwek et a l, 
2003a) and turkeys (Saceo e ta l,  1994a).
In cattle, however, most immunogenetic studies have concentrated on daiiy health 
traits. There have been many QTL studies in dairy cattle almost universally using 
somatic cell count as the indicator trait (Ashwell et a l, 1996; Heyen et a l, 1999; 
Klungland et a l, 2001; Kuhn et aï., 2003; Schulman et aï., 2004). The 
inflammatory protein eonglutinin, envisaged as protective against both viral and 
bacterial infections is under heritable control in cattle, although some sex-based 
variation may also exist (Holmskov et a l, 1998). Quantitative trait loci for the 
phenotypic traits anaemia, bodyweight and parasitaemia, relevant to host 
resistance against Trypanosomosis, have been described in breeds of African cattle 
(Hanotte et a l, 2003). However, a QTL search for resistance against the nematode 
Trichostrongylus spp. in another ruminant species, sheep, indicated only limited
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Isuccess (Bell et a l, 2002). Quantitative trait loci have been identified for resistance and susceptibility to bovine spongiform encephalopathy in Holstein 
cattle (Zhang et a l, 2004).
To produce cattle with improved health, specific criteria for selection of disease 
resistance must be established. Standardised vaccination, a method of stimulation 
of immune responses allows all study individuals to be equally exposed to the 
same antigenic stimulus. The results provide a good approximation of the 
underlying immunogenetic variation, much more clearly than by studying wild- 
type clinieal respiratoiy disease and associated immune responses (Snowder et a l,
2005). Using indirect ELISA, an established, repeatable, sensitive and specific 
assay, the antibody responses induced by viral vaccination have been assessed 
(Chapters 3 and 4). Models were developed to partition the phenotypic 
performances of individual animals into additive genetic components plus intrinsic 
{sex, age, etc) and extrinsic {year-of-hirth, dam-age, etc) factor contributions.
The objectives of the current study were to exploit the genetic diversity between 
Charolais and Holstein cattle breeds to detect associations between microsatellite 
markers and QTL controlling immune function traits in cattle for antibody
response to respiratory vaccination and antigen-stimulated cellular responses.
::Using thoroughly analysed phenotypic data, putative QTL were mapped over the 
entire bovine genome and their effects quantified. This experiment was unique due 
to the structured breeding programme employed, the relatively large number of 
progeny involved, the type of immunological phenotype observed, and the extent 
of the bovine genome covered.
5.2 Materials
n.
f
I
f
5.2.1. Cattle
The current study used the RoboGen experimental cattle herd, described in detail 
in Chapter 2, with the entire pedigree population comprised of 954 genotyped 
animals (281 males and 673 females). This overall number included 587 F2 
animals and 152 FI animals. Phenotypic data was collected from 463 second- 
generation Holstein-Charolais calves (BH, BCH and F2 crosses), in four cohorts 
between 1998 and 2001, as described earlier in Chapters 2 , 3 and 4.
5.2.2. M arkers and M aps
Deoxyribonucleic acid (DNA) was prepared from semen samples collected from 
FO and FI bulls and from blood collected from the FO and FI dams and all the F2 
progeny. DNA extraction was performed using a lysis and phenol/chloroform 
standard protocol (Maniatis et a l, 1982). For the genome scan, 139 microsatellite 
markers were selected at -2 0  cM (Kosambi) intervals on all 29 Bos taurus 
autosomes (BTA) using published cattle linkage maps as a guide for intermarker 
distances (Barendse et a l, 1997; Kappes et a l, 1997). Markers were tested for 
position, technical clarity and potential informativeness (minimum target 
informativity -0.50) and substitutions made as required (Table 5.1). Microsatellite 
genotypes were determined initially by an independent laboratoiy (Geneseek Inc, 
Nebraska, USA) then verified in-house (ARK-Genomics, Midlothian, UK).
The microsatellite markers used in this study are shown in Appendix C.l on a per- 
chromosome basis. Up to eight markers were assigned per chromosome, the 
maximum and minimum intervals between markers being 63.2 cM (BTA7) and 
0.2 cM (BTA 13) respectively, with the mean interval being 20.5 cM to make a 
total mapped length of 2202.3 cM (Table 5.1). Estimated total BTA length and the 
number of linkage groups are based on the bovine genome map reported by Everts 
van der Wind et a l (2004).
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Total genome coverage was approximately 80% of current published chromosome 
lengths (Band et a l, 2000). The mean marker interval per chromosome, ranged 
between 6.8 cM (BTA25) and 26.5 cM (BTA 12) with a genomewide average of
Map Average BTA Heterozygosity
Table 5.1 Bos taurus autosomes (BTAl to BTA29): number of autosomal markers; total mapped 
length (centiMorgans; cM); average marker interval (cM); estimated total BTA length (number of 
linkage groups); minimum, maximum and average chromosomal heterozygosity; "measured in 
centiRay CR5000 where 4cR ~ IcM; ^overall genome total; ‘^ overall genome average; *BoLA- 
containing autosome.
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INO Ol L.eiigth Interval length
BTA markers (cM) (cM) (cRsoo) mill max average ■’■I
■'■I■1 7 126.8 18.1 256(3) 0.5721 0.8320 0.6643
2 6 108.7 18.1 502(5) 0.7363 0.8085 0.7672
3 8 123.0 15.4 303(2) 0.5141 0.8189 0.6798
4 6 93.6 15.6 431(5) 0.4455 0.8689 0.6701 ?
5 5 111.6 22.3 508(1) 0.6357 0.7822 0.6909 #
6 6 85.2 14.2 521(3) 0.5042 0.7933 0.6295 %7 5 109.6 21.9 547(3) 0.4833 0.7476 0.6096
8 6 101.7 17.0 513(5) 0.4544 0.8870 0.6825 1
9 5 76.2 15.2 345(2) 0.4800 0.7944 0.6580
10 6 73.9 12.3 466(1) 0.5512 0.8226 0.7122
11 6 95.8 16.0 557(3) 0.5851 0.7984 0.6838
12 4 106.0 26.5 226(5) 0.5536 0.8239 0.6747
13 4 44.2 11.1 384(2) 0.6093 0.7403 0.6972
14 5 63.4 12.7 361(6) 0.6268 0.8113 0.7354
15 5 92.4 18.5 452(3) 0.7071 0.8378 0.7672 I
16 5 65.1 13.0 563(4) 0.4742 0.8601 0.6787
17 6 94.6 15.8 440(3) 0.5400 0.7900 0.6709 ?'
18 5 70.5 14.1 549(4) 0.5980 0.7443 0.7069
19 4 65.6 16.4 513(5) 0.6652 0.7009 0.6824 '120 4 64.3 16.1 150(3) 0.6874 0.8241 0.7478 ::
21 3 62.1 20.7 316(2) 0.5370 0.7030 0.6201
22 4 44.2 11.1 291(3) 0.6742 0.8006 0.7321 y
*23 3 64.3 21.4 462(1) 0.7077 0.8148 0.7619
24 4 44.6 11.2 219(1) 0.4985 0.7435 0.6248
25 3 20.5 6.8 286(2) 0.7068 0.8540 0.7755
26 4 60.0 15.0 333(1) 0.5380 0.7972 0.7144
27 3 64.1 21.4 175(2) 0.6397 0.7038 0.6802
28 4 37.4 9.4 170(1) 0.5830 0.8310 0.7075
7 :29 3 32.9 11.0 469(1) 0.6937 0.8504 0.7906
139" 2 2 0 2 .3 " 15.8" 11308(82)" ~ - 0.6971" "i
15.8 cM. Sex-specific maps were used when analysis was based on subsets of 
either mate or female animals. The distribution of markers across the genome is 
presented graphically in Figure 5.1.
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Fig 5.1 Graphical representation of marker distribution and marker density for all 29 Bos 
taurus autosomes (BTAl to BTA29). Autosome number on the horizontal axis; position 
on the autosomes on vertical axis, provided in centiMorgans (cM). Each marker is 
indicated by a small horizontal bar on the vertical line representing the chromosome. The 
y-axis == 0  represents the terminal marker and not the actual end of the autosome.
It should be noted that, in genomic terms, there are large gaps in the marker maps 
for BTA7, BTA 12, BTA21, BTA23 and BTA27.
Most markers were relatively informative. The maximum number of alleles per 
marker was nineteen (BTA 10; TGLA272) and three chromosomes had markers 
with only three alleles (BTA6 ; BP7), (B T A ll; HUJV174) and (BTA 12; 1NRA5). 
Heterozygosity is the expected probability that an individual will have different 
alleles at a given single or multiple loci. For individual chromosomes, 
heterozygosity ranges between 0.000 and 0.900. Heterozygosity values based on 
the microsatellite genotyping were calculated per-autosome using the Windows- 
based TFPGA software package, Version 1.3 (Miller, 1997). Average 
heterozygosity per chromosome ranged from 0.610 (BTA7) to 0.791 (BTA29). 
The lowest marker heterozygosity was 0.446 found on (BTA4; 1DVGA51) and the
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highest was 0.887 found on (BTA8 ; D1K106). Average genome-wide 
heterozygosity across all chromosomes was 0.697 (Table 5.1).
Linkage between sets of markers was analysed using the Unix-based software 
package CRI-MAP Version 2.4 (Green et a l, 1990) and both sex-averaged and 
sex-specific maps constructed using the BUILD function to give most likely 
orders of and recombination rates among markers. The resulting framework 
linkage maps complied with global and interval support levels outlined by Keats et 
a/. (1991).
5.2.3. Phenotypic data
In previous chapters, phenotypic data based on the IgG antibody responses 
folowing vaccination against the viruses BRSV, PIV3 and BHVl were extensively 
assessed. Fixed effects and covariates for those datasets were evaluated using 
REML models and overall pre- and post-vaccination patterns of antibody kinetics 
considered biometrically. Phenotypic data for BCV IgG levels, presumably due to 
field infections (Chapter 2) was also tested for QTL, for comparative purposes.
A further set of immunological data (Young, 2002) for the same Robogen 
population of calves was available, collected from 445 calves at approximately 
five months old. In this case, the phenotypic traits were lymphocyte proliferation 
responses induced by formalin-killed Staphylococcus aureus ANTIGEN, 
phytohemagglutinin (PHA) MITOGEN and a matched blank CONTROL. The 
bacterium Staphylococcus aureus is a common mastitis pathogen of cattle (Sutra 
and Poutrel, 1994) and PHA, a potent T-lymphocyte-specific mitogen (Pearson et 
al, 1979). Lymphocyte proliferation data were generated by incorporation of 
[^Hjthymidine, expressed as counts-per-minute readings on Days 2, 3, 4, 5, 9 and 
10 of in vitro culture and were log transformed before use. This dataset has also 
been analysed thoroughly using REML and the heritable nature of specific traits 
established (Young et a l, 2005). An ideal opportunity presented to further 
characterise and analyze this related dataset for immune-related QTL, in 
conjunction with the antibody response data from the same set of calves.
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5.3 Methods
5.3.1 Background
All phenotypic variance is a product of environment and genetic variation. Genetic 
variance can be partitioned into additive, dominance and epistatic variances 
(Falconer and Mackay, 1995). Additive effects of genes are cumulative over 
generations and are the main source of variation exploited by most animal 
breeding programmes. Interactions between alleles at any single locus are termed 
dominance, while interactions between alleles o f different loci are termed epistasis 
(Lynch and Walsh, 1997).
Estimates of the additive and dominance effects of each prospective QTL were 
obtained from the all animals. Additive effects are the average genotypic effects at 
any locus and depend on the related breeding value. Additive effects (a) were 
defined as half of the deviation in phenotypic expression (fitness) between animals 
homozygous for locus-specific alleles (Figure 5.2).
a = 'A (A2 A2 -A]Ai )
Dominance effects (d) were calculated as the deviation in phenotypic expression 
of locus-specific heterozygous animals from the phenotypic mean of animals 
homozygous for the same locus (Figure 5.2).
d = (A 2 A ])  -  (A 2 A 2  + A j A j )
Genotype A2A2 A 2A 1 AiAi
Genotypic -a d a
value
Figure 5.2 Graphical representation of allelic relationships at a single locus. Alleles A] 
and A2 shown. Additive genetic effect (a) and dominance genetic effect (d)
A third situation also requires definition - overdominance (or heterosis) is when 
the phenotypic expression of the heterozygote eg. A2A 1 is greater than either of the 
homozygotes (A2A2 or A]A|). Overdominance permits the stable coexistence o f 
both alleles within a population and so maintains genetic variability.
In Chapters 3 and 4, the peak heritability h^(±se) of the vaccination-induced 
antibody response traits involved was established as 0.32(±0.17) for BRSV, 
0.54(±0.31) for PIV3 and 0.16(±0.13) for BHVl. The h  ^ values estimated for
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:
antibody responsiveness to vaccination against BRSV and PIV3 are therefore 
medium high and that for BHVl low. The results for BRSV and PIV3 antibody 
confirm that genetic control exists for these traits.
5.3.2 QTL Analysis
Linkage between genetic markers and immunological traits were tested on 29 
autosomes for 34 antibody response traits (BRSV, PIV3, BHVl and BCV). The 
traits comprised of antibody levels on the six sampling days for each vaccine, with 
deviations in antibody levels between days and area-under-eurve also tested. ï
Linkage between genetic markers and phenotypic traits were also tested for 18 
lymphocyte proliferation traits (ANTIGEN, MITOGEN and CONTROL) using a 
multiple marker regression approach (Knott et a l, 1996). The lymphocyte |
proliferation traits comprised of counts-per-minute readings for six days o f in vitro %culture (ranging Day 2 to Day 10) for each agent (ANTIGEN, MITOGEN and 
CONTROL), with Day 0, the commencement o f in vitro incubation. Both data sets 
were log transformed before analysis.
F-statistic values were obtained by regression interval mapping analysis using the 
web-based Java software QTL Express (http://qtl.can.ed.ac.uk) as described by 
Seaton et a l (2002) which uses the multi-marker linear regression method.
Relevant fixed effects and covariates were fitted as determined in Chapters 3 and 4 
for the BRSV, PIV3 and BHVl antibody datasets. Relevant fixed effects and 
covariates were fitted as pre-determined in Young et al (2005) for the ANTIGEN,
MITOGEN and CONTROL lymphocyte proliferation datasets. Due to the large 
sex-based disparity identified in the BRSV and PIV3 antibody kinetic patterns,
QTL analysis for the BRSV and PIV3 sets of traits was performed in data grouped 
on sex, in addition to the population of animals as a whole. 3
The mapped genome was queried to locate regions where the markers explain a Î'large proportion of the phenotypic variation, by regressing the offspring 
phenotypes onto the additive and dominance coefficients on every cM between 
markers. Briefly, a conditional probability o f inheriting a specific haplotype from 
the sire was derived using the marker genotypes in all half-sib offspring. Then the
phenotypic trait value was regressed onto the probability that a particular QTL 
allele was inherited from the sire. To evaluate the resulting putative QTL, a test- 
statistic comparing a model with a QTL at that position against a model without 
the putative QTL was calculated. This test statistic is the ratio of the difference in 
residual sums of squares under the null hypothesis (no QTL) and the residual sums 
of squares under the QTL model over the residual sum of squares under the QTL 
model.
Under the null hypothesis of no QTL, the ratio of the mean squares of the effect of 
the allele to the residual mean squares should have a central F distribution. The 
maximum test statistic (F-statistic) was regarded as the most likely position of a 
QTL. F-statistic testing is robust against small deviations from normality and all 
segregating QTL should increase the F-statistic. F-statistics were calculated at 
intervals of 1 cM on all 29 autosomes. Quantitative trait loci searches across 29 
chromosomes involve a huge number of statistical tests for marker-trait 
associations. In order to keep the number o f false positives to an acceptable level, 
appropriate significance thresholds must be applied to each test. Due to the 
complex multiple test procedures involved in QTL detection, precise calculation 
of threshold F-statistics are inappropriate. Empirical threshold values o f the F- 
statistic were estimated for each chromosome using permutation testing (n = 1 0 0 0 ; 
Knott e/a/., 1998).
Permutation-based testing is based on non-parametric methods and better 
accommodates population-specific characteristics such as missing genotypes, 
differences in marker density and non-normal phenotypic distributions. Briefly, 
the permutation method of Churchill and Doerge (1994) involves random 
reassignment of trait values among individuals within the population. The 
resulting new data set was reanalysed and a new F-statistic calculated. This 
procedure was repeated 1 0 0 0 -fold to derive reliable empirical significance 
thresholds (Lander and Kruglyak, 1995). Thresholds against the null model at the 
5% and 1% chromosome-wide level were derived for each QTL model for all 
traits. When significant QTL were detected, confidence intervals were estimated 
using bootstrapping (Visscher et al, 1996). The 95% confidence interval was 
established as the chromosomal region remaining when the top and bottom 2.5%
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of estimated positions were dropped. Further permutation work on the Robogen 
population has identified a 5% genome-wide significance level of -9 .0  (Weiner, 
2005).
Detection of QTL depends on population size, the genomic distance between 
markers, the actual QTL, other QTL and the size of the effect of the QTL (Weller 
et a l, 1990). Rejection of QTL at too stringent a level defeats the purpose of the 
preliminary genome scan as neither a QTL position or its effect are known a priori 
(Fernando et a l, 2004), According to Lander and Kruglyak (1995), all significant 
results at p <0.05 should be reported. As this was an exploratoiy analysis, to 
prevent missing QTL because o f consei-vative test thresholds, all QTL were 
reported above the 5% chromosome-wide threshold level.
It is possible that two linked QTL with smaller effects can mimic the presence o f 
one QTL with a large effect. A two-dimensional search was performed for 2-QTL 
models, with all combinations of positions for the 2-QTL evaluated. By computing 
and comparing the F-statistic generated by the 2-QTL model against that for the 
best I-QTL model, the null hypothesis of a 1-QTL could be evaluated. An 
informative empty marker interval is necessaiy between two QTL to make 
discrimination possible and with limited marker maps, this may not always be 
possible.
184
5.4. Results
5.4.1 All QTL findings
Inclusion of both antibody and cellular traits for all 29 autosomes resulted in 1508 
trait/chromosome combinations being tested for QTL. All QTL satisfying the 5% 
chromosome-wide F-statistic threshold were reported. The frequency distribution 
of F-statistics for the 1508 trait/chromosome combinations tested is listed in Table 
5.2. Also shown in Table 5.2 are the number of QTL reported at, or greater than, 
the 5% significance level (unshaded) and the number of QTL expected at the 5% 
significance level due to random variation alone (shaded).
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All six types of phenotypic traits; BRSV, PIV3, BHVl, ANTIGEN, MITOGEN
■
and CONTROL, even those previously assigned low heritability, were associated
with putative QTL, with 119 significant trait/chromosome combinations 'A.tabulated for 28 different chromosomes. There were 82 significant .fttrait/chromosome combinations reported for antibody responses (Table 5.3a-e) 
and 37 for lymphocyte proliferation responses (Table 5.4a-c). As some J
phenotypic traits were highly correlated, this reduced the number to 41 distinct
QTL for vaccine-induced antibody responses and 16 distinct QTL for
lymphocyte proliferation responses. Twelve of the antibody response QTL were {
for pre-vaccination sampling days. Only one chromosome (BTAl 5) contained no 
prospective QTL while eight chromosomes contained QTL related to one trait J
only (BTA4, BTA5, BTA13, BTA l4, BTA22, BTA23, BTA25, and BTA29).
Some chromosomes appeared to contain genes for a number of traits; BTA7,
BT A l8  and BTA21 each had four different types of trait, with four, three and 
five different QTL detected, respectively. Taking all chromosomes together, 
there were 21 QTL for BRSV IgG antibody, 13 QTL for PIV3 IgG antibody and 
9 QTL for BHVl IgG antibody. Only two prospective QTL were detected for the 
BCV dataset (BTAl and BTA3) and both had relatively low F-statistics.
Summarized for all chromosomes, six QTL for ANTIGEN lymphocyte 
proliferation reached the 5% chromosome-wide significance level, with two QTL 
reported for MITOGEN lymphocyte proliferation and nine QTL for CONTROL 
lymphocyte proliferation results.
As expected, some traits were highly correlated, especially antibody levels on 
successive sampling days and this is reflected in the series of QTL with the same 
or near same chromosomal position such as BHVl (BTAl; 54-58 cM) and 
BRSV (BTA6 ; 63-65 cM), There were two overlapping QTL for antibody traits 
against more than one type o f virus: P1V3 and BHVl (BTA24; 44 cM) and 
BRSV and PIV3 (BTA28; 0-2 cM). However other QTL were identified, which 
were clearly specific to particular times in particular antibody response profiles.
There were also two overlapping QTL for lymphocyte proliferation traits on 
BTA7 (0-1 cM) and BTAl 8  (63-70 cM), both associated with ANTIGEN and 
CONTROL.
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No evidence was found to favour the 2-QTL model over the 1-QTL model on 
any chromosome in the current study and testing for such provided little 
additional information to the analysis.
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5.4.2 S ignificant Q T L  findings
Figures 5.3 to 5.7 show F-statistlc curves for a number o f traits, selected due to high 
peak levels of significance. They act as examples, illustrating how the patterns of F- 
statistics typically vaiy according to chromosomal position.
5.4.2.1 BRSV antibody
A significant QTL (p <0.01) was detected on BTA8 , located between markers 
DIK106 and HUJ174, with a peak F-statistic of 8.96 and a positive additive (±se) 
effect of 0.336 (±0.086) for post-vaccination levels of BRSV-specific IgG antibody 
in the male calf group (Figure 5.3). The position of this QTL was estimated as 42.9 
cM with a 95% confidence inteiwal (CI-95) between 25 cM and 92 cM.
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Figure 5.3 F-statistic curve of single QTL (BTA8 ) for level of BRSV-IgG antibody on 
Day 49, relative to first vaccination (male calves only). The x-axis indicates the 
chromosomal position in centimorgans (cM). The y-axis represents the F-statistic at each 
chromosomal position. Horizontal lines indicate chromosome-wide significance 
thresholds of p <0.05 (green) and p <0.01 (red).
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5.4.2.2 PIV3 antibody
Another significant QTL (p <0.01) was detected on BTAIO between markers 
CSRM60 and TGLA272, with a peak F-statistic of 6.75 and a dominant negative 
effect (±se) of -0.410 (±0.114) for post-vaccination levels of PlV3-specific IgG 
antibody in the male calf group (Figure 5.4). The position of this QTL was 
estimated as 58.9 cM with a CI-95 between 12 cM and 67 cM.
10-,
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Figure 5.4 F-statistic curve of single QTL (BTAIO) for level of PIV3 IgG antibody on 
Day 77, relative to vaccination (male calves only). The x-axis indicates the 
chromosomal position in centimorgans (cM). The y-axis represents the F-statistic at 
each cln-omosomal position. Horizontal lines indicate chromosome-wide significance 
thresholds of p <0.05 (green) and p <0.01 (red).
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5 4.2.3 B H V l an tibody
A significant QTL (p <0.01) was detected on BTAl between markers 1NRA128, 
with a peak F-statistic of 7.03 and an additive negative effect (±se)of -0.331 
(±0.117) for post-vaccination levels of BHVl-specific IgG antibody (Figure 5.5). 
The position was estimated as 48.6 cM with a CI-95 between 9,5 cM and 106.5 cM.
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Figure 5,5 F-statistlc curve of single QTL (BTAl) for level of BHVl IgG antibody 
on Day 63 relative to first vaccination. The x-axis indicates the chromosomal position 
in centimorgans (cM). The y-axis represents the F-statistic at each chiomosomal 
position. Horizontal dotted lines indicate chromosome-wide significance thresholds of 
p <0.05 (green) and p <0.01 (red).
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S.4.2.4 Lymphocyte proliferation (CONTROL)
A significant QTL (p <0.01) was detected on BTAl 8  between markers HAUT4 and 
DIK67, with a peak F-statistic of 9.51 and a positive additive (±se) effect o f 0.336 
(±0.086) for levels of lymphocyte proliferation in the CONTROL group (Figure 
5.6). The position was estimated as 59.8 cM with a CI-95 between 32 cM and 70 
cM.
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Figure 5.6 F-statistic curve of single QTL (BTAl8 ) for level of lymphocyte proliferation 
(CONTROL) on Day 3, relative to stimulation. The x-axis indicates the chromosomal 
position in centimorgans (cM). The y-axis represents the F-statistic at each chromosomal 
position. Horizontal dotted lines indicate chromosome-wide significance thresholds of p 
<0.05 (green) and p <0.01 (red).
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5 4.2.5 BCV  an tibody
A putative QTL (p <0.05) for levels o f BCV antibody due to presumed exposure to 
wild-type virus had a peak F-statistic of 5.47 and a pattern suggestive that the 
detected QTL may lie just outside the available marker map (Figure 5.7). The 95% 
confidence intervals for this QTL tended to be quite large, with minimum and 
maximum values of 38cM and 97cM, respectively.
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Figure 5.7 F-statistic curve of single QTL (BTAl) for level of BCV IgG antibody. The 
x-axis indicates the chromosomal position in centimorgans (cM). The y-axis represents 
the F-statistic at each chromosomal position. Horizontal dotted lines indicate 
chromosome-wide significance thresholds of p <0.05 (green) and p <0.01 (red).
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5 .5 . Discussion
A  comprehensive genome scan was performed to detect QTL associated with 
antibody responses to vaccination and antigen/mitogen stimulated lymphocyte 
proliferation in a young, crossbred cattle population. Quantitative phenotypic data 
generated using standard laboratory techniques (ELISA and [^H]thymidine- 
incorporation lymphocyte proliferation assay) were used to explore the novel area 
of immune system genetic control. With ~ 80% of the genome covered, the results 
strongly support a multilocus model for both genetic control of antibody response to 
respiratory vaccination and genetic control o f lymphocyte proliferation in cattle. In 
particular, QTL on BTAl, -2, -6 , -7 for antibody response and QTL on BTAIO, -18 
and -21 for lymphocyte proliferation, show high significance. This is consistent 
with the paradigm discussed by Glass (2004), with the contribution o f many genes 
with small and interacting effects determining overall vaccine responsiveness. Most 
of the other immune QTL reported satisfy lower significance thresholds only and so 
must be regarded as prospective rather than definitive.
This study was novel in many respects. Much previous research on the role of 
genetic variation on the functioning o f the immune system has concentrated on 
qualitative issues o f high or low responses, essentially phenotypic extremes 
(Mallard et a l, 1998). By introducing a continuum model for antibody 
responsiveness, it is hoped to provide a more inclusive representation of in vivo 
immune processes. Unlike most cattle QTL experiments which are based on the 
grand-daughter design (Weller et a l, 1990), this project used a F2/backcross (two 
commercial cattle breeds) test population explicitly designed for QTL detection. 
This approach has advantages: 1) as three genotypes can be found at loci, both 
additive and dominance effects can be estimated; 2) increased power for QTL 
analysis than backcross (alone) design; 3) any identified QTL may be more 
precisely investigated in subsequent crossing experiments (Liu and Zeng, 2000). 
However as the experimental population size was limited, both in size and structure, 
some relevant alleles and genes may be inadvertently excluded from the study.
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Unlike most previous antibody response studies, which were based on selected
M
lines; mice (Fuel et a l, 1996), pigs (Magnusson et a l, 1997), chickens (Yunis et a l, M
2002b) and turkeys (Sacco et a l, 1994a) divergent for antibody production, the ■S
current study was based on breed lines developed for production traits alone. As 
such, all results are relevant and pertinent to commercial cattle production. Eighty- 
two QTL F-statistics for antibody response met or exceeded the 5% 
chromosomewide significance threshold in this study, 34 more than the 48 QTL f
expected due to stochascity alone, given the number of trait and chromosome |
combinations. Similarly, although 26 QTL were expected due to stochascity, based 
on the lymphocyte proliferation data, 41 (an excess of 15) were detected by this 
experiment. Although in terms of both antibody and cellular traits, many more QTL 
were detected than could be expected by chance alone, it is probable that some of 
the putative QTL represent Type I errors (false positives adopted). This limitation is 
accepted but all available QTL were reported both to allow future research access to 
the fullest set o f “raw” results possible and to lower the probability that true QTL 
for antibody response to vaccination were ignored, a Type II error (true positives 
rejected).
The immune system is under complex balance and control. Each immune response
to vaccination is dependent on host immune status, immunological memory, ®
administration route, antigen type, inoculate dose, pathogen predilection sites and
many other factors. Although the three viruses used are together described as
respiratory pathogens, each virus has a unique niche: epidemiological,
immunological and pathological and this is reflected in their corresponding vaccines
(Chapters 3 and 4). Sources o f variation additional to those discussed in those
chapters include parenteral versus mucosal administration; DNA-type versus RNA-
type viruses; primary, secondary and subsequent immune responses and prevailing
levels of pathogen-specific herd immunity and infections. For these reasons, as well
as the complexity and multiplicity of cellular interactions in an immune reaction, it 
,is unsurprising that a wide variety o f genes could be involved in the immune 
responses to vaccination. The three antibody responses studied here seem to 
represent distinct immunostimuiatory events, perhaps under separate genetic 
influence and control.
As discussed in Young et al. (2005), MITOGEN lymphocyte responses tend to be 
independent of both ANTIGEN and CONTROL lymphocyte responses. A similar 
disparate pattern is reflected in the QTL results for lymphocyte proliferative 
responses reported here, emphasizing how the innate and acquired types of 
immunity interact in cattle. The divergent and unique characteristics of each type of 
immune response tends to reflect their genetic origin. It would seem that many non- 
MHC QTL (not located on BTA23) are involved in the immune responses tested, 
which is consistent with the hypothesis that MHC genes have a supervisory role: 
modifying and regulating the influence of non-MHC genes (Behnke et a l, 2003).
Prior to this experiment, QTL mapping for immune function traits, especially 
humoral immunity, has been limited in cattle, with other species being much more 
thoroughly investigated. Mouse chromosome (Mmu) 6  (located at 20-36 cM), 
M mul2 (at 23-66 cM) and Mmu 17 (at 18-27 cM) were found to influence antibody 
responsiveness following immunisation with sheep erythrocytes (Fuel et a l, 1995). 
The same author found that Mmu4 (at 49-54 cM), Mmu 10 (at 65cM) and Mmu8  (at 
30-52 cM) were also involved in control of antibody response though to a lesser 
extent (Fuel et a l, 1996). On Mmu3 (at 49 cM), Mmu8  (at 38cM) and Mmu9 (at 34 
cM), QTL for antibody responses against Salmonella flagellar antigens were 
reported by De Souza (2004). The ITAM (immunoreceptor tyrosine-based 
activation motif), interleukin (IL)12a and IL6 Ra loci were proposed as likely 
candidate genes controlling antibody phenotype in mice (Takai, 2002). Due to the 
lack of resolution in the current bovine map, it was difficult to accurately align the 
prospective cattle QTL found here, relative to the published mouse map.
Fourteen QTL were described for antibody responses to Escherichia coli and 
Salmonella enteritidis in chickens (Yunis et a l, 2002b), six of which were common 
to both types of antigen. That study reported quite large genetic contributions of up 
to 1.84 phenotypic standard deviations and implicated a homologue of the human 
BMF2 gene. In baby chicks, QTL were detected by Siwek et al (2003a) for 
antibody responses against keyhole limpet hemocyanin (KLH) on Gallns gallns 
autosome (GGA)-14 and GGA18 and against Mycobacterium butyricum on 
GGA14, GGA16 and GGA18. The same author was able to classify QTL
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1controlling antibody responses into private (antigen-specific) and public (non­
specific). Such classification o f QTL was not possible in the current study, probably 
due to an overdiversity among the phenotypes studied, leading to a low number of 
common QTL.
Another study in chickens (Yunis et a l, 2002a), found strong correlations between 
genetic control of antibody responses to both bacterial and viral antigens, 
suggesting a non antigen-specific common mechanism of antibody response in that 
species. No correlation was found between antibody response and body weight in 
that population tested, a finding also confirmed by Siwek (2004). In chickens.
transforming growth factor (TGF-p) genes were found to exert genetic control over 
antibody responsiveness (Zhou and Lamont, 2003), a finding further refined to the 
TGF-(32 gene by Malek and Lamont (2003). The latter group also found 
associations between antibody levels induced by Salmonella spp vaccination and 
polymorphisms of inducible nitric oxide synthase (INOS) and immunoglobulin G 
light chain (IgL) genes in young chickens. In pigs, polymorphisms on MHC class II 
{DRB, DQB) and complement factor B genes were found to influence levels of A.antibody to AD virus (Wimmers et a l, 2004). Furthermore, QTL determining 
antibody responses to Escherichia coli antigens K 8 8  and 0149 were detected on pig 
chromosomes SSC5 (at 64 cM) and SSC6  (at 69 cM), respectively (Edfors-Lilja et 
al, 1998).
The vast majority o f the QTL related to antibody response in cattle reported here are 
original, simply because there has been virtually no previous QTL research for 
these types of immune trait. In cattle, Elo et a l (1999) described a QTL on BTA23 
(linked to marker RM 185) associated with general veterinary treatments although 
metabolic-type as well as infectious disease was included. There was evidence of a 
QTL for prevaccination levels o f antibody (Day 0-P1V3) on BTA25 (INRA222) in 
the current study and this corresponds to a QTL proposed on the same chromosome 
related to diseases other than mastitis and fertility problems by Holmberg and -f::Andersson-Eklund (2004). Significant QTL were characterised by the same author 
for diseases other than mastitis and fertility problems, associated with B T A ll 
(linked to INRA177) and BTA25 (linked to ILSTS102). Although INRA177 was
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included in the current study, there was no direct evidence of linkage and only 
putative evidence that B T A ll contained any immune function QTL, those for late 
antibody response (Day 63-PIV3) antibody and unstimulated lymphocyte 
proliferation (Day 3-CONTROL). Schulman et a l (2004) found QTL (position) for 
veterinaiy treatments (other than mastitis or infertility) on BTAl (22 cM), BTA2 
(28 cM), BTA5 (76 cM), BTA8  (121 cM), B T A l5 (101 cM) and BTA23 (1 cM).
None o f these were confirmed by the QTL results from the current study.
Along with many other immunomediators, viral infections induce type I interferons 
(IFN-a and -(3) which in turn stimulate the myxovirus (Mx) protein family designed 
to provoke apoptosis of virus-infected cells. Genes for bovine M xl are on BTAl 
(BM1824; 128 cM) and have been implicated in resistance to the viral pathogens 
BVDV, BHVl and bovine rotavirus (Muller-Doblies et a l, 2002; Muller-Doblies et 
al, 2004). The current study found a concordant QTL on BTAl (BMS4044; 126 :cM) for levels of antibody induced by field infections with bovine coronavirus.
There appeared to be no evidence of similar QTL associated with levels of antibody 
induced by BRSV, PIV3 or BHVl vaccination.
In the current study, BTA8  contains both QTL for antibody response and 
lymphocyte proliferation. BTA8  holds four IFN loci (Eggen and Fries, 1995) which 
have been demonstrated to influence the severity of disease induced by BHVl 
(Ryan and Womack, 1997). Quantitative trait loci for both antibody and lymphocyte 
proliferation traits, early ANTIGEN/CONTROL rates o f lymphocyte proliferation 
and late post-vaccination levels o f PIV3 antibody, coincided with QTL on B T A l8  
(-60 cM). The gene for the immunomodulant cytokine, transforming growth factor 
(TGF-pi), is located at this point on BTAl 8  (Sonstegard et a l, 2000).
4
Many cattle-based QTL studies include somatic cell count (SCC), which is linked to 
.the cellular immune response within the mammaiy gland. Somatic cell count is an 
indirect measure o f udder health, reflecting both subclincial and clinical mastitis 
(Koivula et a l, 2005). Previously published results related to SCC and incidence o f 
mastitis (*), are shown in Table 5.5 along with any corresponding lymphocyte 
proliferation QTL as determined by the current study. The following list is not 
exhaustive but does illustrate that QTL for SCC in cattle are accumulating through 
consensus and continuously evolving research. The number of genetic markers used
206
by each study is also listed. (A) (Reinsch et a l, 1998), 45 markers; (B) (Schrooten 
et a l, 2000), 277 markers; (C) (Zhang et a l,  1998), 206 markers; (D) (Ashwell et 
al, 1998b), 16 markers; (E) (Ashwell et a l, 1996), 17 markers; (F) (Ashwell et a l, 
1998a), 16 markers; (G) (Schulman et a l, 2004), 150 markers; (H) (Van Tassell et 
al, 2000), 105 markers; (I) (Heyen et a l, 1999), 174 markers; (J) (Rodriguez-Zas 
et a l, 2002), 174 markers; (K) (Kuhn et a l, 2003), 263 markers; (L) (Holmberg 
and Andersson-Eklund, 2004), 116 markers; (M) (Van Tassell et a l, 2004), 22 
markers; (N) (Ron et a l, 2004), 73 markers; (P) (Bennewitz et a l, 2003), 133 
markers; (Q) (Ashwell et a l, 2004), 367 markers, (R) (Schulman et a l, 2002), 101 
markers, (S) (Klungland et a l, 2001), 288 markers.
Quantitative trait loci identified for lymphocyte proliferation on B T A l2, B T A l7, 
BTA l9, BTA20 and BTA24 are novel to the current study and unreported 
elsewhere. The cellular phenotype tested in the current study is a much more precise 
and limited trait than the rather rather broad indicator trait, SCC used by the 
aforementioned studies. SCC is a complex summary trait, potentially influenced by 
the environmental, physiological, immunological, pathological and genetic 
backgrounds. It is therefore unsurprising that a more restricted number of QTL were 
identified in the current study, than those which dealt with SCC. This phenomenon, 
where some studies confirm a QTL, while others provide conflicting results, is 
relatively common and is due to a lack o f consensus about how phenotypic data 
should be collected, organised, analysed and the appropriate levels o f significance 
to apply when reporting. Furthermore, biological variation between populations 
means that real differences may exist in the relative importance of specific 
immunological QTL.
207
BTA Study*
Other studies 
Marker'
(marker bracket)
Current study
Position'
Marker^
(marker bracket) Position BTA Type
1
1
1
2
3
3
4
5 
5 
7 
7 
7 
7 
7
7
8 
8 
10 
1 1  
13
13
14 
14 
16 
18 
18 
18 
18 
18 
20 
21 
21 
22 
23 
23 
23 
23 
23 
26 
26 
27 
27 
29
MAF4&
HUJ1I77
C
^  V*-'# ' 1
fl8-TG
CreLA3SL
T
TE2tANffl 
(RW l^O-TQLAUé) 
EtHT3l
^flM 804)
Œ-XPLA179)
BP41
(D1K74 - CSSM47)
TGLA272
ILSTSIOO
(BM121 -TGLA53) 
(HAUT14-DIK67)
16.3
(98-121)
98
60
(26-39)
(42-68)
(TGLA337 - IDVGA39) (34-7/J
ABS12 3
(RM209 - BM203) (13-27)
A/C
8 C 
8
10 M
11 C 
13
13
14 
14
16 M 
18 C 
18 
18 
18 
18 
20
21 A 
21
22 
23 
23 
23 
23 
23 
26 
26 
27 
27 
29
A
C
Table 5.5 Published QTL for SCC traits and mastitis (*) traits over Bos taurus autosomes (BTA) 1 
to 29; 'Lymphocyte proliferation QTL taken from other studies in literature (shaded), coded as in 
preceding text (p206); ^Lymphocyte proliferation QTL taken from current study (unshaded), typed 
ANTIGEN (A), MITOGEN (M) and CONTROL (C). Where necessary marker positional data taken 
from Band et al. (2000).
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Cellular immune traits have been investigated for likely QTL in other species too. 
Using flow cytometry, significant QTL (positioned at) for resting lymphocyte 
counts were found on human chromosomes HSAl (200-231 cM), HSA2 (28-54 
cM), HSA8  (15-18 cM) and HSA9 (38-39 cM) (Hall et a l, 2002). Chen and 
Harrison (2002) found QTL on Mmul (63 cM) and Mmul9 (12 cM) for peripheral 
blood percentages of B-cells and cytotoxic T-cells, respectively.
BTA23 carries the bovine MHC (BoLA), which is intricately linked to infection, 
resistance and immunity (Ashwell et a l, 1998b; Elo et a l, 1999; Heyen et a l, 
1999). However, the extremely low density of markers on this autosome precluded 
evaluation of its immunological role in the current study. Due to technical 
difficulties, BTA23 was mapped with only three markers, giving a very low map 
resolution and coverage. Only one QTL on BTA23 was identified (related to early 
postvaccination levels of BRSV IgGz), a probable reflection of the low QTL 
detection rate possible. Where marker spacing exceeds 15 cM, particularly with 
BTA23, additional markers need to be selected and genotyped to prevent missing 
QTL due to inadequate genotypic information.
The power and mapping resolution of all QTL searches is constrained by the size 
and genetic content of the individual mapping population (Snelling et a l, 2005). As 
there were limited numbers of progeny in the project, a certain degree of 
imprecision must be accepted for QTL located on chromosomes; thus their exact 
positions must be regarded as provisional only. Similarly the non-detection of QTL 
on any specific chromosome may be due to the restricted number of alleles and 
markers available. The interval mapping technique for QTL discovei-y uses 
information from consecutive informative markers simultaneously to estimate QTL 
position and effect (Knott et a l, 1992). A significant problem is that QTL outside 
the interval tested may remain undetected or give false positive results.
Although dictated by experimental practicalities, only two cattle breeds were used 
in this experiment and some QTL, either described or excluded, may be breed- 
specific. If, as the heritabilities (Chapters 3 and 4) suggest, antibody responses to 
vaccination are sire-specific rather than breed-specific, using twelve sires may have 
restricted the number of alleles available. In the strictest sense, the sires used were 
not representative of the entire Bos taurus genome as their very availability is based 
on many cycles o f production-based progeny testing. As this was preliminary work
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ill a new area there was no way of devising a breeding strategy to knowingly ensure 
parental lines were homozygous for loci related to relevant traits: future studies may 
concentrate on the loci identified here to make maximum use o f their experimental 
populations.
Despite differences in the resource population tested, the experimental approach 
and the method of analysis from previous related experiments, several previously 
identified QTL were confirmed by the current study. More than twenty of the QTL 
identified were common to both sexes, operating across both dairy and beef suckler 
farming systems. Such QTL are therefore robust and flexible enough to be of 
practical value across quite disparate production schemes. Many of the analysed 
traits included in the study, such as antibody levels on successive sampling days, 
are well correlated. A possible improvement would be to use multi-trait phenotypic 
analysis which would increase power and permit the detection o f pleiotropic effects. 
Intrachromosome searches for multiple QTL had limited usefulness in this 
exploratoiy study. Unless two QTL are separated by two informative markers, they 
prove difficult to discriminate. More focussed marker placement would help resolve 
this weakness. Confidence inteivals for QTL positions tended to be rather large. 
Due to the limited number of informative meiotic events inherent in the project’s 
design, such imprecise results are expected. Expanding the number of informative 
families as well as increasing the number of markers would improve the precision 
o f the experiment.
The approach of integrated gene-mapping for heritable molecular phenotypes in 
large organised pedigrees is a veiy powerful tool for unravelling the complex 
effects of polymorphic genes in health and disease. Based on the results presented 
here, there is strong evidence for the segregation of QTL for immune function, even 
with the rather coarse marker map used.
To prevent declines in health and immunity, QTL for antibody and cellular immune 
function should be incorporated into cattle breeding goals. The detection here of 
immune function QTL ensures that this will be, in principle, possible although 
further fine mapping is likely to be necessary for implementation. Mapping of QTL 
is an ideal method of identifying regulatory proteins or rate-limiting enzymes in 
veiy complex physiological and biochemical pathways, such as serum antibody
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response, with the eventual aim of identifying causative genes at a molecular level 
(Korstanje and Paigen, 2002).
Even before that stage, the QTL identified here, which are closely linked to genetic 
markers, could be used to introduce immune function into traditional progeny 
testing leading to more healthy and productive cattle with improved welfare.
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Chapter 6
General discussion
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6,1 General Discussion
Reducing losses due to infectious disease is an excellent method of improving
production efficiency and animal welfare. Selection for disease resistance in farm
animals is a sustainable approach which avoids many of the difficulties of
traditional disease control methods. Resistance to infection is under polygenic
control. Functional polymorphisms in host resistance genes manifest themselves
as a spectrum of immunological responses. The kinetic profiles o f IgG antibody
discussed in Chapters 2, 3 and 4 typify the extent of this variation occurring even 
.after a standardised respiratoiy virus vaccination protocol. The opportunity to 
normalise environmental conditions is a critical advantage o f experimental 
genetic studies such as this, so diminishing somewhat the complexity of 
multifactorial phenotypes such as antibody response (Kramnik and Boyartchuk, 
2002).
The results presented here show that when calves were reared using dairy-type as 
opposed to beef-type systems, there were no long term effects on their ability to 
develop an antibody response to vaccination. Even though this contrast in calf- 
rearing management was also confounded by calf-sex, the eventual convergence 
of post-vaccination antibody levels in both groups suggests a common 
mechanism controlling humoral responses in male and female calves, aged 
between 60 and 160 days.
Maternally-derived passive antibody progressively decays as calves grow older. 
Calf-age and serum levels of passive antibody are therefore inherently linked and 
as pre-existing serum antibody can suppress the subsequent response to 
vaccination, this is important. The current study found that in calves over two 
months o f age, the effect of calf-age was primarily to determine the level of pre­
existing antibody before vaccination. The direct effects o f age on the induced 
antibody response following vaccination were much weaker, suggesting that the 
bovine immune system is competent beyond 60 days. The use of logisitic 
regression analysis to establish the thresholds at which the inhibitoiy effects of 
pre-existing ELISA antibody act is novel to the current study. If it is accepted
i
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that serum antibody is an indicator of vaccine responsiveness, maximising post-
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vaccination levels of serum antibody is a legitimate aim in all calf production 
systems. An accurate cut-off threshold for interference of pre-existing antibody 
with vaccine-induced antibody, as derived here, would therefore prove extremely 
useful when optimising existing vaccination regimes.
Due to the design of the project, it was possible to observe the transitions within 
the phenotypic variance induced by vaccination in particular detail for BRSV 
IgG. Total transmissible variance accounted for about a third of the overall 
phenotype variance before and after vaccination. Before vaccination the majority 
of this was due to the maternal heritable component but after vaccination the 
additive heritable component dominated. This period coincides with the window 
of vulnerability for BRSV clinical disease in calves. However, in a more general 
sense, a fuller understanding o f this juncture is critical as disease resistance 
becomes a breeding goal in farm animals. If “super” resistant parents transfer 
shoit-term passive immunity to progeny, sufficient to interfere with endogenous 
immune responses, break-downs in immunity could occur. As all farm species 
rely heavily on transfer o f passive immunity for neonatal survival, it is vital to 
investigate this area in tandem with progress on other heritable resistance traits.
The heritability of IgG responses to vaccination was established as -0.3 for 
BRSV and -0.5 for PIV3. If  host genetic variation can account for a third or 
more o f antibody responses, a priority for all future vaccine studies must be to 
ensure as genetically diverse a test population as possible to prevent biased 
results. In contrast, no heritable effects were detected for antibody levels to 
presumed field infections o f bovine coronavirus (although seroprevalence was 
high) or to the poorly sero-active BHV1 vaccine. Antibody responses were more 
sire-specific than breed-specific, a useful finding allowing the overall productive 
character of particular breeds to be retained while incorporating beneficial 
immune function traits into progeny selection.
All disease resistance can be regarded as a complex genetic trait in that there is 
no direct correlation between particular genetic polymorphisms and traits 
(Lander and Schork, 1994). Instead gene-gene and gene-environment interactions 
contribute to and determine the emerging immune response, with perhaps the 
primary environmental component being the infecting pathogen itself. Each
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pathogen has a unique set o f epidemiological and virulence characteristics. To 
counter this, the immune system has devised qualitatively and quantitatively 
adjusted responses, all of which emanate from quantitative trait loci on the host 
genome. Although constituents of the same multivalent vaccine, the PIV3 and 
BHVl components studied in Chapter 4 were independent entities 
immunologically, with strikingly different vaccine response, the final 
contribution of immune system genes varies according to the pathogen, the 
environment and the host physiology.
Antibody response is a complex trait involving networks of different molecules 
and pathways, all of which have genetic origin. Eighty-two QTL for antibody 
response were reported by the current study which, even after excluding Type 1 
errors, is a reflection of the multitude of cell-types, receptors, cytokines, 
chemokines, growth factors and others involved in each antibody response. A 
further forty-one QTL related to lymphocyte proliferation were identified, again 
demonstrating the complex nature of the cellular immune response. Indicator 
traits such as serum antibody are likely to remain the chief in vitro method for 
immune phenotype detection in farm animal species. Deliberately exposing large 
scale populations to pathogens, necessaiy for genetic studies o f clinical disease, 
is hugely expensive and is fraught with standardisation and ethical issues.
A
Genetic influences on immune responses can also be more oblique. For 
respiratory virus responses, less direct considerations include the morphology of 
the respiratory tract such as chest volume, tracheal cross-section, etc; non­
specific immunity such as the chemical nature o f the bronchial mucus, the 
efficiency of the mucociliaiy escalator, the number of active patrolling 
leukocytes in the lungs and respiratoiy mucous membrane and the destructive 
efficiency of these cells. Genetics can control animal behaviour with factors such 
as maternal recognition, stress-handling, aggression, avoidance of excretoiy 
products while grazing, and levels o f social interaction allowing pathogen 
transmission (Le Neindre et a l, 1998; Mackenzie et a l, 1997). Finally as eveiy 
immune response is largely mediated via protein molecules, there is an energy 
and resource cost. The partitioning and processing of nutrients is under genetic
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control in cattle (Funk, 1993; Galyean et a l, 1999) and as such the immune 
system is dependent on those genes.
Marker-assisted selection is the obvious objective following confirmation of 
relevant QTL. Cattle-breeding is particularly suited to marker-assisted selection 
(MAS), as in this species conventional phenotypic selection is hampered by a 
long generation interval, the predominance of sex-limited production traits, 
expensive progeny testing programmes for artificial insemination (AI) bulls and 
the generally low heritability of disease resistance traits. The widespread use of 
AI in cattle production means a small nucleus of key breeding animals exists 
which facilitates implementation of MAS. Furthermore MAS could act as a 
useful genetic filter to reduce the number of genetically undesirable bulls before 
they enter production-based progeny testing schemes (pre-selection). Dekkers 
and Hospital (2002) concluded that it would too risky to abandon phenotypic 
evaluation completely once MAS is introduced, as high levels of environmental 
variation, genotype/environment interaction or epistasis could each subvert the 
intended breeding goals. The same authors suggested that applying MAS in 
conjunction with in vitro fertilisation and embryo transfer technologies, 
effectively “pre-pregnancy pre-selection”, could accelerate the production of 
prospectively high merit animals ten-fold.
Although QTL with major effects are easily identified, genome scans may not 
detect those QTL with smaller effects if they fail to reach the stringency level 
applied. A secondaiy phase of positional candidate cloning following initial QTL 
mapping will continue. It would be extremely costly to generate pedigrees large 
enough to provide a map resolution capable of gene-level precision. The many 
chromosomes and QTL identified here, related to antibody response in cattle, 
imply that selection based on MAS from a F2 generation may be the more 
effective method of introducing these genetic elements into a population, rather 
than attempting marker assisted iiitrogression.
The ultimate aim when mapping trait loci has to be confirmation of causative 
genes and causative mutations. The results presented here have the potential to 
help delineate physiological pathways involved in humoral immunity to
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infectious disease and steer intelligent searches for relevant polymorphic 
molecules and candidate genes. The emergence of detailed comparative genome 
maps means that these results are useful outside the test species - cattle. 
Comparative mapping between species using expressed sequence tags (ESTs) is 
continuing and gene expression correlations between human and bovine genes is 
approximately 0.52(±0.07) (Cosseddu et a l, 2004). In conjunction with 
expanding micro-array technologies (Donaldson et a l, 2005; McGuire and Glass, 
2005), this synteny between cattle and other species means that homologues of 
immune function genes and models of mammalian immune processes can be 
transferred between species. Such cross pollination will greatly enhance progress 
towards a fuller understanding of the immune system in all mammalian species.
6.2 Future Work
In this study the earliest post-vaccination sampling point was fourteen days. To 
test for specific IgM and I g A, both of which have peaked and subsided by Day 
1 0  post-infection, an earlier sample or preferably set of samples would be 
required. Even if sera was only collected in the first ten days after vaccination, 
additional phenotypic datasets could be generated if interferon-y and/or the acute 
phase proteins such as serum amyloid A, haptoglobin and alpha 1-acid 
glycoprotein were measured. Another informative extension would be to test for 
IgGz antibody specific to BHVl and PIV3 vaccination. Mucosal immune 
responses are notoriously difficult to assess as they are often unrelated to serum 
antibody levels (Mestecky, 1987). Assays based on circulating antibody- 
secreting cells have been used as a correlative indicator of mucosal immunity in 
sheep (Premier et a l, 2004). A logical progression of the current study would be 
to evaluate mucosal immune responses e.g. IgA. To do this on a scale sufficient 
for genetic experiments, the methodology used by Premier et a l (2004) could be 
adapted to cattle.
The RoboGen herd was virtually clean o f BVDV but because of the profound 
immunosuppressive effects of this virus, some research is necessary on how it 
affects antibody responses to vaccination, particularly with inclusion of genetics.
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6 3  Conclusion
2 1 8
#Due to technical problems, BTA23 was only weakly mapped in the current study.
As it is the primary location o f the BoLA, this is a considerable defiency. It is 
important to reanalyse the immune system phenotypic datasets for QTL using an 
adequate, preferably dense, map of BTA23. Generally, more markers over the 
whole genome would improve our results, in terms of precision and also 
informativity as not all sires were heterozygous at the selected markers used.
Expanding the number of cattle-breeds (only two were used in the current study) 
would inevitably increase the number of possible alleles per gene and could 
change the emphasis onto different QTL.
It is crucial to determine if any negative effects exist on other economically 
important traits such as milk yield and feed conversion rates before embarking on 
MAS based on any QTL for immunological function. Unfavorable genetic 
correlations have been reported between milk productivity and some funetional 
traits in dairy cows (Castillo-Juarez et a l, 2000). With the wealth of production f
data available for the RoboGen herd, it is an ideal opportunity to study this 
controversial relationship in cattle. It is unknown how long term selection for 
disease resistance may influence the equilibrium between subclinical and clinical 
disease.
A;,Eradication of bovine respiratory disease pathogens is unlikely to be an "A
economic or feasible option on a commercial scale unless production practices 
change radically. Selecting for resistant or vaccine hyper-responder animals does 
not mean all animals need to be perfectly resistant within a population to prevent 
an epidemic -  just a sufficient number to lower virus transmission rates below 
epidemic self-sustenance (Bishop and MacKenzie, 2003). Vaccination will
■ 7continue to be used as an effective disease management tool in many types o f a
cattle production systems. Host genetics must now be integrated into vaccine 
development programmes to optimise and maximise their efficacy.
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Skewness is a measure of the asymmetry o f data around the sample mean. If  skewness 
has a negative value, the long tail of data distribution is more on the left of the mean 
than on the right. If skewness has a positive value, the long tail of the data distribution 
is more on the right of the mean than on the left.
Skewness of a distribution is defined as
n
E ( Y , - Y )
/=!
( n - \ )
Where Y is the mean of Y, s is the standard deviation of Y and n is the sample size.
Appendix A.l Definition of sample skewness
The trapezoid rule permits accurate estimation of the area under a line. It is based on 
the formula used in geometry to find the area of a trapezoid of height (h) and base 
length (bi) and base length (b]). By subdividing any area under a line into trapezoids 
and then summing each trapezoid area, the total area under a line can be calculated.
Area of trapezoid is
Where
bi
h
b2
Appendix A.2 The trapezoid rule for calculation of area of a trapezoid.
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Appendix A.3 Raw data for Chapter 3. Trellis plots for levels o f total BRSV-lgG (non­
transformed) on pre-vaccination Days -28, -14, 0, grouped on sex.
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Appendix A.3 (contd) Raw data for Chapter 3. Trellis plots for levels o f total BRSV-lgG
(non-transformed) on post-vaccination Days 14, 35 and 49, grouped on sex.
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Appendix A.4 Raw data for Chapter 3. Trellis plots for levels o f BRSV-lgG; (non­
transformed) on Days 0 and 14, grouped on sex.
272
Day 35 BRSV lgG2
80
60
45
§3=
K 25 
15
80 
60 
_  45 
g  35 
2  25 
15
100 80 60 40 20 0 20 40 60 80 100
No. of animals
Day 49 BRSV IgG2
80 60 40 20 0 20 40 60 80
No. of animals
Appendix A 4 (contd) Raw data for Chapter 3. Trellis plots for levels of BRSV-lgG; (non­
transformed) on post-vaccination Days 35 and 49, grouped on sex.
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Appendix A.5 Normal order statistics for Day 35 BRSV-lgG REML model as an example. 
Normality, random nature and balance o f residual data was verified for each REM L model 
by exam ining their linearity against norm al order statistics
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Appendix B.l Raw data for Chapter 4. Trellis plots for levels o f PIV3-lgG (non-transfomied)
on Days 0, 14 and 28, grouped on sex.
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Appendix B.l (contd) Raw data for Chapter 4. Trellis plots for levels o f PIV3-lgG (non­
transformed) on post-vaccination Days 42, 63 and 77, grouped on sex.
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Appendix B.2 Raw data for Chapter 4. Trellis plots for levels o f BHVl-IgG (non­
transformed) on Days 0, 14 and 28, grouped on sex.
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Appendix B.2 (contd) Raw data for Chapter 4, Trellis plots for levels o f BHVl-IgG (non­
transformed) on Days 42, 63 and 77, grouped on sex.
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